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1. Introduction 
Ever since the discovery that DNA is the carrier of genetic information in 1944 by Oswald Avery and 
collegues1 and the revelation of the DNA structure in 1953 by Watson, Crick2 and Franklin, 
humanity searched for changes in DNA that explain phenotypical traits, especially those that cause 
diseases. This search was simplified around 1975 as the Sanger DNA-Sequencing method was 
established, that allowed to obtain the nucleotide sequence of DNA molecules, which was used to 
generate the sequence of the complete human genome for the first time. It took about ten years 
and millions of dollars before the first two drafts of the human genome were published in 2001. 
With the advent of next generation sequencing in 2005, the ability to sequence whole genomes 
changed dramatically. Today, sequencing of whole genomes only takes days and costs some ten 
thousands of dollars. Additionally, the already published human (reference) genomes allow for an 
easy identification of genetic variation, which has been used to identify disease causing variants. So 
far, next generation sequencing has most notably helped to find the genetic cause of multiple 
Mendelian diseases and chances are that the genetic cause of most Mendelian diseases will be 
discovered within the next decade.3 
In my thesis, I focus on two related aspects that aim to identify functional genetic variants 
underlying inflammatory bowel disease (IBD) as a complex trait by next-generation sequencing. In 
the first part of the study, next generation sequencing was used to analyze the whole genome and 
transcriptome of a family trio with a severe early onset case of Crohn’s disease. Crohn’s disease is a 
subentity of IBD in which more than 70 risk loci have been identified using genome-wide 
association studies. Elaborating on this knowledge of immune and non-immune related pathways 
that are linked to etiology, I developed an algorithm that allows interrogating the different layers 
of information comprised in the genome sequence data from SNVs to larger structural variants. The 
introduction will focus on the pre-existing genetic knowledge on IBD and describe molecular 
mechanisms (e.g. autophagy, innate immunity) that are disturbed in the diseases. 
The second part of the thesis focuses on the transcriptome as a key element linking genome and 
function. The establishment of comprehensive RNA expression profiles, including information on 
expression levels, alternative splicing, allele specific expression patterns and mRNA editing is 
essential to our understanding of the molecular basis of a disease. In the Introduction, concepts for 
next generation sequencing of transcriptomes and the link between transcriptional landscapes and 
potential disease mechanisms will be presented. 
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1.1. Pathogenesis of inflammatory bowel diseases 
Chronic and progressive inflammatory diseases affecting the gastrointestinal tract, such as Crohn’s 
disease (CD) and ulcerative colitis (UC), are linked to a breach of the intestinal mucosal barrier and 
defects in the innate and adaptive immune system. Among these defects are an impaired 
macrophage activation,4 multiple genetic variants in receptors of the innate immune system such 
as NOD-like receptors (NLRs, i.e. NOD2 in CD), and defects in Toll-like receptors (TLRs, i.e. TLR4 in 
UC)5 (Figure 1). Crohn’s disease and ulcerative colitis are clinically distinct diseases; however both 
diseases have common symptoms, i.e. both can lead to anemia due to gastrointestinal bleeding, 
fever, abdominal pain, malabsorption and weight loss, joint pain and diarrhea (often bloody in UC). 
CD is commonly found in the ileum but can affect any part of the digestive tract and may manifest 
in inflammatory patches. The colon wall may be thickened and uneven, and the ulcers are deep, 
sometimes extending into all layers of the wall.  UC is usually restricted to the large intestine and 
manifests continuously across the affected areas, the colon wall is thinner and the mucus may have 
ulcers that do not extend beyond the inner lining. 
Studies have shown an increase of CD cases in distant, unrelated populations in the last few years, 
suggesting this to be a global trend.6 One study showed a slight decrease of pediatric IBD 
incidence in a southwestern population of Ontario while in the same region the incidence of CD 
nearly doubled over the last decade.7 A second study showed an increase of CD incidence in Korea 
between 2003 and 2008, where the mean annual incidence increased from 1.8 per 100,000 persons 
in 2003 to 2.7 per 100,000 persons in 2008.8 Very recently a rapid increase of CD and UC cases was 
shown in the Irish population, where the number of cases increased 2-3 fold between 2001 and 
2010.9 
The genetic background of both diseases is different, although some risk genes are shared. As this 
work is focused on Crohn’s disease, only the genetic background of CD will be mentioned in detail. 
Genetic factors are estimated to contribute to about 50-60% (sometimes up to 80%) of the risk to 
develop CD, but only about 20% of the genetic heritability has been identified yet.10,11,12 More than 
70 genes and loci have been associated with Crohn’s disease. A large proportion of these loci have 
been identified by genome wide association studies (GWAS). Supplementary tables 1 and 2 show 
the genes and loci for CD included in the GWAS catalog ordered by highest odds ratio 
(http://www.genome.gov/gwastudies/). Most of these variants have been identified in individuals 
of western origin and studies have shown that risk variants detected in certain populations can not 
necessarily be transferred to other populations. NOD2 is a prominent example of a susceptibility 
gene that differs between ethnicities. Genetic variants in NOD2 have shown that NOD2 plays a 
major role in CD pathogenesis among individuals of European ancestry, but this link could not be 
made for other populations. Recently, Adeyanju et al. (2012) studied the contribution of four 
known disease causing NOD2 single nucleotide variants (SNVs) to CD in African Americans.13 They 
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identified an association of one SNV with CD in African Americans, who are of about 80% West 
African and 20% European ancestry, but could not detect any known NOD2 risk alleles in the West 
African reference genomes from the 1000 Genome project. They suggest that the association is a 
result of recent European admixture, i.e. by common children of West Africans and Europeans 
carrying the risk allele. 
As mentioned above, the risk to develop CD can only be attributed by 50-60% to genetic variation. 
The remaining risk is explained by environmental factors, such as smoking, nutrition, composition 
of the bacterial flora and maybe other unknown factors. The probably most important 
environmental factor in CD is the composition of the intestinal bacterial flora. The intestinal 
epithelial cells are, separated by a mucus layer, permanently in close contact to potential 
pathogenic substances from the intestinal lumen. Under normal circumstances, a healthy host and 
its intestinal microflora have a symbiotic relation. Alterations in the microfloral composition 
however can turn the symbiosis into malignancy, causing a disease phenotype. Strong evidence for 
the involvement of intestinal bacteria in CD is provided by the observation, that mice of numerous 
IBD models do not develop disease after germ-free rederivation.11,14 The presence of crosstalk 
between the host and microbiome is evidenced by numerous experiments. In 2008, Vaishnava et 
al. showed that Paneth cells sense enteric bacteria through toll-like receptor activation regulating 
the expression of antimicrobial molecules.15 Further, Umesaki et al. demonstrated that the 
inoculation of germ-free mice by oral administration of a fecal suspension induces or increases the 
expression of T-cell receptors on T-cells.16 Thus the presents or absents of microbes triggers 
responses of the host, that in turn can change the microflora. It is not conclusively determined if 
changes of the microflora cause IBD or if an individuals’ genetic background causes IBD and 
promotes alterations of the microflora. Most likely both play a role in IBD. It is therefore not 
surprising that many mechanisms impaired in CD affect microbial defense mechanisms. Genes 
associated with CD are generally involved in physical barrier function (i.e. mucins), pathogen 
recognition (TLRs, NLRs), antigen processing (autophagosome, proteasome, and MHC antigen 
presentation), B- and T-cell function and cytokine production. 
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Figure 1 Modified schematic for Crohn’s disease associated genes (red) and gene interactions according to 
(Fransen et al. 2011).17 
Defects in the physical barrier, the mucosa (MUC1, MUC19) and epithelial cells (ITLN) lead to an increased number of intruding 
pathogens. Pattern recognition receptors, like the NOD-like receptors (NLRs, NOD2) and toll-like receptors (TLRs, TLR4) are 
activated and lead to a downstream activation of NF-κB. CARD9 cross links the NLR/TLR signaling cascade with the signaling 
cascade of the ITAM (immunoreceptor tyrosine-based activation motif) tyrosine kinase pathway (i.e. induced by activation of 
members of the lectin family, such as the dectin-1 or CD16 receptors (not shown here)). Mediated by CARD9, both pathways 
can activate the effectors of the other, which in case of the TLR/NLR pathway is NF-κB activation and in the case of the ITAM-
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TK pathway the induction of MAPK activation.18 NF-κB signaling induced by pathogen recognition leads to production of pro-
inflammatory cytokines and migration of antigen presenting cells into the intestinal mesenteric lymph node, where T-cell 
proliferation and differentiation is stimulated involving the IL-2 receptor (IL2RA) and the T-cell activation RhoGTPase activating 
protein (TAGAP). Interaction of ICOS-LG with ICOS enhances T-cell proliferation and IL-2 dependent cytokine production.19 T-
helper (Th0) cells differentiate in a cytokine dependent manner into various T-cell subtypes. Activation of the IL-23 receptor 
promotes differentiation into Th17 cells, which are involved in several immune-related diseases. The JAK-STAT-TYK pathway is 
induced and production of pro-inflammatory cytokines enhanced. Activation of TYK2 in dendritic cells induces IL-12B 
production, which is a subunit of the IL-23 receptor, already mentioned above, and IL-12, which is a strong promoter for Th1 
differentiation. It has been suggested that IL-18 is also involved in the development of Th1 cells and associations between CD 
and IL18 receptor proteins have been made.12,20 The transforming growth factor beta (TGF-β) promotes differentiation of naïve 
T-cells into regulatory T-cells (Treg). However, in the presence of IL-6, TGF-β also promotes differentiation into TH17 cells.21 
SMAD3 was identified as a CD risk gene.12 It acts as a mediator of transcriptional activation by the TGF-β receptor and can 
induce strong ligand independent TGF-β like responses in synergy with SMAD4.22,23 Both helper T-cell subtypes (Th1 and Th17) 
are pro-inflammatory, while differentiation into T-regulatory cells has an anti-inflammatory effect by IL-10 secretion. The 
autophagosome is another important pathway involved in CD pathogenesis (ATG16L1, VAMP3, and IRGM). In the 
autophagosome, microbial intruders are degraded for antigen presentation to CD4+ T-cells, which triggers the production of 
inflammatory cytokines and maintains inflammation. Both, the activation of CD4+ T-cells and the differentiation of pro-
inflammatory Th1 and Th17 cells can lead to the recruitment of neutrophils to the site of inflammation (CCR, ICAM1, ICAM3), 
which ultimately increases inflammation, and thus ulceration and additional microbial penetrance. One of the CD risk genes with 
higher odds ratio (1.44) is PSMB10. PSMB10 is part of the immunoproteasome in cells which degrades proteins for presentation 
via MHC class I molecules to CD8+ cytotoxic T-cells. Linked to this, ERAP2 is required for trimming of the antigen precursor 
molecules. Summarized this demonstrates the high complexity of pathways involved in CD and the large number of genes 
which can be involved in CD pathogenesis. 
 
A detailed overview of mechanisms underlying CD pathogenesis and genetic variants affecting 
these mechanims is presented in the following chapters. 
 
1.2. Physical barrier function of the gut 
The intestinal physical barrier is the first line of protection of the body against luminal bacteria. A 
breach of the physical barrier allows bacteria to intrude the underlying tissue and cause various 
diseases. Epithelial cells are closely connected by tight-junctions that prevent trafficking of 
molecules from the apical site (here the intestinal lumen) into the intercellular space and vice versa. 
The cell-cell connections are further stabilized by additional junctions, the desmosomes and 
adherence junctions that consist of transmembrane proteins of the cadherine family. Disruption of 
the physical barrier, i.e. due to loss of cell-cell connections is a hallmark of Crohn’s disease. In 2009, 
a study by Muise et al. raised evidence that polymorphisms in the CDH1 (E-cadherin) gene are 
associated with CD and cause a cytoplasmatic accumulation of truncated E-cadherin.24 
The intestinal epithelial cells are covered by a continuous layer of mucus that protects the cells 
from potentially aggressive environmental stimuli. The mucus layer consists mainly of mucin, O-
glycoproteins with high density that influence the viscosity of the mucus,25 and that are produced 
and secreted by goblet cells within the intestinal epithelial layer.26 About 20 mucin genes (MUC1-
MUC22) have been identified so far that can be divided into two groups of soluble and membrane 
bound proteins. In CD patients, deep ulceration of the mucus layer was observed, which might be 
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caused by variants affecting the expression or function of mucin genes, or variants that change the 
mucus viscosity, for example by altered secretion. Indeed, genetic variants conferring a higher CD 
risk were identified in CD patients by GWAS in proximity of the mucin genes MUC1 and MUC19.12 
The epithelial cells below the mucus layer not only serve as a physical barrier, separating the host 
from the intestinal contents, but also secrete antimicrobial defensins into the mucus layer to keep 
microbes at bay. The defensins can be divided into two classes, α- and β-defensins, with the latter 
being more broadly distributed along the epithelial, and the former mainly expressed by Paneth 
cells, typically located at the bottom of the intestinal crypts, and neutrophils.27 Disturbances in the 
defensin mediated antimicrobial defense, often associated with altered Paneth cell differentiation 
or a diminished number of beta-defensin gene clusters, seem to be critical in IBD pathogenesis.28 
In this context, GWAS identified a CD associated risk variant in intelectin (ITLN) that is strongly 
expressed in goblet and Paneth cells. ITLN is thought to exhibit antimicrobial properties, and thus, 
changes affecting ITLN expression or function could be involved in alteration of the mucus 
characteristics, as has been shown by experiments in sheep respiratory tract epithelium and 
intestinal nematode infections of resistant mice strains.29 
Should microbes overcome the physical barrier, other defense mechanisms, i.e. microbial sensing, 
become important. 
 
1.3. Pathogen recognition 
Pattern recognition receptors (PRRs) are part of the innate immune system and can be divided into 
Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-like helicases (RLRs) and C-type lectins 
(CLRs). PRRs recognize two distinct pattern types. The first type includes the so called damage-
associated molecular patterns or DAMPs. For example uric acid and β-amyloid belong into this 
category. The second types of patterns are of microbial origin and are thus named pathogen 
associated molecular patterns (PAMPs). Under normal conditions, PRRs are able to discriminate 
between harmless bacteria and potential pathogenic microbes, which could be due to recognition 
of specific PAMP combinations. It is assumed that perturbed recognition of these patterns 
contributes to etiopathogenesis of CD. As an archetype of this disturbed recognition, NOD2, a 
member of the NLR family, has been identified as one of the strongest CD susceptibility genes in 
European individuals. 
In the intestine, NOD2 has been reported to influence the composition of bacteria in mice, possibly 
by reduced bacterial killing ability of the host,30 which is in agreement with strong NOD2 
expression in Paneth cells and the suggested link between NOD2 and antimicrobial α -defensin 
secretion.31 After stimulation with the muramyl dipeptide (MDP), a component of bacterial cell wall 
peptidoglycan, NOD2 is thought to undergo conformational changes that lead to the activation of 
downstream signal cascades involving RIP2, TRAF6 and NEMO that induce the production of pro-
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inflammatory cytokines by activation of NF-κB and MAPKs. Multiple variants associated with an 
increased CD risk have been identified in NOD2. They are often affecting the leucine-rich-repeat 
(LRR) domain and interfere with NOD2s ability to recognize PAMPs leading to diminished signal 
transduction (“loss-of-function variants”). NLRs and TLRs are likely activated simultaneously during 
pathogen infection, which amplifies cytokine production. For example, upon activation of TLR2 to -
5, TLR7, and TLR9 by their corresponding ligands secretion of TNF-α, IL-1, IL-8, and IL-10 is 
increased in the presence of MDP.11,32 The role of NOD2 in CD has not been precisely defined, 
speculation is that NOD2 might be involved in the negative regulation of TLR signaling, promotion 
of IL-10 expression, regulation of inflammatory cytokine production by CD4+ T-cells in a NF-κB 
dependent way and Paneth cell function by direct regulation of α-defensin expression.11 
 
1.4. Complement System 
The complement system is part of the innate immune system and involved in pathogen clearance. 
In some cases, deficiencies in the complement system have been reported to be associated with 
Crohn’s disease. The complement system includes a large number of plasma proteins that react 
with each other to opsonize pathogens and induce inflammatory responses. Several components 
of the complement system are proteases that are present as precursor enzymes (zymogen) which 
require proteolytic cleavage to become active. The inactive zymogens are widely distributed 
throughout body fluids and become activated at sites of infection. The cleavage of the precursor 
enzymes triggers a cascade where one complement enzyme cleaves a second complement 
enzyme which then cleaves another. This allows a large amplification of the complement response. 
Three pathways can activate the complement system. The first pathway, also called classical 
pathway, is dependent on the complement component C1q. C1q can either bind directly to the 
pathogen surface or to antigen:antibody complexes, which is a key link for effector cascades 
between the adaptive and innate immune system. Activation of the C1s subunit of C1q leads to 
cleavage of other complement components (C4 and C2). Based on one case, it has been suggested 
that C2 deficiency might predispose for inflammatory bowel disease.33 However, Marks et al. 
argued that this ‘link’ probably happened by chance, as the occurrence of C2 deficiency is the most 
common hereditary complement deficiency (1 in 10,000 people).34 Marks et al. also reported a 
number of studies which showed CD-like small bowel enteritis in the context of C1 esterase 
deficiency. The second pathway depends on mannan-binding (MB) lectins, a serum protein that 
binds mannose-containing carbohydrates that can be found on bacteria. Very recently, in 2011 
Bak-Romaniszyn et al. showed that the number of individuals carrying a MBL2 (mannose-binding 
lectin) variant causing MBL deficiency was significantly higher in CD patients than in normal 
controls or children with UC.35 The third pathway, called alternative pathway, is triggered by 
binding of spontaneously activated complement components to pathogen surfaces. Activation of 
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all three pathways converges by generation of the protease C3 convertase. This protease is 
covalently bound to the pathogen surface where it cleaves C3 to generate large amounts of C3a 
and C3b. C3b is the main effector molecule of the complement system and opsonizes pathogens 
for destruction by phagocytes. C3b also binds to the C3 convertase to form a C5 convertase that 
produces C5a and C5b. C5a is the most important small peptide mediator of inflammation and is 
involved in recruitment and activation of phagocytes. C5b activates the ‘late’ events of 
complement activation, which leads to the formation of a membrane-attack complex by multiple 
terminal complement components. This complex integrates into bacterial membranes and 
generates pores which leads to osmotic destruction of the pathogens.36 
According to the literature available, a decisive involvement of the complement system in CD 
pathogenesis cannot be shown. However, some existing indications suggest a role of the 
complement system in some cases of CD or CD-like phenotypes. 
A much stronger association with CD has been made for another mechanism involved in pathogen 
clearance, namely autophagy, involving ATG16L1, NOD2, LRRK2 and VAMP3. 
 
1.5. Autophagocytosis 
Autophagy evolved as a mechanism for removal of damaged organelles, invading microbes and 
recycling of cellular compounds during cellular starvation. The unwanted contents is enclosed by a 
double-layered membrane and fused with lysosomes, which then leads to degradation of the 
contents. Proper autophagosome function is linked to removal and regulation of the 
inflammasome. The inflammasome is induced by inflammatory cytokines (i.e. TNF-α) and signaling 
resulting from recognition of DAMPs and PAMPs. Activation of the inflammasome activates 
caspase-1 which mediates the cleavage of immature IL-1β and IL-18 into their mature forms and 
extracellular secretion.11 Polymorphisms in NLRP3 (NOD-like pyrin containing protein 3), a critical 
component for caspase-1 activation in the inflammasome, have been strongly associated with 
CD.37 However, the very strong association could not be replicated in a follow-up study.38 Another 
gene possibly involved in inflammasome function that has been associated with increased CD risk 
is ATG16L1. Mice deficient for ATG16L1 show unregulated inflammasome function in response to 
combined TNF and TLR stimulation.11 
The pattern-recognition receptor NOD2 has also been identified as a key-regulator of autophagy 
induction. Upon activation, NOD2 induces the formation of autophagic vesicles in epithelial and 
dendritic cells, whereas NOD2 deficiency results in reduced autophagic uptake and impaired 
intracellular bacterial killing.11 In a study using Shigella flexneri, the authors could show that NOD2 
localizes to the site of invasion and mediates translocation of ATG16L1 to these spots, involving 
direct physical interaction of both molecules. Whereas NOD2 molecules carrying CD risk variants 
were unable to recruit ATG16L1 and showed impaired autophagy induction.39 ATG16L1 molecules 
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carrying the CD risk variant T300A also impair autophagy induction upon MDP stimulation, raising 
further evidence for the involvement of ATG16L1 and NOD2 in the same pathway.11 Other than for 
autophagy induction in epithelial cells, RIP2 has been shown to be mandatory for NOD2 
dependent induction of autophagy in dendritic cells. An impairment of autophagy in dendritic cells 
might affect the adaptive immune function.39 
Besides the above mentioned genes, GWAS identified multiple loci attributing to a higher CD risk 
in proximity of other autophagy related genes. These genes include IRGM, that has been shown to 
induce autophagy and establish large autolysosomal organelles for elimination of intracellular 
bacteria;40 VAMP3 that has been linked to membrane traffic and mediates the delivery of TNF-α 
from the recycling endosome to sites of phagocytic cup formation at the cell surface;41 and LRRK2.12 
Experiments with siRNA induced knockdown of LRRK2 lead to an increased autophagy activity and 
reduced apoptosis in starving conditions. Further evidence for the involvement of LRRK2 in CD are 
increased levels of LRRK2 in inflamed tissue of CD patients compared to noninflamed tissue.42,43 
Both, the sensing of pathogens by PRRs and autophagy are closely connected to endoplasmic 
reticulum (ER) stress. Several studies have shown that the unfolded protein response (UPR), a 
consequence of ER stress, induces autophagy and that decreased autophagy can increase ER 
stress.11 
 
1.6. Unfolded protein response 
The unfolded protein response (UPR) is a result of endoplasmic reticulum (ER) stress and has been 
shown to be involved in CD. The X box binding protein-1 (XBP1) has been identified as critical 
mediator of ER stress, and presents the first UPR component that has been associated with CD 
risk.44 Various genetic variants in XBP1 have been associated with CD and deletions of XPB1 in 
intestinal epithelial cells results in spontaneous inflammation of the small intestine and increased 
susceptibility to DSS induced colitis, involving functional and phenotypic impairment of Paneth 
cells and hypersensitivity toward inflammatory cytokines by increased JNK and NF-κB signaling.11,44 
Later, a second gene linked to UPR, namely ORMDL3, has been associated with CD by GWAS. 
ORMDL3 is a membrane bound protein that regulates the Ca++ uptake from the cytosol to the ER. 
Variations changing ORMDL3 function might thus lead to protein misfolding.45,11 A third gene, 
AGR2, that regulates protein folding in mice has been linked to CD. Decreased levels of AGR2 
mRNA are associated with an increased risk for CD and UC. Also, AGR2 deficient mice develop 
spontaneous enteritis and colitis, and these mice show increased ER stress in the intestinal 
epithelial indicated by higher levels of GRP78 and XBP1 with no mucus in goblet cells and 
expansion of Paneth cells prior inflammation.11 
These findings demonstrate the high relevance of ER stress in CD. ER stress is generated by 
accumulation of misfolded proteins, caused by genetic changes (change of amino acid sequence) 
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or environmental factors (i.e. salt concentration, temperature, inflammation, excess of iron). Cells 
whose main function is secretion of proteins are highly dependent on a normal UPR. Among these 
cells are immune cells (plasma cells, plasmacytoid dendritic cells, macrophages, and CD8+ cytotoxic 
T-cells), parenchymal cells and in context of CD very importantly, intestinal epithelial cells, 
especially Paneth and goblet cells.11 Invocation of UPR by ER stress involves three pathways, which 
sense changes in the ER and lead to the expression of transcription factors that influence a variety 
of factors for stress adaptation, such as translation, the quantity of ER membranes by lipid 
metabolism, expression of chaperones, other protein quality controls through ER-associated 
degradative pathways and possibly apoptosis. Three gene products known to regulate UPR, 
namely PERK, IRE1 and ATF6 are in an inactive state while they are bound to the ER-associated 
chaperone GRP78. Upon engagement of GRP78 with unfolded proteins, the associated proteins are 
released and initiate UPR specific pathways. Release of PERK causes phosphorylation of eIF2 and 
thereby attenuation of translation, except for the transcription factor ATF4 that induces expression 
of proapoptotic CHOP. ATF6 migrates to the Golgi, where it undergoes proteolytic cleavage and 
releases its cytoplasmic domain that enters the nucleus and regulates transcription. The kinase 
activity of released IRE1 leads to activation of JNK and NF-κB pathways. Also, IRE1 exhibits an 
endoribonuclease activity directed at the mRNA of XBP1. Only the spliced XBP1 mRNA leads to a 
functional protein, as proteins from the unspliced form are lacking the DNA binding domain.11 
 
1.7. Proteasome 
Disregulation of the immune cells’ ability to present antigens can negatively influence the success 
of pathogen clearance. Vital components of antigen presentation are autophagy and the allocation 
of small peptides by the proteasome. Proteasomes are responsible for degradation of poly-
ubiquitylated proteins in eukaryotic cells. A 20S core catalyzes the degradation while at least one 
19S subunit is attached to one end that exhibits a regulatory role by recognition and unfolding of 
proteins before degradation. Many essential cell processes are regulated and maintained by the 
proteasome. Among these are cell growth, cell differentiation, cell signaling, DNA repair, gene 
transcription, apoptosis, and generation of antigenic peptides presented by major 
histocompatibility (MHC) class I cell surface molecules to CD8+ T-cells.46 
A second form of proteasomes was identified, called the immunoproteasomes (IP) that shows 
affinity for low molecular weight polypeptides (LMP). These LMPs were identified by co-
precipitation with MHC class I molecules and have small sizes of about 20 to 30 kDa. Structurally 
both types of proteasomes are very similar but some proteins have been identified that are unique 
to the IP. Among these proteins are PSMB9 (LMP2) and PSMB8 (LMP7), which replace the β1 and β5 
subunits of the standard proteasome (SP) 20S core respectively. Other than genes of other 
proteasome subunits that are spread across the genome, PSMB8 and PSMB9 are concentrated 
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within the MHC class II region, upstream of the TAP-transporter (transporter associated with antigen 
processing) associated genes TAP1 and TAP2. PSMB8 and PSMB9 are, like other molecules in the 
MHC regions, polymorphic and IFN-γ induces their expression. Incorporation of both proteins into 
the SP has been reported to influence the quantity and quality of peptides generated by 
degradation of a 25-mer polypeptide containing the IE pp89 Ld-restricted YPHFMPTNL naturally 
processed dominant antigenic peptide.46,47 It has been shown that PSMB8 or PSMB9 deficient mice 
exhibit impaired presentation of bacterial- or viral-derived epitopes to CD8+ cytotoxic T-cells and 
show a reduced number of naïve CD8+ T-cells.46,48,49  
GWAS identified a variant in a related proteasome component (PSMB10) that replaces the β2 
subunit of the SP in the IP, and is associated to confer a higher CD risk.46,50 Additionally, PSMB9 and 
PSMB10 were found to be up-regulated during Crohn’s disease pathogenesis,46 and variants in 
UBE2L3, a gene involved in ubiquitination of the NF-κB precursor protein (p105) with possibly 
cytotoxic NK function, has been suggested to confer a higher CD risk.12,51 Impaired proteasome 
function might therefore be involved in CD pathogenesis. 
The immunoproteasomes are mainly found in hematopoietic cells like macrophages, T-cells and 
activated and resting B-cells. There is some evidence of IPs being expressed in dendritic cells, but 
current data on their role in DCs is not decisive. Ebstein et al. showed that in dendritic cells PSMB8 
to 10 expressions were only inducible by activation of TLRs, i.e. by LPS stimulation, which leads to 
an IFN-β autocrine loop.46 
PSMB8 expression was also detected in other cells, i.e. in small intestine epithelial cells and colon. It 
has been suggested that IPs are more efficient in IκB degradation than SPs, and thus lead to an 
increased translocation of NF-κB into the nucleus. Disruption of the PSMB8 subunit inhibits the 
release of pro-inflammatory cytokines like IL-23, TNF-α and IL-6 from peripheral blood 
mononuclear cells (PBMCs),46 highlighting the potential involvement of the immunoproteasome in 
inflammatory processes. 
The antigens provided by the proteasome are finally presented to immune cells by the 
components of the major histology complex. An impairment of the ability to present antigens 
could also contribute to a disease phenotype and is therefore discussed below. 
 
1.8. Major histocompatibility complex and antigen presentation 
Genetic variants occurring in genes located in the major histocompatibility complex (MHC) regions 
seem to be of high importance in Crohn’s disease pathogenesis. The MHC is located on 
chromosome 6 and spans 4-7 million base pairs containing about 200 genes.36 Among these genes 
are the Human Leukocyte Antigen (HLA) genes (MHC I and MHC II), genes involved in proteasome 
function (MHC II) and genes of the complement system and cytokines (MHC III), like TNF-α and -β 
which are strong mediators of apoptosis. The link between cytokines and CD will be explained in 
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the next chapter. Here, I will focus on the role of the HLA genes in antigen presentation and CD. 
Multiple studies tried to identify variants in the HLA genes that contribute to CD risk. In previous 
studies, four class II alleles (HLA-DRB1*07, HLA-DRB1*0103, HLA-DRB1*04, and HLA-DRB3*0301) show 
reproducible associations with CD.52 Additionally, a study by Zhang et al. in 2011 reported that the 
HLA-Cw*12 allele might confer a higher CD risk, based on a study of 73 CD patients and 106 
healthy controls.53 Therefore, the HLA genes might play an important role in CD pathogenesis. The 
HLA genes can generally be categorized into three class I α-chain genes (HLA-A, -B and -C) and three 
pairs of MHC class II α- and β -chain genes (HLA-DR, -DP, and -DQ). Other than the mentioned β-
chain genes, the β 2-microglobulin (B2M) gene is located on chromosome 15 and the invariant 
chain (CD74) on chromosome 5. MHC class I molecules consist of one α-chain and one β2-
microglobulin chain. The α-chain is divided into three domains (α1, α2 and α3). The α3 part contains a 
transmembrane domain and works as the anchor of the protein. The antigen is presented in a 
binding groove formed by the α1 and α2 domains that is stabilized by the β2-microglobulin chain. 
MHC class I molecules present antigens from pathogens within a cell to CD8+ cytotoxic T-Cells (i.e. 
during viral infection), which subsequently kill the infected cells. MHC class I molecules are highly 
expressed on all nucleated immune cells like T- and B-Cells, macrophages and other antigen 
presenting cells (i.e. dendritic cells) and neutrophils. Other nucleated cell types express MHC class I 
molecules on a low to moderate level and red blood cells do not show MHC class I molecules. 
MHC class II molecules consist of one α -chain and β-chain. Both chains contain two domains, with 
the α 2 and β 2 parts having a transmembrane domain each and α1 and β 1 forming the binding 
groove. MHC class II molecules interact exclusively with CD4+ (helper) T-Cells and are highly 
expressed on B-cells, macrophages, other antigen presenting cells and in the epithelial cells of the 
thymus. Other cell types do not express MHC class II molecules, except for T-cells when they are in 
an activated state. B-cells presenting antigens via MHC class II are stimulated to produce antibodies 
when encountered by CD4+ T-cells. Similar CD4+ T-cells stimulate macrophages presenting 
antigens via MHC class II to destroy the pathogens in their vesicles (see chapter about autophagy). 
Besides the functional differences of the two MHC class molecules, they also differ in the size of the 
peptide they can bind. The binding groove of MHC class I molecules is not as open for antigen 
binding than the binding groove of class II molecules. As a result, MHC class I molecules binds 
smaller peptides of 8 to 10 amino acids by both ends, while class II molecules bind peptides which 
contain more than 13 amino acids. 
 
1.9. Cytokines 
A broad range of genes related to cytokines and cytokine targets (i.e. IL2RA, IL10, IL12B, IL18RAP, 
IL19, IL23R, IL27, CCR6, CCL2, CCL17, CPAMPD8, TNFSF11, and TNFSF15) have been identified as 
potential Crohn’s disease risk genes. One of the strongest CD risk genes is the gene coding for 
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IL23R that will be discussed in more detail later. Cytokines can be separated into three major 
structural families: members of the TNF family, members of the hematopoietin family and the 
chemokines. Members of the TNF family are involved in adaptive and innate immune function, 
most of them being soluble molecules. The hematopoietin family consists mainly of growth 
hormones and interleukins, which are involved in both parts of the immune system. The 
chemokines again can be divided into two major classes differentiated by different motifs at the 
amino terminus. The first class contains the CC chemokines, with the Cs representing adjacent 
cysteines near the amino terminus. CC-chemokines promote the migration of monocytes and other 
cell types from the blood stream into the surrounding tissue and the infiltration of leukocytes (T-
effector cells) into tissues. The other class contains the CXC chemokines, in which an additional 
amino acid is introduced between the two cysteines at the amino terminus. These chemokines 
include two subgroups, members of the first group contain a Glu-Leu-Arg (ELR) motif before the 
first cysteine that promote migration of neutrophils and the members of the second group that are 
lacking this motif are usually involved in homing of lymphocytes, like effector T-cells. 
Explaining the functions of cytokines involved in CD pathogenesis would be beyond the scope of 
this work, thus only IL2RA and IL23R will be exemplified. 
GWAS identified the receptor of IL-2 (IL2RA) and TAGAP (that is co-regulated with IL2 during T-cell 
activation) as potential CD risk genes. Interleukin-2 (IL2) is produced by lectin- or antigen-activated 
T-cells and acts as a growth hormone for both, B- and T-cells and might be involved in 
programming the development of CD8+ memory T-cells.12,54,55,56 
One of the strongest risk genes for CD is the gene coding for the IL-23 receptor (IL23R). IL-23 does 
not bind to IL-23R directly, but to IL12-RB1, which pairs with IL23-R in cells co-expressing both 
molecules. IL-23 is a composite molecule of the IL-12 p40 (IL12B) subunit and IL-23A (p19). Variants 
detected in IL12B have also been associated with an increased CD risk. IL-23, together with IL-6 and 
IL-1β, mediates generation of Th17 cells by initiation of IL-17 production in naïve precursor cells 
independently of TGF-β. Additionally, IL-23 enhances IFN-γ secretion by memory T-cells in an IL-2 
dependent manner.12,57,58,59 
In this context, variants in BCL3 might also be associated with a higher CD risk. Impaired BCL3 
expression leads to an increase of IL-23 production in dendritic cells stimulated with bacterial 
lipopolysaccharides of IL10 deficient mice, which might lead to an increased adaptive immune 
response in CD patients that show lower expression of BCL3.51 
 
As shown in the above chapters, Crohn’s disease is a complex disease involving numerous genes 
and mechanisms. Although each CD associated gene and CD risk loci identified by GWAS could be 
investigated by conventional methods, such as PCR, chances are high to miss disease relevant 
variants in yet unknown CD risk genes, as only about 20% of the genetic heritability is explainable 
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by the known risk loci. Therefore a more complete assessment of the genetic variation in the 
individuals of the presented case trio is desirable. To accomplish this, next generation sequencing 
was used to sequence the whole genome of all three individuals that allows, in theory, the 
identification of all genetic variants. 
 
1.10. Next generation sequencing as diagnostic tool for clinical application 
Next generation sequencing (NGS) is still a young technology. The first commercial machine was 
launched in 2005 by 454 Life Science (GS20, Roche) and since then several companies started 
selling their own sequencers. Currently, the most popular sequencers are from Illumina 
(HiSeq2000, miSeq) and Applied Biosystems (SOLiD, Ion Torrent/Proton), generating a large 
amount of sequencing data (200 Gb per run Hiseq2000; 90 Gb per run SOLiD 5500) for moderate 
costs, basically allowing to sequence one whole human genome in about 3-4 days in a single run 
with a genome-wide coverage depth of 30x (See the material and methods section for the 
workflow of SOLiD sequencing). In early 2011, Kahn illustrated how rapid the development of NGS 
proceeds. Even Moore’s Law, a rule of thumb for the inexpensive doubling of transistors on an 
integrated circuit in a two year period falls far behind. The first GS20 generated roughly 200 Mb per 
day in 2005, current NGS machines generate 10-20 Gb per day.*,†
In the past few years the cost of whole genome sequencing (WGS) decreased from several millions 
to less than 50.000$ for one genome in 2010, about half as much today (2012) and is still 
dropping.61 This drop in costs makes WGS more feasible in disease diagnostics that can be already 
noticed by the emerging number of published disease related genomes and exomes.62–72  
,60 
Several studies were successful in the discovery of causative genes in Mendelian diseases, here 
exemplified by two studies. In an exome sequencing approach, Ng et al. were able to identify the 
causative gene responsible for Miller syndrome.66 In a different study, whole genome-sequencing 
of a patient with metachondromatosis, revealed PTPN11 as the likely disease gene.71 Recently, 
Green et al. predicted, probably also encouraged by the high success rate in the identification of 
Mendelian disease genes by next generation sequencing that most Mendelian disease genes will 
be identified over the next decade.3  
However, using NGS to solve the genetic basis of complex diseases proofed, unsurprisingly, to be 
much more difficult. Baranzini et al. studied multiple sclerosis in discordant monozygotic twin pairs 
but could not detect any differences in the genome, epigenome or transcriptome that could 
explain the observed discordant differences.63  
                                                             
* 5500 SOLiD™ System Information Sheet 
† HighSeqTM 2000 Sequencing System, Specification Sheet 
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Very recently, an exome sequencing study was published, which aimed at the identification of rare 
and novel variants in IBD patients. The study focused on the detection of variants in known CD risk 
genes and was able to detect some novel variants, besides several already known variants.73 
In this thesis, I aimed for the extraction of the full genetic variants in the genomes of a family trio of 
two healthy parents and one child with early onset of a severe case of CD. Other than the above 
mentioned study, this thesis is not restricted to known CD risk genes but rather aims to identify the 
causative variants(s) in the child’s genome, assuming a strong genetic background and mendelial 
model of inheritance. Additionally, next generation sequencing was used to investigate the 
transcriptomes of the family that allows identification of expression changes and functional studies 
of genetic variants that occur in regulatory regions. Extending transcriptome work done in the trio, 
a method for assessing sense/anti-sense transcription events was developed that allows 
integrating of transcriptomic data with genetic and epigenetic information. The tool may 
ultimately be used to assess context-dependent regulatory events. 
 
1.11. RNA sequencing 
Transcriptome sequencing (or RNA-Seq[uencing]) can be a very powerful tool for investigation of 
functional consequences of genetic variations. This is especially true if the underlying genetic 
changes are known, as SNV-calling from RNA-Seq data is difficult for various reasons (i.e. allelic 
imbalance, RNA editing). Genetic variants affecting splice-sites for example can lead to decreased 
expression of an isoform (i.e. heterozygous SNVs) or even the complete loss of expression 
(homozygous SNVs). Also, nonsense SNVs or SNVs preventing correct protein folding may cause 
visible changes in gene expression (i.e. the absence of a protein might lead to an up-regulation of 
the corresponding gene as a compensatory mechanism or transcription aborts early). The effect of 
SNVs outside of exonic regions is difficult to assess with genomic data alone, but RNA-Seq data can 
add information towards functional relevance. Expression changes of genes involved in 
inflammation can be detected between inflamed and non-inflamed samples, which can be helpful 
to identify genes involved in inflammatory diseases. The following two examples further underline 
the use of RNA-Seq in disease interrogation. Using RNA-Seq, Hawkins and Kearney identified 
several novel candidate genes for epilepsy in mice.74 Wu et al. compared the transcriptomes of 9 
patients with schizophrenia and 9 controls and identified more than 2000 genes with 
schizophrenia-associated alternative promoter usage and more than 1000 differentially spliced 
genes.75 Transcription by itself is a very complex network involving a broad range of regulatory 
mechanisms, such as allelic imbalance, RNA editing, RNA-RNA interactions, alternative splicing and 
antisense transcription. Most of these mechanisms are part of research by many groups, also in 
connection with NGS. However, the genome-wide assessment of antisense transcription by NGS is 
still hardly touched. Antisense transcripts might have a regulatory effect on the expression of the 
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sense transcript, which has been reported for several sense/antisense (S/AS) pairs before. One very 
well known S/AS pair (XIST and TSIX) is involved in X-chromosomal inactivation.76 Another example 
is given by Morris et al., who reported that expression of the p21 antisense transcript mediates 
methylation of the p21 sense promoter by recruitment of epigenetic regulatory complexes and 
showed that this effect was reversible by siRNA induced knockdown of the antisense transcript.77 
Published data about antisense transcription is sometimes contradictory, underlining the high 
complexity of the matter. In 2008, He et al. investigated S/AS patterns in different human cell lines 
using the Illumina GA and detected a high abundance of antisense tags within exons.78 In contrast, 
in a paper published by Klevebring et al. in 2010, who used the SOLiD system, only few antisense 
tags were detected in the coding regions of genes.79 However, both papers agree on an abundance 
of antisense transcription occurring in promoter and terminator regions. 
To fill the gap left by no publicly available tool for the identification of sense/antisense transcript 
pairs on the genome-wide level, I developed a program, namely Janus, during this thesis. Janus 
observes transcription of the two stranded DNA, which can occur in sense and antisense direction.   
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2. Aims of the study 
The setup includes a family with a severe case of Crohn’s disease and unusual early onset (1.5 
years). Whole genome and transcriptome sequencing potentially allows the identification of 
known and novel functional genetic variants in all genes and other genetic regions without an a 
priori biased approach. In this exemplary setup I have used next generation sequencing to address 
the following questions: 
 
- Do genetic variations occur in genes known to cause monogenetic diseases phenocopying 
Crohn’s disease? 
- Do variants following the recessive model of inheritance or genes showing compound 
heterozygous variants occur in the child? 
- Are there any de novo variants in the child, which effect known or novel potential risk genes? 
- How much of the known risk loci does the child carry and how does this contribute to CD risk 
compared to the parents and other unrelated individuals? 
- Are there any novel variants in known Crohn’s disease risk genes? 
- Genetic variants might occur in genes associated with other inflammatory diseases, which 
could hint towards a common link to inflammation. Does the child carry genetic variants in 
these genes? 
- Are there any hitherto unassociated genes showing genetic variants which might contribute 
to CD risk? 
- Regions of homozygosity (ROH) can hint towards risk loci. How do the ROHs differ between 
the three individuals and does the child have more known CD risk genes located in ROHs? 
- Genetic variants might have an effect on gene expression. How different is the gene 
expression in the child compared to the parents? Which are the genes differentially 
expressed? Are the most differentially expressed genes affected by genetic variants? 
- How prevalent are regulative mechanisms like antisense transcription? Are sense/antisense 
pairs differentially- or co-expressed? How do (epi)genetic variants influence sense/antisense 
transcription and is there a potential link to disease related transcript signatures? 
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3. Material and methods 
 
3.1. Extraction of nucleic acids from blood samples 
DNA was extracted from frozen blood samples using the “Blood Giga kit” from InvitekTM (Berlin, 
Germany) following the manufacturer’s protocol. In the first step erythrocytes are lysed and 
removed. Afterwards, DNA from leukocytes is extracted in a second lysis step, without interfering 
hemoglobin. Protein components are digested using Proteinase K and DNA is precipitated with a 
96% ethanol containing solution, washed with 70% ethanol, dried and finally resuspended in low 
salt buffer for downstream applications. 
Preparation of total RNA was performed with “mirVana miRNA isolation kit” from AmbionTM 
(Paisley, UK) according the manufacturer´s instructions. Similar to the DNA extraction method, at 
first a cell lysing step is performed. Afterwards, most DNA is removed by Acid-Phenol:Chloroform 
extraction of the samples. Ethanol is added and the solution is passed through a glass-fiber filter 
that binds the RNA. The filter is washed multiple times before total RNA is eluted with a low ionic-
strength solution. 
 
3.2. Library generation 
Independent of the type of application (miRNA, mRNA, exome enrichment, genomic DNA (gDNA)) 
the first step of library generation is the fragmentation of the input material. The following 
description is for fragment library preparation. The DNA (gDNA or cDNA in the case of RNA 
libraries) is sheered by sonication to fragments with a mean length of 160 bp (150-180 bp). 
Afterwards enzymes for end-repair are used to generate blunt-ended fragments (End-polishing 
enzyme 2) with a phosphorylated 5’-end (End-polishing enzyme 1 + ATP). Libraries are purified 
with PureLinkTM columns before ligation of adapter sequences. A final size selection for fragments 
of 200 to 230 bp of the library is performed, which corresponds to the length of the fragmented 
DNA plus adapter sequences. To close potential gaps in the sequences, the eluate of the size 
selection undergoes nick-translation before the library is amplified by PCR. Before sequencing the 
library is purified with the “SOLiD™ Library Column Purification Kit” and measured by quantitative 
PCR. 
The generation of long mate-pair (LMP) libraries requires a slightly different workflow. Library 
generation aims for an insert size distribution of fragments with lengths from ca. 1500-3500 bp. 
LMP CAP adapters are ligated to the ends of the sheared DNA fragments, which are then 
circularized by biotinylated internal adapters. The LMP CAP adapters do not have 5’-phosphate in 
one of their nucleotides, which results to a circular DNA molecule with nicks in both strands. The 
nick is then ‘moved’ in 5’- to 3’-direction by DNA polymerase I in a time and temperature 
25 
 
dependent manner. Subsequently T7 exonuclease and S1 nuclease cut the circle at positions 
opposite to the nicks, which releases a piece of DNA that contains sequences of both ends of the 
original fragment. Afterwards adapter sequences are ligated and library preparation proceeds as 
described above. 
One library used the “Agilent Sure Select kit Human All Exon Kit V1” for targeted sequencing of 
exons. This introduces an additional step after the purified library has been generated. The 
prepared library is hybridized to the SureSelect capture library, consisting of biotinylated RNA 
library ‘baits’ for exon sequences. The hybridized libraries are incubated with streptavidin coated 
magnetic beads, which binds to the biotin. Beads and supernatant are magnetically separated. The 
beads are washed to separate the beads and the DNA and RNA libraries. After RNA digestion of the 
capture library, an exon specific DNA library (exome library) remains. 
For each individual, four libraries were generated from genomic DNA and one library from RNA. 
The four genomic libraries consist of three paired-end libraries, two for the whole genome and one 
restricted to exonic regions, and one long mate-pair library. The RNA library was generated as 
paired-end library (see Table 1 for library and run chemistry used). 
 
Table 1 Overview of applied library and run chemistry 
library type library kit run chemistry 
long mate-pair SOLiD™ Long Mate-Paired Library Construction Kit V3+ 
SOLiDTM Top Mate Paired Sequencing Kit 
MM 50/50 v4 
paired-end (1st) SOLiD™ Paired-End Library Construction Kit V3 SOLiD
TM Top Paired End Seq DNA Frag Kit 
MM 50/25 v3 
exome and 
paired-end 
(2nd) 
SOLiD™ Paired-End Library Construction Kit V4 SOLiD
TM Top Paired End Seq DNA Frag Kit 
MM 50/35 v4 
transcriptome 50+25 bp, SOLiD™ Total RNA-Seq Kit V4 Opti Fragment Library Sequencing Kit MM 50 v3+ 
 
3.3. Sequencing 
Before sequencing, an emulsion PCR (ePCR) is performed for all prepared libraries. The ePCR is 
required to generate clonal bead populations for sequencing. An aqueous phase containing the 
PCR ingredients (template, primers, polymerase and SOLiD™ P1 DNA Beads) and an oil phase 
containing emulsifiers are prepared and emulsion is created using the ULTRA-TURAXX® Tube Drive 
from IKA®. This results in micro-reactors (small droplets) containing a small fraction of the aqueous 
components. The quantity of aqueous components is chosen to favor droplets containing only one 
bead and template. The P1 adapter sequence of the template binds to the P1 sequence of the DNA 
bead, where the template is then amplified by PCR. Depending on the number of different 
templates and beads per droplet multiple results are possible, i.e. micro reactors containing no 
template or template fragments with two P2 adapters attached will not bind to the bead and will 
not be amplified, micro reactors containing multiple templates will result in non-clonal beads and 
26 
 
micro reactors containing multiple beads may lead to clonal beads, but lead to a small 
amplification bias of a fragment. The emulsion is abrogated by addition of 2-butanol and the beads 
are washed to remove any remaining oil and emulsifiers. Polystyrene beads coated with a P2 
adapter are used for enrichment of amplifying beads. Non-amplifying beads and beads containing 
only fragments with P1 adapter will not bind to the polystyrene beads. In the subsequent 
centrifugation step polystyrene beads (with and without attached beads) result in a layer at the top 
and the non-amplifying beads form a layer at the bottom. The polystyrene beads are extracted and 
denatured to release the template beads. A 3’-terminal dUTP is added to template sequences 
before deposition of the beads on a glass slide for sequencing. 
Sequencing was done on the SOLiD 4 platform, which uses 2-base encoding in a sequencing-by-
ligation system. Generated sequences are written in SOLiD specific “color space”. Sequential 
rounds of ligation with different labeled probes are carried out. The probes are eight nucleotide 
long molecules, two known bases which are interrogated, followed by three degenerated bases 
and three universal bases. Only four different dyes are used, thus each color corresponds to four 
dinucleotide combinations (including the 3 degenerated bases, there are 45/4 = 256 combinations 
per dye). For each cycle another sequencing primer is used which binds to multiple positions in the 
adapter sequence, shifted by one base-pair. As a consequence, each base is interrogated twice, by 
two different probes (i.e. in a subsequence of ATC two probes, ATNNN and TCNNN will bind and 
the T is interrogated twice). Each produced sequence starts with a T, followed by number 
corresponding to the colors (0-3). This allows for bijective translation into base space. This allows 
for a high accuracy, as valid nucleotide exchanges require two adjacent color space mismatches in 
relation to the reference sequence, which permits differentiation from sequencing errors (single 
color space errors). 
 
3.4. Sequence analysis 
Primary analysis (image analysis/base calling) and secondary analysis (mapping, calling of single 
nucleotide variants (SNVs) and detection of insertions and deletions) was performed with 
BioscopeTM (Applied BiosystemsTM). All sequence data was mapped against the non-masked human 
reference (hg18) using Bioscope’s standard parameters. BAM files (the binary format of SAM 
(Sequence Alignment/Map format),80 http://samtools.sourceforge.net) were generated with 
Bioscope’s “mark duplicates” option and coverage has been calculated using Samtools (v.0.1.8) 
mpileup command. Ambiguous bases (Ns) in the reference and sequences marked as duplicates 
were ignored for the calculation. SNV calling was restricted to perfect pairs (same strand, correct 
orientation and without deletion and insertion) with a minimum quality value of 6 and a mapped 
bases to read length ratio of >= 0.85. 
For tertiary analysis I developed a multi-threaded Windows application in C/C++. 
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3.5. SNV annotation 
The SNVs included in dbSNP build 130 were used to identify known and novel SNVs. SNVs present 
in dbSNP130 were assigned the respective rsIDs. Transcript information (refGene Oct. 2012, 
available at the UCSC Genome Browser81 Website http://genome.ucsc.edu/) for transcripts within 2 
kb range of the SNV was added to the SNVs. This includes the refSeq ID, gene symbol, the relative 
position of the SNV to the transcripts ([2 kb] neighborhood, 3’- or 5’- UTR, exonic, intronic), the type 
of nucleotide exchange (synonymous, nonsense, altered M[ethionine], new M[ethionine], read-
through and splice-junction), the reference triplet and amino acid and the triplets including allele A 
and allele B of the SNV, as well as the respective amino acids. Information concerning the 
conservation of the SNV position was added using PhyloP82 scores for mammals (available at the 
UCSC Genome Browser Website). PhyloP generates negative scores for predicted acceleration and 
positive scores for predicted conservation. For all SNVs contained in the result tables, allele 
frequency information for the CEU population based on the 60 sample pilot of the 1000 Genome 
project was added, when available. Additionally, SNV lists for each individual were complemented 
for SNVs only present in the other individuals by inclusion of consensus calls. Modified SNV data 
has been correlated to the Illumina SNV-Chip data that was converted from Illumina’s TOP/BOT 
annotation to forward strand designation first. Additionally genes were screened for compound 
heterozygous variants (genes in the child that carry at least one but exclusive heterozygous SNV 
from each parent) and SNVs that are heterozygous in the parents but homozygous in the child. 
Figure 2 illustrates the workflow of SNV characterization. 
 
Figure 2 Filtering step for SV characterization. 
On the top level genetic variants are compared to a list of monogenic disorders phenocopying CD. Next de novo variants are 
searched that could be functionally linked to CD pathogenesis. During the following two levels the detected variants are 
compared with known associated variants identified by GWAS and novel variants in the associated genes are searched. On the 
28 
 
next lower level, the search is extended to other autoimmune diseases. The bottom level regards all genes that could present 
potential novel CD risk targets. To narrow down the more likely disease causing variants on every level a secondary filter was 
applied that screens for variants following the recessive model of inheritance, accumulation of variants unique for either parent 
(compound heterozygosity), conservation and prediction of protein changes. 
 
In a top-down approach, variants were screened for in genes involved in diseases phenocopying 
CD83 (with the addition of two monogenic syndromes involving IL10 and XIAP), genes and loci 
involved in CD pathogenesis based on data available in the GWAS catalog, meta-analysis12 and 
OMIM database, genes known to be involved in other inflammatory diseases (based on the GWAS 
catalog) and lastly all other genes, restricted to SNVs that follow the recessive model, are 
compound heterozygous, located in a site of high conservation or were predicted to have an 
damaging effect on protein function by SIFT84 and/or PolyPhen85. Detection of de novo SNVs was 
performed using two different approaches (see below) and exonic SNVs detected by both 
approaches were sequenced by Sanger. 
 
3.6. Detection of de novo SNVs 
Two different approaches were used to detect de novo SNVs in the child. In the first, simple 
approach, Mendel errors (de novo SNVs and back mutations) were extracted from the SNV-Calling 
results of the child. The number of false positive Mendel errors was reduced by investigating the 
raw allele counts. Alleles with >=5% of the total coverage were considered as present. SNVs with 
more than 2 different alleles were excluded, as these might pose difficult regions for SNV-Calling. 
In the second approach, variants that were detected in the parents were excluded from further 
analysis. The remaining variants (~230,000) were annotated using a custom annotation pipeline, 
including overlap with dbSNP, overlap with our in-house variant database, genomic location 
according to refSeq and predicted amino acid consequences. I prioritized for unknown non-
synonymous variants that were detected in five reads or more that made up at least 30% of the 
total amount of reads. This resulted in 37 potential de novo variants that were subsequently 
checked by retrieving the raw sequence calls of these positions in the parents’ data. Subsequently, 
all exonic SNVs that were detected by both approaches were sequenced using Sanger sequencing. 
 
3.7. Analysis of short structural variations (sSVs) 
Similar to SNVs short insertions and deletions (InDels) were categorized according to current gene 
annotations. InDels following the recessive model of inheritance were identified and described by 
using the same databases as for the SNVs. 
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3.8. Analysis of long structural variations (lSVs) 
Two approaches were used to detect lSVs. For the first approach structural rearrangements were 
detected using paired-end mapping.86 Such methods rely on the expected mapping distribution 
and orientation of the sequenced library. The sensitivity is dependent on the spanning coverage 
(synonymously called physical coverage) and hence, large insert libraries can increase the power to 
detect structural rearrangements. All discordantly mapped paired-ends either show an abnormal 
distance or abnormal orientation and any such pair can indicate a rearrangement. To confidently 
call structural variants, discordant paired-ends were clustered into groups that support the same, 
putative structural rearrangement. For the second approach the Bioscope “Find Large Indels” tool 
was used applying standard parameters. All large deletions ≥ 3.000 bp that were detected by both 
approaches were manually checked, independent of the individual in whom they were detected. 
 
3.9. Demographic origin of sequenced subjects 
The geographic position of all three individuals was assessed in a SNP-based Principal component 
analysis (PCA) with 1,296 individuals from 11 HapMap populations87 using 41,163 SNPs shared 
between subjects. Principal component analysis was performed with default settings using the 
Eigensoft program88 and genotype data available from the HapMap ftp 
site:http://hapmap.ncbi.nlm.nih.gov/downloads/genotypes/2009-01_phaseIII/plink_format/.  
 
3.10. Single nucleotide variant distribution along chromosomes 
To asses changes in the SNV distribution across the genomes of the family trio compared to the 
genomes of the ‘normal’ CEU population, R was used to plot the chromosomes reflecting regions 
of high SNV density in red and regions of low SNV density in blue. Each pixel represents 137360 bp 
(= 1800 pixel for chromosome 1). The color of the pixel is determined by the number of SNVs in the 
region, where 500 or more SNVs equals an RGB value of 1,0,0 (=red) and zero SNVs equals 0,0,1 
(=blue). 
 
3.11. STRING network analysis of missense single nucleotide variants 
Enrichment of Gene Ontology terms was performed for all missense SNVs in the child using fisher’s 
exact test, followed by Benjamini-Hochberg correction for multiple testing. To investigate SNV 
burden of networks, STRING (http://string-db.org/) interaction analysis was performed for all genes 
contained within the GO term “immune system process”. Ten white nodes were allowed and 
connections based on text mining, gene fusion and neighborhood were excluded. 
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3.12. Selection of differentially expressed transcripts 
Between 127 and 151 million reads (5.0-5.7 Gb) of transcriptomic data were generated per 
individual. Of the transcriptomic data 60% of forward and 17% of reverse reads could be mapped 
to the hg18 reference. Expression was calculated with Cufflinks v0.9.3 (cufflinks.cbcb.umd.edu)89 
using the UCSC knownGene table (March 2011) as reference that contains 66.8k transcripts. 
Between 35.5k and 38.0k transcripts were detected by at least 0.01 Fragments Per Kilobase of exon 
per Million fragments mapped (FPKM) per individual (Supplementary table 3). The number of higher 
abundant transcripts with FPKMs above 1 varied between 11k and 13k. About 29k to 31k 
transcripts could not be detected (< 0.01 FPKM) per individual. The RNA-Seq expression profiles 
reflect the child’s inflammatory condition. Several IBD and general inflammation associated genes 
(e.g. MAPK14, MMP9, TLR5 and members of the S100/calgranulins family) are differentially 
expressed, which means at least 5-fold higher or lower, in the child compared to its parents. For 
higher expressed transcripts, only those with a FPKM > 0 in the parents and FPKM > 1 in the child 
were regarded, while lower expressed transcripts required the parents’ FPKMs to be > 1 and child 
FPKM > 0. 
 
3.13. Regions of homozygosity 
A reasonable assumption for at least some proportion of variants, such as loss-of-function 
mutations, is a recessive risk model. Therefore it was investigated if known risk genes/loci for 
Crohn’s disease are overrepresented in autozygous regions. Autozygosity presents as extended 
homozygous regions, or runs of homozygosity (ROH), in the human genome. ROHs are genetic 
regions that contain a large number of homozygous SNVs with a very limited number of 
interrupting heterozygous variants. ROHs were identified in all three individuals using an adapted 
version of the previously suggested GWAS-based definition in PLINK [REF Purcell et al. 2007 AJHG]. 
Due to the close relation to GWAS, PLINK uses only few SNVs compared to the much denser set of 
NGS-inferred variants that increases the chance that a heterozygous variant might interrupt the 
homozygous stretch. To strike a balance between very few ROHs, due to a long sliding window, 
and too many ROHs, due to a small sliding window, a sliding window of 250 kb (instead of 1000 kb) 
was used with 1) at least 50 SNVs, 2) at most one heterozygous SNV, 3) at most five missing SNVs 
and 4) a proportion of overlapping homozygous windows of 0.05. A ROH was defined by 1) a 
minimum size of 50 kb, 2) containing at least 100 SNVs, 3) a density of 1 SNV/10 kb and 4) a 
maximum distance between SNVs of 50 kb. 
Finally, the overlap of ROHs with the 71 published CD risk loci1 was calculated, combining the 
length of ROHs overlapping any risk loci and dividing by the combined length of all ROHs detected. 
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3.14. Calculation of child’s CD risk relative to its parents 
Assuming small and independent contributions of known risk mutations to the probability of 
becoming affected with CD, it is possible to calculate the relative mutational load, or burden, of the 
child given the genotypes of the parents. Consider 1, …, n autosomal variants and let Xj,i denote the 
odds ratio conferred by the j-th pair of alleles at variant i present in the child. Assuming non-
preferential transmission of alleles, the expected logOR conferred by variant i in the child 
conditional on the parental alleles is the average of the four possible parental allele combinations 
E𝑋𝑖 =  �14 log𝑂𝑅𝑗,𝑖4
𝑗=1
 
with expected variance  
Var𝑋𝑖 =  �14 log2 𝑂𝑅𝑗,𝑖 − (E𝑋𝑖)24
𝑗=1
 
In accordance with the central-limit theorem, the sum of equally weighted standardized variant 
risk contributions in the child  
𝑍 = � log𝑋𝑖 − E𝑋𝑖
�𝑛Var𝑋𝑖
𝑛
𝑖=1
 
 
follows a standard normal distribution: Z ~ N(0,1). Evaluation of Z allows assessing the mutational 
load of the child relative to the parents.  
 
3.15. SNV verification by Sanger sequencing 
Polymerase-Chain-Reaction (PCR) was performed to amplify regions containing SNVs using the 
primers given in Supplementary table 4 and genomic DNA as input material. A second PCR was 
performed with the product of the first with separate reactions for the forward and reverse primer. 
The product of the second PCR has been sequenced using Sanger sequencing. 
 
3.16. Identification of sense/antisense pairs in transcriptomic data 
As currently no tool is publicly available to deal with strand-specific transcriptomic data sets from 
next-generation sequencing platforms in an automated way, I developed a tool (Janus) that allows 
the identification of sense/antisense pairs in this type of transcriptomic data sets. Janus is written in 
C/C++ and can be run under both Windows and Linux but requires a 64 bit environment. The 
workflow of Janus is shown in Figure 3. Janus expects a BAM file as input, and uses the reads to 
generate one wig file per chromosome and strand. A wig file contains the information on how 
many reads cover each base of the genome that can be used to assess the genomic coverage, e.g. 
for graphical representation. For further analysis, a transcript annotation file in gene transfer format 
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(GTF) is required. Janus is designed to convert an existing GTF file or the refGene.txt, which can be 
obtained by the table browser of the UCSC Genome Browser Website (http://genome.ucsc.edu/cgi-
bin/hgTables), into a merged GTF file that contains one entry per gene symbol, including the 
merged meta-exons of all transcript isoforms of the same gene. Although Janus can make use of 
commonly available gene annotations in GTF format, it is recommended running the built-in 
converter of Janus to improve the results. If the built-in converter is omitted, GTF-files might 
generate multiple, similar results for different isoforms of the same gene. 
 
Figure 3  Janus workflow. 
Input files are marked by circles and final analysis output in boxes shaded in grey. Janus generates wig files from a BAM file, 
which is the primary input. The wig files can be converted into bigwigs and are used to estimate the level of antisense noise and 
to detect transcriptionally active regions. To determine the location of an antisense event relative to other transcripts, Janus 
depends on a gene annotation file, which can be either a refGene.txt file or a GTF file. Finally Janus detects antisense events 
above the estimated background noise and annotates them using the gene annotation file. Optionally Janus can incorporate 
methylation data. Multiple lists of sense-antisense (S/AS) pairs can be compared with Janus to detect differentially expressed 
and equally co-expressed S/AS pairs. Additionally Janus includes the functionality to determine AS:S ratios in proximity of 
methylation sites, quantify the amount of antisense transcription in promoter and terminator regions and the ability to detect 
strand specific allelic imbalance. 
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Using the reference annotation, the level of ‘antisense-noise’ is calculated (Figure 4). I defined this 
noise as transcription on the opposite strand of known exons, which is a result of imperfect library 
generation and mismapping of reads. Often, transcription extends beyond the 3’-end of annotated 
transcripts. As this would bias the noise estimation in case of two adjacent transcripts in tail-to-tail 
orientation, exons within 1 kb of other exons on the opposite strand were excluded. The mean and 
standard deviation of the noise are calculated and reported in a detailed tab-delimited file for every 
investigated meta-exon. Additionally the average mean and standard deviation are reported in a 
stats file that also contains the total coverage of the sample. 
 
Figure 4 Estimation of antisense noise level. 
At first all exons which are located in the same strand are merged. Next all exons which within 1 kb range of another exon, 
which is located on the opposite strand, are discarded. For all remaining merged exons the antisense to sense ratio is 
calculated using the coverage contained in the wig files. Finally the mean and standard deviation of the ‘noise’ level is 
calculated. 
 
The wig files are used to identify transcriptional active regions (TARs) (Supplementary figure 1). 
Three criteria must be met for a TAR to be regarded as an antisense event. First, the TAR must have 
a minimum length (default = 51 bp) and minimum average coverage per base (default = 5). The 
coverage criterion uses unnormalized values, i.e. the raw mapped coverage for the identification of 
TARs. Second, on the strand opposite to the identified TAR, transcription must occur within a given 
distance (default = 10 kb). Third, each TAR requires an antisense- to sense-transcription ratio above 
the estimated noise level. Events that do not differ by more than 1.96 standard deviations (p-value 
<= 0.05) from the mean noise level are discarded. An antisense event is regarded as known if it is 
overlapping an exon on the same strand and novel otherwise. Each antisense event is classified 
depending on its location in relation to the sense event (Figure 5). 
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Figure 5 Antisense classes. 
Coverage is shown for the first strand (red) and second strand (blue). Regions showing coverage on both strands (S/AS pairs) 
are shown in lighter colors. 
 
Janus includes the functionality to compare antisense events of multiple samples to identify 
differences in gene expression that might affect only one strand or both strands equally. 
Supplementary figure 2A-C illustrates possible types of AS events, which show equally strong 
expression as the sense transcript and Supplementary figure 2D an S/AS pair with mutually 
exclusive expression of either the sense or antisense transcript. The workflow to identify potential 
self-regulatory S/AS pairs is shown in Figure 6. First, all overlapping antisense events are merged 
for all samples and expression values are calculated for each strand and sample. The expression 
values are normalized by event length and total genomic coverage before scoring. Two quality 
scores are incorporated in the scoring algorithm: the mean value of covered length to full event 
length (score1) and the number of samples which have a minimum coverage of 1 for the whole 
event (score4). For identification of differential expressed S/AS pairs two scores based on the AS:S 
ratio are used: the mean of the difference of the AS:S ratio from an equal distribution (1:1) and the 
distance between the minimum and maximum AS:S ratio. For the final score, the four sub-scores 
are weighted slightly in favor of the ratio-depending scores (2 and 3) as they are more important 
for detection of expression differences than the quality scores (1 and 4). Additionally a flag is 
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generated, which marks the more extreme cases, in which one sample shows an AS:S ratio below 
0.2 and another above 0.8 representing empirical borders determined from our training data set. 
 
Figure 6 Scoring algorithm for S/AS pairs. 
First the lists of antisense events detected in different samples are merged and overlapping events fused into single events. 
Sense-antisense ratios are calculated and expression values are normalized for total genomic coverage and event length. 
Antisense events are given scores for mutually exclusive expression. All scores, including the total score, are between 0 and 1. 
Score1 represents the fraction of the event which was covered. Score2 (0 to 1) marks the distance of the event’s S/AS ratio to an 
equal expression on both strands. Score3 calculates the maximum S/AS-ratio-distance between the sample with the lowest 
S/AS ratio to the sample with the highest S/AS ratio. Additionally a flag (either TRUE or FALSE) is generated, which tells the 
user if a sample with a very low and another with a very high S/AS ratio was detected. Score4 represents the fraction of samples 
which achieved a normalized coverage of at least 1. The total score weights all four scores in slight favor of the expression 
ratios that are more important for the detection of differentially expressed S/AS pairs than the quality scores 1 and 4. 
 
The chosen scoring algorithm was not designed to preferentially identify S/AS events exhibiting 
the exact same number of reads on both strands, as this will not commonly be the case in 
regulatory events. However, it is possible to filter for them using additional parameters which are 
also calculated during the scoring step for differential expressed S/AS pairs (Figure 7). Samples are 
grouped by their AS:S ratio for a given S/AS pair using a clustering threshold of 0.25 that was 
empirically identified in the testing data set. For an equally co-expressed S/AS pair only one group 
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should be present. Also, the similarity score, used in the calculation of differential S/AS pairs, is 
supposed to be low (0 indicates a AS:S expression ratio of 0.5) and the maximum difference of the 
highest and lowest AS:S ratio should be very low as well. For identification of equally co-expressed 
S/AS pairs the fold-change of overall expression of the S/AS transcripts between samples needs to 
be high. Janus generates a score for the co-expression by calculating the coefficients of variation 
for the forward and reverse strand expression and AS:S ratio. The score grows with higher 
expression dissimilarities between samples while maintaining a similar AS:S expression ratio. 
 
Figure 7 Calculations helping to identify S/AS pairs which are showing an equal expression (Co-expressed S/AS 
pairs). 
The Co-Expression score is a value for the dispersion of the coverage values in relation to the dispersion of the ratio. The value 
gets better/higher when the dispersion of coverage is high, while the dispersion of the ratio is low. 
 
Methylation data can be incorporated in the results (list of antisense events) by specifying a tab-
delimited file with methylation data. With this data, Janus can generate an additional file for the 
AS:S ratio in 100 bp, 500 bp, 2.5 kb and 10 kb range of the given site of methylation (Figure 8). 
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Figure 8 Estimation of sense and antisense expression near methylated CpG islands 
The sense and antisense expression ratios are calculated within different ranges (100, 500, 2500 and 10000 bp) to given 
locations of methylation sites. Changes of the sense to antisense expression ratio in either range bracket in proximity of 
methylation sites with a different degree of methylation could hint to a control mechanism of S/AS transcription by methylation. 
 
S/AS pairs that might derive exclusively from either homolog, i.e. one transcript is transcribed from 
the maternal chromosome while the antisense transcript is transcribed from the paternal 
chromosome, can be investigated based on a list of single nucleotide variants (SNVs) or without 
prior SNV information. VCF files can be processed, which results in tab-delimited files that are then 
used by Janus (see documentation for file formats). For all SNV positions located within detected 
S/AS events, Janus counts the number of reads for each allele, which might be evenly distributed 
on both strands or prefer one strand for the sense and antisense transcript each (Supplementary 
figure 3), and calculates a p-value based on Fisher’s exact test for a 2x2 contingency table (first, 
second strand and allele A, B). Only single nucleotide variants are considered for this analysis. Read 
counts for all SNV loci that show at least one allele, without requiring reads on both strands, will be 
reported and a warning will be displayed at the end of each entry if the ‘inferred’ (=dominant allele 
per strand) alleles differ from the alleles specified in the SNV file. This type of analysis can be used 
to identify genes where one haplotype is preferentially expressed, possibly in a strand-specific 
manner, which can be a sign of regulatory variation in cis. However, Janus was not specifically 
designed to detect monoallelic expression. Without a specified SNV list, Janus will investigate all 
positions covered by TARs and search for allele differences between the two strands. By this 
method, only loci which are covered by forward and reverse reads showing two distinct alleles will 
be reported and Fisher’s exact test will be applied using the dominant allele from each strand. 
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4. Results 
 
4.1. General mapping and variant calling statistics 
Five different genomic libraries and one transcriptome library from blood samples were sequenced 
per individual, with the addition of one transcriptome library of a colon biopsy of the child. A 
Robust detection of genetic variants is strongly dependent on a decent genomic coverage. For all 
three genomes an average coverage of 35 to 40x (for bases not designated N) was generated, 
which is comparable to the coverage attained by other whole genome sequencing studies (Table 2, 
Supplementary table 5-8).63,65,70 The genomes of all three individuals are almost completely 
(>99.85%) covered by at least one read and more than 84% by at least 20 reads. More than 48 
million reads (130 mio. total reads) were mapped per transcriptome library which is in the upper 
range of what many other studies using human samples generated and mapped.90–93 
 
Table 2 Per library numbers of generated sequences, mapped sequences and coverage depth across the 
genome. 
All individuals show a comparable number of generated sequences (>100 Gb) and >99.5% of the genomes are covered 
by at least one read. More than 80% are covered by 20x and more. Resulting in an average coverage per coverable base 
of 34 to 40x. 
generated sequences 
 lib_MP lib_PE1 lib_PE2 lib_PE3 lib_EXM lib_TRANS lib_TRANS2 
mother 920,348,453 939,401,482 930,584,259 1,046,748,964 205,889,144 131,457,938 - 
father 969,530,350 900,078,995 1,074,093,601 882,420,484 210,193,250 151,026,450 - 
son 891,794,740 908,963,316 901,806,883 1,258,255,210 200,649,856 127,103,413 149,329,469 
mapped sequences [N] 
mother 727,227,180 533,163,835 449,813,371 524,773,007 111,801,312 48,937,125 - 
father 709,232,320 548,006,777 668,768,996 535,440,522 119,306,238 65,126,226 - 
son 702,691,390 500,487,153 514,134,371 642,785,699 109,316,862 59,741,433 51,449,910 
mapped sequences [Gb] 
mother 36.3614 21.7825 17.7922 24.2766 5.0619 2.1965 - 
father 35.4616 22.1349 27.1026 23.7637 5.3737 2.8693 - 
son 35.1346 20.6031 21.0426 29.8446 4.9322 2.7352 2.2794 
total coverage across the genome (excluding Ns in the reference) 
 0x 1x 3x 10x 20x 
average coverage 
per coverable base  
mother 0.14% 99.86% 99.47% 96.49% 84.44% 35.59  
father 0.12% 99.88% 99.55% 97.34% 89.58% 40.28  
son 0.13% 99.87% 99.48% 96.51% 84.81% 36.57  
MP = mate-pair library; PE = paired-end library; EXM = exome library; TRANS = transcriptome library from blood, TRANS2 = transcriptome library from 
biopsy sample. 
 
The subsequent step was the identification of genetic variation in comparison to the putatively 
healthy reference genome (here hg18). More than 3.3 million single-nucleotide variants (SNVs) 
were identified per individual by the Bioscope SNV caller and the robustness of the calls was 
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assessed by comparison with a SNV chip, which achieved a concordance rate of >99% for SNVs 
called by Bioscope and >97% when including positions covered by the chip which did not result in 
a SNV call by Bioscope (Table 3, Supplementary table 9-10). More than 200k small structural 
variants were identified per individual (Table 3, Supplementary table 11), but only a small fraction is 
located within exonic regions, which is expected as these variants are likely to produce 
nonfunctional transcripts (frame-shift) or proteins. Both methods used for identification of large 
structural variants differed by a large margin and resulted in about 5,000 lSVs called by Bioscope 
and 15-113k lSVs called by the second method that was performed according to Korbel et al. 2009 
(Table 3, Supplementary table 12).86 Manual inspection of multiple lSVs showed that both 
approaches report a larger number of false positive lSVs, especially the zygosity did not seem to be 
correct in many cases. Thus for the following analysis the number of lSVs was reduced to large 
deletions with a minimum length of 3 kb which were called (at least overlapping) by both 
approaches (N=1185). These 1185 large deletions were manually inspected to further assess the 
most probable zygosity (Supplementary table 13). 
 
Table 3 Variant detection statistic. 
Gene associated SNVs include intronic SNVs and SNVs in gene neighborhood. Large structural variants were called using two 
different approaches. The first approach used the Bioscope Large InDel caller and the second approach is based on Korbel et 
al. 2009.86 The overlap of large deletions >= 3,000 bp between both approaches (1185 lSVs) was manually investigated. 
single nucleotide variants 
 mother father child 
SNP-type/location known novel known novel known novel 
rsID SNVs: 2,995,470 - 3,055,342 - 3,027,916 - 
novel SNVs: - 312,818 - 319,877 - 315,156 
gene associated SNVs: 1,173,779 112,517 1,199,115 113,088 1,194,183 112,535 
short structural variants 
SNP-type/location known novel known novel known novel 
total sSVs detected: 145,477 48,722 170,158 49,395 149,450 43,328 
no gene association: 88,918 31,585 104,652 32,332 91,224 28,300 
exonic: 196 83 213 81 212 68 
large structural variants 
 Bioscope Korbel Bioscope Korbel Bioscope Korbel 
Total lSVs detected: 5099 15892 5059 22763 4693 113104 
 
4.2. Verification of de novo SNVs using Sanger sequencing 
Potential rare variants with major contributions to CD are expected to be unique to the child and 
thus cannot be detected in the parents or other healthy, unrelated individuals. About 230k SNVs 
were identified in the child, that were not detected in the parents and about 300k SNVs per 
individual that are not included in the dbSNP build 130. More than 249k of SNVs detected in the 
child are not included in the SNV data of 60 individuals of the 1000 Genome Project (Figure 9 A+B). 
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Figure 9 Diagrams showing shared genetic variants between the family, dbSNP and the 1000 genome. 
A Venn diagram showing the overlap of the child’s SNVs with parents’ SNVs. The child shows about 230k SNVs that were not 
detected in the parents. B Venn diagram showing the overlap of child’s SNVs with dbSNP130 and 1000G SNVs. While most 
SNVs were also identified in the 1000G individuals or dbSNP about 250k SNVs remain that are yet novel. 
 
The SNVs unique to the child (potential de novo SNVs) were further investigated. More than 230k 
potential de novo SNVs (230k) were identified which exceeds the number of expected de novo SNVs 
by far. In humans, the mutation rate has been reported to be 3.0 x 10-8 mutations per nucleotide 
and generation.94 The human genome has about 3.0 x 109 million base pairs, which, in a diploid 
organism, is equivalent to 20 nucleotide exchanges per generation. Therefore, two algorithms (see 
methods) were applied to narrow the number of potential de novo SNVs. Both approaches did not 
result in convincing data for de novo SNVs in coding regions. Despite this, the overlap of weaker 
exonic de novo SNV candidates from both approaches was investigated (23 SNVs) and resequenced 
using Sanger sequencing. Additionally three SNVs with convincing data for a de novo variant were 
included that are located in noncoding regions (Table 4 and Supplementary table 14), and 
potential de novo SNVs in IKZF1 (Figure 10), CD19 (Figure 11), MST1 (Figure 12) and MUC2 that were 
called by only one algorithm.  None of the coding SNVs could be confirmed, but one de novo SNV 
in the UTR of NF1 (neurofibromin, Figure 13) and one intragenic SNV between SYT4 
(synaptotagmin) and SETBP1 (SET-binding protein 1). Two of the investigated loci proved to be 
false negative calls in one of the parents (MST1 and FAM190A), which could be due to low coverage 
in the respective region. No de novo variants in coding regions could be identified in the child. 
However, it is possible that a de novo mutation remained undetected by the SNV callers. 
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Figure 10 Sanger sequencing result of IKZF1 recessive SNV. 
All three individuals show the reference G allele in all sequencing reactions. 
 
 
 
Figure 11 Sanger sequencing result of CD19 novel SNV. 
All three individuals show the reference G allele in all sequencing reactions. 
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Figure 12 Sanger sequencing result for MST1 recessive SNV. 
The SNV was found heterozygous (supported by fw and rev reactions) in the mother and child (only rev. primer reaction) and 
homozygous for the reference allele in the father (only rev. primer reaction). Thus this SNV can be excluded as recessive SNV. 
 
 
 
Figure 13 Sanger sequencing result for NF1 de novo SNV 
The SNV was not detected in the parents, but heterozygous in the child. The SNV is located in the UTR and thus its function, if 
any, remains unclear. 
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Table 4 Verification of de novo SNVs using Sanger sequencing. 
Two non-coding SNVs were verified (NF1 UTR, SYT4-SETBP1 intergenic). Two SNVs (FAM190A and MST1) were detected to 
be heterozygous in one of the parents and thus represent false negative SNV calls.  All remaining potential de novo SNVs show 
the reference allele and present false positive SNV calls.  
gene Sanger result gene Sanger result gene Sanger result 
FAM190A (intron)  (parent het) MST1  (parent het) IL18BP  
SYT4-SETBP1 (intergenic)  PAK6  RASA3  
NF1 (UTR/exon)  CD19  IKZF1  
AURKAIP1  KIAA1522  IRF5  
FUT4  MUC2  KLC3  
PNKP  WNT9B  MMP9  
KCNAB1  LDOC1L  OGFOD2  
HCN4  ITGAV  NOS3  
C19orf6  SPZ1  NUMB  
 
4.3 Geographic origin determination based on genetic variants 
As has been exemplified by NOD2 as an ethnic specific CD risk gene, it is important to investigate 
the ethnic background of individuals used in genome analysis to assess the involvement of known 
risk factors. Principal component analysis of called SNVs positioned the trio closest to the European 
population (Figure 14). This data is further supported by mitochondrial variation (analysis was 
performed according to Röhl et al. 2001),95 positioning the family in Eastern Europe 
(Supplementary figure 4).  
 
Figure 14 SNV-based principal component analysis (PCA) of the family trio with 11 HapMap populations. 
Individuals of African origin (left side), Asian origin (right side) and European origin (upper- right side) form distinct clusters. The 
family trio (red) is located close to other European populations. 
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4.4. Genetic variants in genes associated with monogenic phenocopies of Crohn’s disease  
Multiple diseases are known to cause a Crohn’s disease like phenotype but are based on a very 
limited number of genes as would be expected for Mendelian diseases. To investigate whether the 
child suffers from one of these phenocopies the corresponding genes were screened for genetic 
variants (Table 5, Supplementary tables 15-18). 
 
Table 5 Genetic variation in genes of monogenic disorders phenocopying Crohn’s disease. 
No genetic variants with known association to disease phenotypes have been identified in the child. Several of the disease 
genes did not show any variant (WAS, X-linked Agammaglobulinemia, IPEX, Hyper-IgM syndrome, C1 esterase inhibitor 
deficiency). Some not disease associated variants were identified in genes for the remaining monogenic phenocopies of CD. All 
but one of them are included in dbSNP130. The novel SNV was not verified by Sanger sequencing. 
disease impaired function / associated genes identified coding variants (SNVs, sSVs, lSVs) and additional information 
GLOBAL LYMPHOCYTE DYSFUNCTION 
Wiskott–Aldrich 
Syndrome 
The etiology is mutation of WASP, which encodes a signal 
transduction protein between transmembrane receptors and the 
actin cytoskeleton in hematopoietic-derived cells, resulting in 
multiple leukocyte deficits. 
- no variants in WASP gene 
Common Variable 
Immunodeficiency 
(CVID) 
Decrease of at least two of IgA, IgM and IgG along with impaired 
antibody production following immunization, and propensity to 
infection (Mutations in ICOS, CD19, TNFRSF13B/TACI, 
TNFRSF13C/BAFFR). 
- nonassociated SNVs detected in 
CD19 and TNFRSF13B: 
o two CD19 SNVs: rs2904880 
and one novel SNV 
o three TNFRSF13B SNVs 
detected: rs11078355, 
rs34562254, rs8072293 
- Sanger sequencing of novel CD19 
SNV negative 
X-linked 
Agammaglobulinemia 
Absence of B cells and concomitant inability to produce antibody 
(Mutations in BTK). 
- no variants in BTK detected 
- child has no agammaglobulinemia 
T-CELL DYSFUNCTION 
Immune 
Dysregulation, 
Polyendocrinopathy, 
Enteropathy, X-linked 
Syndrome (IPEX) 
T-Lymphocytes escape apoptosis and proliferate in an uncontrolled 
manner. 
(X-linked, caused by mutations in FOXP3). 
- no variants in FOXP3 
Hyper-IgM syndrome 
Patients possess normal to high concentrations of serum IgM, but 
markedly diminished IgG, IgE and IgA 
(X-linked, caused by mutations in CD40LG). 
- no variants in CD40LG 
COMPLEMENT DYSFUNCTION 
C1 esterase inhibitor 
deficiency 
A Series of patients developed small bowel enteritis. C1 esterase 
inhibitor deficiency is usually associated with hereditary angioedema 
(Mutations in SERPING1). 
- no variants in SERPING1 
DEFECTS IN INNATE IMMUNITY 
Blau syndrome 
Mutations in nucleotide binding site of NOD2/CARD15, possibly 
disrupting interactions with LPSs and NF-kB signaling (Mutations in 
NOD2). 
- nonassociated SNVs detected in 
NOD2 
o three SNVs in NOD2 detected: 
rs2066842, rs2066843, 
rs2066845. 
- no insertions or deletions in coding 
regions of target genes detected 
Chronic 
granulomatous 
disease (CGD) 
Impaired killing (faulty O2- production) (Mutations in CYBA/p22phox, 
NCF1/p47phox, NCF2/p67phox). 
- nonassociated SNVs: 
o two coding CYBA SNVs 
detected: rs4673, rs8053867 
o one coding NCF1 SNV detected: 
rs62475423 
o two coding NCF2 SNVs 
detected: rs17849501, 
rs2274064 
- NBT-test CGD negative 
CROHN’S DISEASE LIKE MONOGENIC SYNDROMES 
IL10Ra, IL10Rb, IL10  
- nonassociated SNVs: 
o two SNVs in IL10RA detected: 
rs2229113, rs2256111 
XIAP/BIRC4  
- nonassociated SNVs: 
o one SNV in XIAP detected: 
rs5956583 
- gene has been Sanger sequenced 
without finding.  
 
No variants were observed in BTK (X-linked agammaglobulinemia), FOXP3, (Immune Dysregulation, 
Polyendocrinopathy Enteropathy, X-linked Syndrome (IPEX)), WAS (Wiskott–Aldrich Syndrome), 
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CD40LG (Hyper-IgM syndrome) or SERPING1 (C1 esterase inhibitor deficiency), hence these diseases 
were excluded. Common Variable Immunodeficiency (CVID) was excluded as no causative variants 
could be identified, however TNFRSF13B showed three SNVs, two synonymous (rs11078355, 
rs8072293) and one missense SNV (rs34562254) that affects a conserved nucleotide and is not 
known to be associated with CVID. The two prediction tools are discordant considering the impact 
of the SNV, SIFT predicted it to be tolerated while PolyPhen predicted it to be probably damaging. 
No variants were found in ICOS or TNFRSF13C, but CD19 showed one known (rs2904880) and one 
novel SNV following the recessive model. The known SNV has not been described as pathogenic 
and was predicted to be benign by both SNV prediction tools (SIFT and PolyPhen). The novel SNV 
was sequenced using Sanger sequencing and identified as false positive SNV (Figure 11). NOD2 was 
screened for variants that are known to cause Blau Syndrome. Three SNVs were detected, but none 
of them is associated with Blau Syndrome. One of the SNVs was synonymous (rs2066843) while the 
other two are missense SNVs (rs2066842, rs2066845). The SNV rs2066842 is not described as 
pathogenic, while rs2066845 is associated with an increased susceptibility to Crohn’s disease.96 
Several SNVs were identified in the genes responsible for chronic granulomatous disease (CGD) 
(CYBA, NCF1 and NCF2). The gene for CYBA shows two SNVs (rs8053867, rs4673), whereas the first is 
synonymous and the second a missense SNV that is reported as CYBA polymorphism without 
known pathogenic associations. One missense SNV in NCF1 (rs62475423) was detected that is not 
described as pathogenic but has been marked as *suspected* in the dbSNP database, as it might 
be a sequencing artifact. One synonymous SNV (rs17849501) and one nonsynonymous SNV 
(rs2274064) were detected in NCF2. rs2274064 is located in a site of acceleration and is not 
described as pathogenic nor predicted to be damaging. No known pathogenic variants were 
identified for CD-like monogenic syndromes involving IL10 or XIAP. Two coding SNVs were 
identified in IL10RA. The first SNV (rs2256111) is synonymous and the second a missense SNV 
(rs2229113) predicted to be tolerated that has not been associated with disease. XIAP shows one 
coding SNV (rs5956583) that is not known to be pathogenic and that has been predicted by both, 
SIFT and PolyPhen, to be tolerated. The whole XIAP gene was sequenced using Sanger sequencing 
and no SNV could be confirmed. Thus none of the investigated monogenic syndromes is likely 
responsible for the child’s phenotype. 
 
4.5. Genetic variants with known CD-association and other variants in the associated genes. 
Known risk variants for Crohn’s disease might be overrepresented in the child, compared to the 
healthy parents. To investigate this, CD associated risk variants reported by GWAS studies were 
identified in the child. Of 71 known CD risk loci12 25 were homozygous for the risk-allele in the 
child, 20 heterozygous and 26 homozygous for the non-risk allele (Table 6). These numbers are 
comparable to the parents, who showed 18 and 25 homozygous and 25 and 22 heterozygous loci. 
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Table 6 Zygosity of the 71 meta-analysis Crohn’s disease risk SNVs for the risk-allele. 
Both, father and child carry 25 SVNs homozygous for the risk allele, while the mother has slightly less (18). Instead the mother 
has few more SNVs heterozygous for the risk allele than the father (22) and child (20). No major differences concerning the 
known CD risk loci can be observed in the family trio. 
 homozygous for risk allele heterozygous homozygous for non-risk allele 
mother 18 25 28 
father 25 22 24 
son 25 20 26 
 
For all three individuals, for the Watson and Venter genomes and for 60 individuals of the 1000 
Genome Project the combined risk for the 71 CD risk loci from meta-analysis was calculated (Figure 
15). The combined risk calculated for the trio does not exceed the combined risk of other 
individuals. In the trio, the father shows the highest combined risk, located at the lower end of the 
upper third of individuals showing the highest combined risk. The son is located in the middle and 
the mother in the upper end of the lower third. 
 
Figure 15 Contribution of known CD risk loci to overall risk in comparison with other genomes. 
Combined CD risk of the family trio compared to 60 individuals from the 1000 Genome Project and the Watson and Venter 
genomes. The family trio does not show major differences in the combined risk than the other genomes. The child’s risk lies 
within its mother’s and father’s risk. 
 
Assuming independent and additive contributions of the known risk alleles at the 71 CD risk loci 
Gaussian approximation was used to investigate whether the child received a higher CD burden 
than would be expected by chance (Figure 16, see methods). No significant enrichment of CD 
variants could be detected in the genome of the child. 
47 
 
 
Figure 16 Gaussian approximation assuming independent and additive contributions of the various risk alleles at the 
71 known CD-risk loci. 
The black line represents the normal distribution for all genotypes possible determined by the parents’ genomes. The child’s 
combined risk is shown in red. It does not exhibit an unusual high inherited burden of known CD risk loci and received only 
slightly more known risk loci than expected, which are more than in the mother (shown in light grey) and fewer than in the father 
(shown in dark grey). 
 
A larger number of genetic variants were detected within genes in the proximity of the known CD 
risk loci (Supplementary table 19-25). Three of these SNVs (in IKZF1, CD19 and MST1) were already 
mentioned in the section dedicated to de novo variants and excluded as causative variants. One 
known CD risk conferring variant was detected in NOD2. Several additional variant were identified 
in the genes associated with CD risk loci. This includes a nonsense variant in the fucosyltransferase-
2 gene (FUT2) that has been detected and verified in both, father and child (Figure 17). Sanger 
sequencing of the FUT2 nonsense variant also revealed an additional missense SNV in the FUT2 
gene, which was again detected in the father and child only. 
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Figure 17 Sanger sequencing result of FUT2 nonsense SNV. 
A The nonsense mutation could be confirmed and was detected heterozygous in the father and child and homozygous 
reference in the mother. B A second variant (missense) was identified in FUT2, which is heterozygous in both, father and child 
and homozygous reference in the mother. 
 
Another SNV (rs11549656, P200L) affecting a conserved nucleotide was detected in the glutathione 
peroxidase gene GPX1. Also a variant was indentified in the glucokinase regulatory protein (GCKR, 
rs1260326), that introduces a new proline. This variant has been strongly associated with lower 
A 
B 
A B 
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fasting glucose levels and fasting insulin levels and higher triglyceride levels that reduces type II 
diabetes risk in the French population.97 Only one SNV that has been predicted to be damaging 
and follows the recessive model was identified. The SNV is located in a site of high acceleration in 
SNAPC4 (small nuclear RNA-activating protein complex). Two small structural variants (sSVs) were 
observed. The first sSV is a 2-bp deletion in a member of the tumor necrosis factor superfamily 
(TNFSF18) that was not predicted to cause nonsense mediated decay, and was detected 
homozygous in the mother and child. The second sSV is a 1-basepair insertion in proximity of a 
splice-site in DENND1B (DENN/MADD domain-containing protein 1B) (Supplementary table 25). 
The variant was detected hemizygous in the father and child. 
Regions (or runs) of homozygosity (ROHs) are long stretches without heterozygosity in the diploid 
state. Multiple studies have identified ROHs associated with other complex traits, such as 
schizophrenia and late onset of Alzheimer’s disease and there is evidence that ROHs can be used to 
uncover hidden recessive variants in complex disease. This has been proven to be particular useful 
in investigating autosomal recessive disorders in populations with a high prevalence of 
consanguinity. Additionally, larger differences in ROHs could be shown between cases and controls 
in various studies.98 Here, the previously suggested GWAS-based definition in PLINK was adapted 
for identification of ROHs in all three individuals. The overlap of ROHs with the 71 published CD risk 
loci12 was calculated by combining the length of ROHs overlapping any risk loci and dividing by the 
combined length of all ROHs detected. Using a variant-density adapted definition, a comparable 
numbers of ROHs was detected in each of the three genomes covering similar proportions of the 
genome (Figure 18). 
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Figure 18 Regions of homozygosity identified in the family trio using a variant-density adapted definition. 
The child’s genome contains 2,220 ROHs (mother: 2,267; father: 2,108) which cover about 222.3 Mb (mother: 234.8 Mb; father: 
201.9 Mb). ROHs unique to the child cover 164.6 Mb in total. 
 
The child’s genome contained 2,220 ROHs (mother: 2,267; father: 2,108) that covered about 222.3 
Mb (mother: 234.8 Mb; father: 201.9 Mb). ROHs unique to the child cover 164.6 Mb in total. These 
unique ROHs covered CD-associated genes such as NOD2 (Figure 19), IL18R1 and ORMDL3 (Table 7). 
 
Figure 19 Example of a region of homozygosity in the child. 
The region of homozygosity was only detected in the child (dot, green) and overlaps NOD2. 
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Table 7 Regions of homozygosity overlapping Crohn’s disease associated genes. 
A substantial number of ROHs are overlapping genes in regions associated with CD risk. The number of genes completely contained within ROHs is higher in the child (17) compared to the 
parents (11 and 10), while the number of genes partially inside ROHs is highest in the father (9) and equal in the mother and child (6). In summary, the child has more potential CD risk genes in 
ROHs than its parents. 
 RoH overlap with gene  RoH overlap with gene  RoH overlap with gene 
gene mother father child gene mother father child gene mother father child 
APOB48R - - - ICAM1 - - - PRDM1 - - - 
ATG16L1 complete - - ICAM3 - - - PRDX5 - - complete 
BACH2 - - - ICOSLG - complete - PTGER4 - - - 
BSN - - - IKZF1 - - - PTPN2 - partial (50%?) - 
C11orf30 - - - IKZF3 - partial (80%?) partial (90%?) PTPN22 - - - 
C13orf31 - - - IL10 - - - RASIP1 - - - 
C1orf106 - - partial (90%?) IL12B complete complete - REL - - - 
C2orf74 - - - IL18R1 partial(90%?) - complete RTEL1 - - - 
SLC22A23 - - - IL18RAP partial (90%?) - complete SBNO2 - - - 
CARD9 - - - IL19 - - - SCAMP3 complete complete - 
CCL11 - - complete IL1RL1 complete - complete SH2B1 - - - 
CCL2 - - - IL23R - partial (90%?) - SLC22A4 complete - - 
CCL7 - - complete IL27 - - - SLC22A5 complete - - 
CCL8 - - complete IL2RA - - - SMAD3 - - - 
CCR6 - - - IL3 - - - SNAPC4 - - - 
CD19 - - - IRF1 - complete - SP140 - - - 
CD244 partial (90%?) - - IRGM - - - STAT3 partial (40%?) - - 
CDKAL1 partial (10%?) - - ITLN1 - - - TAGAP - - - 
CPEB4 complete complete - JAK2 - - - THADA - partial (50%?) - 
CREM - - - KIF21B - - - TMEM174 - - - 
CSF2 - - - LRRK2 - partial (10%?) partial (9%?) TNF - - - 
DENND1B - - - LST1 - - - TNFSF11 - complete - 
DNMT3A - - - LTA - - - TNFSF15 - partial (20%?) - 
EIF3C - - - LTB - - - TNFSF18 - - - 
ERAP2 - partial (90%?) - TAB1 - complete - TNFSF4 - - - 
ESRRA - - complete MCCD1 - - - TNFSF8 - complete complete 
FADS1 - - - MLX - - - TYK2 - - - 
FASLG - - - MST1 - - - UBE2D1 - - - 
FUT2 - - - MTMR3 - - - VAMP3 - - - 
GALC complete - complete MUC1 - complete - YDJC - - - 
GCKR - - - NCR3 - - - ZFP36L1 complete - complete 
GPR65 complete - complete NDFIP1 - - complete ZMIZ1 - - - 
GPX1 - - - NKX2-3 complete - complete ZNF365 - - - 
GPX4 - - - NOD2 - - partial (20%?) ZPBP2 - partial (10%?) complete 
GSDMB - - complete ORMDL3 - - complete MUC19 - complete partial (80%?) 
HLA-DQA2 - - - PLCL1 - - - NELL1 partial (10%?) partial (10%?) partial (9%?) 
total no 
overlap 92 90 86 
total complete 
overlap 11 10 17 
total partial 
overlap 6 9 6 
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As there could be an over-representation of known CD risk loci in ROHs detected in the child in 
comparison with putative healthy individuals, the overlap of ROHs with CD risk loci was calculated 
for ROHs detected in 60 CEU individuals of the 1000 Genome Project using the same criteria for 
ROHs. The size of the overlapping regions of the family trio was compared to the overlap of the 60 
1000 Genome individuals (Figure 20).  No significant differences can be observed between the data 
sets. 
 
Figure 20 Overlap of regions of homozygosity with GWAS annotated CD risk regions of the family trio in with 
unrelated individuals. 
Regions of homozygosity (ROHs) for 60 individuals of the 1000 Genome Project were detected with the same definition of a 
ROH as has been done for the family trio. Compared to the unrelated individuals the family trio does not show any major 
differences in the ROH distribution concerning CD risk regions. The child (shown in red) does not have a higher proportion of 
ROHs in CD risk regions than its parents. 
 
 
4.6. Genetic variants in genes associated with other inflammatory diseases 
Many risk genes associated with inflammatory traits are shared between multiple diseases. 
Therefore it is possible that genetic variants in genes involved in other inflammatory diseases could 
contribute to the child’s phenotype. Based on the GWAS catalog, risk loci and genes associated 
with the following diseases were investigated: ankylosing spondylitis, asthma, celiac disease, 
inflammatory bowel disease (IBD, which is a distinct entry to ulcerative colitis and CD in the GWAS 
catalog), leprosy, multiple sclerosis (MS), psoriasis, rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), type 1 diabetes and ulcerative colitis (UC). Genetic variants identified in the 
associated genes are reported in Supplementary table 26-32. Nine genes carry variants in 
conserved regions and five of them were predicted to be damaging by both applied prediction 
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tools (NOD2, MST1 (already excluded by Sanger sequencing), ITGAX, IRF5 and ERBB3). Four of the 
detected variants are not included in dbSNP130 (FRMD4B, IRF5, KIAA1109 and LRRK2) and might 
represent novel, rare variants. Five large SVs were identified in proximity of the investigated 
inflammatory genes, with only one SV involving the coding region of the growth hormone 
receptor (GHR). The genetic variants affecting genes involved in other inflammatory diseases could 
hint towards shared inflammation associated risk factors that could be involved in the 
pathogenesis of the presented case study. 
 
4.7. SNVs predicted to be damaging including all genes 
Disease causing variants could occur in genes that have not been linked to the pathogenesis of 
inflammatory disease yet. Hence it is important to screen for genetic variants in all genes, 
independent on their described function. As this leads to a vast number of variants, further filtering 
is required. Here, the focus was put on potential damaging variants that contribute to compound 
heterozygosity, follow the recessive model of inheritance or are located in sites of high 
conservation. Among the SNVs following the recessive model, only 15 were identified in sites of 
conservation (Supplementary table 33). Ten of them show minor allele frequencies >0.2 (BRWD1, 
C2orf73, GBE1, GOLGA4, LOXL4, NOM1, OBSL1, both SNVs in PCDHA1 and PSDM9). The remaining five 
were detected in PCDHB7, MPHOSPH8, KRT76, KCNJ12 and BEST2. Besides MPHOSPH8 and BEST2 all 
SNVs are included in dbSNP130. The BEST2 SNV has been verified by Sanger sequencing 
(Figure 21). 
 
 
Figure 21 Verification of BEST2 SNV by Sanger sequencing. 
Both parents show a heterozygous genotype (A/G) while the child is homozygous for the alternative allele A. 
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Expression of BEST2 could only be detected in the colon biopsy of the child, but not in the blood of 
any individual of the trio, while MPHOSPH8 expression was detected in all samples (Supplementary 
table 34). Additionally the occurrence of the BEST2 variant in the 1000 Genomes data set (1092 
samples, Oct. 2011 release) was assessed. Only 84 individuals heterozygous for the variant and four 
homozygous individuals were identified, suggesting a very low allele frequency across the 
investigated human ethnicities. Encouraged by the low occurrence in the general population, the 
SNV was genotyped in large cohorts of Crohn’s disease and ulcerative colitis patients that did not 
confirm the potential association of this SNV with disease risk (Table 8 and Table 9). 
 
Table 8 Plink Allelic Association Test with confidence interval and case/control-only. 
No significant p-value was detected for an association of the BEST2 SNV with CD or UC. The odds ratio (OR) is only slightly 
higher (1.037) than for neutral risk association (1). A1 minor allele, A2; major allele; F_A frequency in cases; F_U frequency in 
controls; SE standard error; L95/U95 lower and upper bound of 95% confidence interval for odds ratio. 
trait CHR SNP BP A1 F_A F_U A2 CHISQ P OR SE L95 U95 
Crohn's 
Disease 19 
BEST2 
R8Q 12863429 2 0.07873 0.07616 1 0.1168 0.7325 1.037 0.1053 0.8433 1.274 
Ulcerative 
Colitis 19 
BEST2 
R8Q 12863429 2 0.06671 0.07601 1 1.312 0.2520 0.8689 0.1227 0.6832 1.105 
allele 1 = G, allele 2 = A 
 
 
Table 9 Plink Hardy-Weinberg calculation. 
No significant differences concerning the observed heterozygosity between the cases and controls were detected. A1 minor 
allele; A2 major allele; GENO genotype; O(HET) observed heterozygosity, E(HET) expected heterozygosity. The number of 
individuals homozygous for this variant is generally very low (10 of 2537 = 0.39%), but indifferent between cases (0.38%) and 
controls (0.41%). 
CHR SNP TEST A1 A2 GENO* O(HET) E(HET) P 
19 BEST2_R8Q ALL 2 1 10/370/2157 0.1458 0.1419 0.2062 
19 BEST2_R8Q AFF 2 1 4/159/903 0.1492 0.1444 0.3944 
19 BEST2_R8Q UNAFF 2 1 6/211/1251 0.1437 0.1404 0.4577 
*Genotype counts: 11/12/22 
 
Several genes show SNVs that possibly contribute to compound heterozygosity, whereas only few 
of these SNVs include at least one SNV that was predicted to be damaging (Supplementary table 
35) or were not predicted at all. The HLA-A gene and three mucin genes (MUC2, MUC4 and MUC16) 
carry at least one SNV predicted to be damaging from either mother or father and additional SNVs 
from the other parent. For the remaining genes with compound heterozygosity only few have 
known functions (Supplementary table 36). Multiple genes that are likely involved in immune 
system processes were identified by screening for genetic variants in conserved exonic sites 
(Supplementary tables 37-40). Three large deletions were identified that probably follow the 
recessive model of inheritance affecting exons of SPINK5L2/SPINK14, GUCY2GP and CCDC135 
(Supplementary table 13). The SPINK5L2 deletion is shown in Figure 22 and nicely demonstrates the 
loss of exon three in the child’s genome, while the parents both still have the respective region, at 
55 
 
least in a hemizygous state. The data is supported by all sequenced libraries, which is a strong 
proof for the existence of this variant.  
 
 
Figure 22 Large deletion affecting the SPINK5L2 exon 3. 
The deletion occurs homozygous in the child (dot) and is either hemizygous in the parents (recessive model of inheritance) or 
de novo in the child. All five libraries (the exome library, long mate-pair library (MP), and the three paired-end (PE) libraries) in 
the child support the loss of the third exon. 
 
4.8. Identification of mutational hotspots 
In an approach to identify mutational hotspots in the genomes of the family trio compared to 60 
individuals of the 1000 Genome Project the number of SNVs in a given region for all individuals was 
plotted (Figure 23). The SNV density is reflected by a color gradient (red = high SNV density, blue = 
low SNV density). 
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Figure 23 SNV density plot for 60 individuals (top 60 lines) from the 1000 Genome Project and the family trio (lowest 
three lines). 
Mutational hotspots carrying many SNVs are shown in red, while regions with few SNVs are shown in blue. No obvious 
differences between the family trio and the 60 individuals are visible, except for the regions adjacent to the centromer and other 
repeat rich regions, which are probably caused by mapping problems. Multiple locations involved in immune processes can be 
identified as red spots (arrows). These locations include the highly polymorphic HLA region on chr6, a defensin containing 
region at the beginning of chr8 and a lectin containing region in chr12p. The black lines above the density plot for each 
chromosome represent CD risk regions identified by GWAS. A high resolution PDF file is digitally available on the 
accompanying CD (compact-disc). 
 
Several known mutational hotspots could be identified using this approach, i.e. the MHC regions 
on chromosome 6, a defensin containing region on chromosome 8 and a lectin containing region 
on chromosome 12. However, no mutational hotspots unique to the trio could be identified, 
except for highly repetitive regions (i.e. the centromers) that are probably subject to problematic 
mapping. 
 
4.9. Pathway analysis of genes affected by missense variants in the child 
All genes with missense SNVs were filtered by the gene ontology term “immune system process” 
and used as input for a functional protein network generated with STRING (http://string-db.org/) 
(Figure 24). 
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Figure 24 String network of identified missense SNVs in the child which are contained in the gene ontology term “immune system process”. 
SNVs predicted to be damaging are shown in red and brackets. Recessive SNVs are marked with green boxes and SNVs shared with either parent in grey boxes. Only links by co-expression, 
experiments, data bases and homology were allowed, but not data mining, gene fusions and neighborhood. Ten white nodes (not included in the missense SNV list) were added for a better network. A 
high resolution copy of this picture is digitally available on the accompanying CD (compact-disc). 
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While many genes remained without connection, several clusters in antigen recognition and 
processing (HLA genes, MHC class I and II), proteasome function (PSMB9), innate immune 
responses to virus infections (2-prime,5-prime oligoadenylate synthetases (OAS) genes), DNA 
repair (XRCC5, MSH3, MSH6, MLH1, EXO1), chemokines (CCL22, CCL23, CX3CR1, CX3CL1), 
complement system (C5AR1, C5, C7, C8A; CFI, CFHR1, CFH; CR1, CR2), NADPH oxidase complex 
(CYBA, NCF1, NCF2) and pattern recognition and signaling associated pathways (NOD2, TLR3, NLRX1, 
IL1RL1, TNFRSF11A, TNFRSF13B, IRAK1, IRAK2, IRAK3, IKBKAP, CHUK) were identified. Only few genes 
carry putative recessive SNVs (HLA-DPB1 (potential damaging SNV), HLA-C, HDAC5, TLR6, TLR10, 
TNFRSF1B, POLL (potential damaging SNV), CYBA (potential damaging SNV) and NLRX1. The number 
of non-recessive SNVs predicted to be damaging is much higher and these SNVs affect all above 
mentioned clusters, except PSMB9 and the OAS genes. 
 
4.10. Expression changes in the child compared to the parents and genetic variants in the 
respective genes. 
The transcriptomes of all three family members were analyzed to identify differentially expressed 
genes. Expression levels were determined with the widely used Cufflinks software89 that are then 
reported as fragments per kilobase of exon model per million mapped fragments (FPKM). In a 
filtering step, genes were identified that show a 5-fold up- or downregulation in the child 
compared to the parents, leading to 75 upregulated and 12 downregulated genes. Among these 
are many genes involved in inflammation, i.e. several genes are associated with immune cell 
function and development (CD177, C19orf59, ARG1, CST7, TNFSF13B, IL4), and with pattern 
recognition and associated downstream signaling (CLEC4D, HMGB2, TLR5, NLRC4, IRAK3, CR1) 
(Supplementary table 41). Comparing regulated transcripts with genetic data, only a very limited 
number of genetic variants was observed in these genes, i.e. in IL4R and MMP9 (Supplementary 
table 42). Yet, no obvious regulatory variant was detected that would functionally link expression 
differences with genetic variation. 
 
4.11. Strand specific transcriptome analysis 
Extending the transcriptome work done in the trio, a method for assessing sense/anti-sense 
transcription events was developed that allows integrating transcriptomic data with genetic and 
epigenetic information. As a benchmarking data set the expression of closely occurring 
sense/antisense (S/AS) transcript pairs was investigated in transcriptomes derived from 
lymphoblastoid (LBL) cell lines of putative healthy individuals (five individuals of the 1000 Genome 
project),99 three classical Hodgkin lymphoma (cHL) cell lines (kindly provided by Ohle Ammerpohl 
and Reinert Siebert)100 and transcriptomes of murine small intestine and colon which were 
generated in duplicates.101 As no tool is publically available to assess S/AS transcription on the 
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genome-wide level using next generation sequencing technologies and S/AS expression may 
represent an important regulatory mechanism that may determine transcript levels beyond cis-
linked transcription factor binding motifs I developed Janus to fill this gap. Janus was applied to the 
transcriptomes mentioned above to demonstrate its use in detection of S/AS pairs in general and 
identification of differentially expressed S/AS pairs. Data for five LBL cell lines was generated using 
two different technologies (SOLiD whole transcriptome analysis kit (WTAK)101 and Illumina GA IIx 
(kindly provided by Ralf Sudbrak and Hans Lehrach).102 Prior identification of S/AS pairs, 
comparison of the performance of both technologies revealed a higher background noise in the 
Illumina data, which manifests as expression in ‘exonic’ regions on the strand opposite to the 
template strand (the “antisense” strand). An example is given in Figure 25A, where the expression 
of FLNA (second strand) generates an echo on the opposite (first) strand in the Illumina data. The 
exon-intron structure is preserved on the first strand, which is highly unlikely, given conserved 
splice-site associated motifs. The SOLiD data on the contrary shows almost no expression on the 
first strand. Therefore, the noise level was investigated in all exonic regions by calculating the mean 
and standard deviation of AS noise across exons (Figure 25B and C). 
 
Figure 25 Antisense noise-level estimation. 
A Expression shown for the same transcript with Illumina data (top) and solid data (bottom). First strand expression is shown in 
light blue and second strand expression in dark blue and the transcript (FLNA) is located on the second strand. Other than the 
Illumina data, SOLiD data shows almost no expression on the first strand. The Illumina coverage on the first strand shows the 
same exon-intron pattern as the expression of the second (sense) strand. B Plotted mean and standard deviation for individual 
GM07347, the solid data shows a smaller mean and std. dev. than the Illumina data. C Mean and standard deviation of noise 
level calculation for SOLiD and Illumina GA IIx data in numbers for all five LBL cell lines. In the SOLID data, about 0.7 to 1.6% 
of coverage in exonic elements considered for noise calculation is located on the antisense strand whereas this contributes to 
5.0 to 6.5% of coverage in the Illumina Data. 
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Previous publications mention a high abundance of antisense tags in both the promoter and 
terminator regions of genes.78,103,104 Therefore, the occurrence of antisense transcription was 
investigated in promoter and terminator regions, here defined as 1 kb before and after the 
transcript start and end site. Using cutoff criteria of a minimum length of 150 bp and a mean 
coverage per base of five for the antisense transcripts, antisense expression was identified in 740 
promoter and 980 terminator regions in the cHL (hg18 mapped data, 32.110 annotated transcripts) 
and 2100 promoter and 2400 terminator regions in the LBL data set (hg19 mapped data, 66.065 
annotated transcripts) (Table 10). 
 
Table 10 Number of antisense events in promoter and terminator regions. 
Promoter and terminator regions were defined as 1 kb before and after transcription start and end site. Valid antisense events 
required a minimum length of 150 bp and a minimum coverage per base of 5. The number of AS events is slightly higher in 
terminator regions and the hg19 gene annotation (LBL cell lines) yielded more events than the hg18 gene annotation used for 
the cHL cell lines. 
Sample AS events in promoter AS events in terminator 
GM11894 2726 1981 
GM07374 1794 2461 
GM12489 1812 2411 
GM12045 2312 2767 
GM11919 1812 2352 
KM-H2 614 894 
L-1236 1083 1215 
U-H01 586 823 
 
When considering antisense events with low coverage in the promoter and terminator regions, the 
amount of antisense tags in promoter regions is higher than in terminator regions, while this shifts 
towards more antisense tags in terminator regions when considering only higher covered 
antisense events (Figure 26). 
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Figure 26 Antisense transcription in promoter and terminator regions of annotated transcripts for five samples (730-
734 = GM11894, GM07374, GM12489, GM12045, GM11919). 
Promoters were defined as up to 1 kb upstream of the transcription start and the terminator region up to 1 kb downstream from 
the transcription end. The sense to antisense ratio is shown as a value between 0 and 1, where 0 is pure sense and 1 pure 
antisense transcription. A Antisense to sense ratios without restrictions. B AS:S ratios in promoter and terminator regions which 
have at least 150 bp covered by antisense reads. C-D AS:S ratios in promoter and terminator regions which have at least 150 
bp covered by antisense reads and a minimum AS coverage per covered AS base of 5 and 20 respectively. With increasing 
minimum AS coverage, the number of terminator regions increases relative to the number of promoter regions. 
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Among the huge amount of detected S/AS pairs, multiple pairs could be detected which show 
mutually exclusive expression of one transcript in some samples, and mutually exclusive 
expression of the other transcript in others. This kind of S/AS pairs was identified in all three data 
sets. Among the best hits in the LBL data set, a S/AS pair consisting of SEPP1 and CCDC152 was 
identified (Figure 27). Four individuals show expression of CCDC152 but not of SEPP1, while for the 
remaining individual the opposite is true. 
 
 
Figure 27 Differentially expressed S/AS pair in LBL cell lines. 
SEPP1 and CCDC152 lie in antisense orientation to another. Expression levels in LBL cell lines from five individuals are shown 
for the first strand (light blue) and second strand (dark blue). Either CCDC152 or SEPP1 show expression, but not both in the 
same individual. 
 
While the number of differentially expressed S/AS pairs was very low in the LBL data set, a slightly 
larger number of differentially expressed S/AS pairs could be detected in the cHL data set. 
Supplementary figure 5 shows an example for this data set. Two of the three cHL cell lines show 
expression of CD59596 but no FSTL5 expression, while in the remaining sample only FSTL5 is 
expressed. Additionally differential S/AS expression does not only occur between individuals, but 
also between different tissues. Expression in antisense direction to Mtus1 was detected in the two 
murine small intestine samples that could correspond to B4300010123Rik expression, but this 
expression is not detectable in the two murine colon samples. Also, expression of the ‘long’ Mtus1 
transcript seems to be slightly diminished in the small intestine samples (Supplementary figure 6). 
Besides differentially expressed S/AS pairs, S/AS pairs that show similar expression for both 
transcripts but differ in expression per sample were identified. An example of a yet unannotated 
transcript antisense to TRIM71 is shown in Figure 28. GLB1 shows a similar expression rate in all 
samples while TRIM71 and the unknown antisense event show a positively correlated expression, 
which differs between samples. 
GM07374  fw 
GM07374  rev 
GM11894 fw 
GM11894  rev 
GM11919 fw 
GM11919 rev 
GM12045 fw 
GM12045 rev 
GM12489 fw 
GM12489 rev 
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Figure 28 Co-expressed S/AS pair in LBL cell lines. 
The antisense event close to the 5’-end of TRIM71 (left side, dark blue) is expressed at a similar rate as TRIM71 (uc003cff.2, 
light blue) itself. In contrast, the expression of GLB1 (right side) is more even between samples. Scale 0-15 for all tracks.  
 
Additional co-expressed S/AS pairs were identified in the cHL data set (Supplementary figure 7) 
and in the different murine tissues (Supplementary figure 8). The antisense transcript in the cHL 
data is novel and no gene has been assigned to this position yet. The antisense transcript identified 
in the murine colon samples is overlapping with the Tcf7l1 gene and is not detectable in the small 
intestine samples, where also expression of Tcf7l1 is barely detectable. In this case the antisense 
transcript is also not included in current gene annotation databases. 
By investigating known SNV positions (generated by the 1000 Genomes Consortium) in the LBL 
data set, some SNVs showing signs of strand specific allelic imbalance (Figure 29) were identified. 
 
 
Figure 29 IGV picture of SNV at chr15:31234064, only reads with unique start points shown. Reads corresponding to FAN1 
expression (red) show both, the C and T allele, while reads corresponding to MTMR10 expression show exclusively the C allele. 
 
GM07374  fw 
TRIM71 CCR4 
GLB1 
GM07374  rev 
GM11894 fw 
GM11894  rev 
GM11919 fw 
GM11919 rev 
GM12045 fw 
GM12045 rev 
GM12489 fw 
GM12489 rev 
15:31234064     C       NA11894=T|C 
 
reads (A/C/G/T) 
forward: 0/3/0/13 
reverse: 0/9/0/0 
 
unique fw: 0/3/0/4 
unique rev: 0/4/0/0 
NA11894 
coverage 
 
NA11894 
reads 
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The example shows expression of FAN1 and MTMR10. Reads corresponding to FAN1 expression 
show both SNV alleles (T/C) with slight favor of the T-allele, while the reads corresponding to 
MTMR10 expression show the C allele only. Antisense transcripts are likely to have regulatory 
effects; either by influencing gene expression (i.e. by alteration of histone methylation) or by 
formation of RNA-RNA-duplexes (due to overlapping antisense transcripts). RNA-RNA-duplex 
formations involving N-myc have been suggested to cause retention of intron 1, linking antisense 
transcripts with splicing.105 Further, double stranded RNA is a feature of multiple viral infections, 
and thus mechanisms exist to detect and destroy dsRNA fragments (i.e. siRNA can be involved in 
this process). Therefore, disturbances in the RNA regulatory machinery can cause disease 
phenotypes, thus it is necessary to gain more knowledge about antisense transcript function. 
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5. Discussion 
 
This thesis focuses on the application of next-generation sequencing to unravel functional genetic 
variants that could be linked to inflammatory bowel disease using the example of a Falk-Rubinstein 
trio with early onset CD in the affected child. I present the first study aiming for the extraction of 
the full genetic variability in a Crohn disease trio and try to utilize this data together with genetical 
genomics analyses by RNAseq as a basis for personalized understanding of genetic variants that 
cause human disease. To assess the genetic disease determinants in the child’s genome, especially 
variants that follow the recessive model of inheritance, the genomes of the child and its parents 
were completely sequenced using different library types. It is self-evident, that robust identification 
of genetic variants is dependent on decent genomic coverage, as sequencing technologies might 
introduce errors during the necessary amplification steps. Also it is important to show that the 
variant calling algorithms applied are reliable, i.e. by comparison with variant calling results of a 
different technology. Therefore, the sequencing and variant calling performance will be described 
first, before the detected genetic variations in the child are discussed. 
 
5.1. Sequencing and variant calling performance 
Multiple libraries were sequenced per individual to achieve a deep and diverse genomic coverage. 
Further, applying different protocols for library preparation has an advantage over sequencing the 
same library repeatedly, as each protocol has its own weaknesses and strengths. Long mate-pair 
libraries for example can be used to link distant genomic regions, which is required for the 
detection of large structural variants, but require a large amount of input DNA, whereas paired-end 
data links more closely located genomic regions and only requires low amounts of DNA. The study 
demonstrates that most of the investigated genomic regions (>99.85%) are accessible with current 
next-generation sequencing technologies and that SNV detection is, in general, very robust, 
evidenced by the high concordance rate (>99%) between the SNV-Calls and state-of the art 
comparative technology (Illumina SNV chip). However, screening for potential de novo variants 
enriches false-positive results. In cases of low coverage or too low quality reads a SNV might not be 
detected in one of the parents or might show an incorrectly called zygosity, which ultimately leads 
to false positive de novo variants. As shown, it is possible to reduce the number of likely false-
positive de novo variants dramatically by re-investigating the mapped sequences (independent of 
the SNV-Call). Two of the highest scoring filtered potential de novo variants could be verified, 
representing 2 of 20 (10%) of the expected de novo variants per generation. Based on the genetic 
variation of the family trio the geographical origin was determined as Central European, which is 
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required knowledge for further analysis as the effect of CD risk variants can differ between 
ethnicities. Also, this allows choosing of appropriate control populations, used in several of the 
applied analyses. While analogous technologies exist for SNVs detection, quality assessment of the 
larger structural variants, which easily span several kbs and have no precisely defined start and end 
positions, proves to be more difficult, as technologies for identification of very large numbers of 
SVs in a manageable way have not been developed. Hence for this type of variation it is highly 
important to verify candidates by conventional methods (i.e. PCR-amplification). 
 
5.2. Investigation of de novo variants 
Variants that appear only in the child (de novo variants) could provide a reasonable explanation 
why the child is diseased while the parents do not show symptoms of CD. Two de novo SNVs could 
be verified, but present non-coding variants. One variant was detected in the UTR of NF1 
(neurofibromin) and one variant intragenic between SYT4 (synaptotagmin) and SETBP1 (SET-
binding protein 1). It is very difficult to assess their impact on pathogenesis, as they do not 
influence protein function directly, but might mediate a change of expression. As this is very 
speculative, these SNVs are not considered as major drivers for CD pathogenesis in the presented 
case study. None of (the weakly scored) coding de novo variants could be verified. Assuming that 
no de novo SNVs were missed by the approach applied, de novo variants can be ruled out as 
causative variants for this case of CD. However, absolute certainty does not exist. 
 
5.3. Genetic variants concerning monogenic phenocopies of Crohn’s disease 
Multiple diseases are known to cause a Crohn’s disease like phenotype but are based on a very 
limited number of genes as would be expected for Mendelian diseases. To exclude that the child 
has one of these phenocopies, the genes underlying these diseases were investigated. No disease 
associated SNVs could be identified, except for a SNV in NOD2 that is however not associated with 
Blau Syndrome but confers a higher CD risk. Some uncertainty remains for the missense SNV 
(rs34562254) detected in TNFRSF13B that affects a conserved nucleotide and that was predicted 
discordantly (damaging/tolerated) by the applied prediction tools. Based on these findings, none 
of the investigated monogenic syndromes is likely responsible for the child’s phenotype. 
 
5.4. Crohn’s disease associated risk variants 
As several Crohn’s disease risk variants are known, another tempting hypothesis is that the child 
carries an extensive burden of risk variants which together would explain the disease phenotype. 
Taking this hypothesis into account it must be postulated that the cumulative risk is higher in the 
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child than in his parents or other healthy individuals. However, despite a high number of CD risk 
variants in all three individuals, the combined relative risk for known CD risk variants in the child 
(and also the parents) does not show differences to the combined relative risk of putative healthy 
individuals. Additionally, I demonstrated that the child did not receive more CD risk variants than 
would be expected for an ‘average child’ given the parents’ genotypes. Apparently, the known risk 
loci do not suffice to explain the disease outbreak in the child, as the observed genetic burden for 
CD is similar to that of putative healthy individuals. This is not surprising, as the known CD risk 
conferring loci only attribute to about 20% of the genetic heritability of CD. Therefore the genes 
associated with variants conferring a higher CD-risk were screened for additional, novel variants. 
Among these variants, a nonsense SNV was detected in the fucosyltransferase gene (FUT2) that was 
verified using Sanger sequencing. The SNV is shared between the father and the son, and thus 
cannot be a major driver of the disease under the postulated recessive model. Another SNV was 
identified in the “macrophage stimulating 1” gene (MST1). At first, the SNV appeared as potential de 
novo variant, however Sanger sequencing revealed that the variant is heterozygous in both, 
mother and child while the father is homozygous for the reference allele. It could be speculated 
that the possibly damaging FUT2 and MST1 SNVs might exhibit a synergistic effect on CD 
pathogenesis. 
The SNV (rs11549656, P200L) detected in a conserved region of GPX1 is located very closely to a 
similar variant (P197L) that has been reported as polymorphism by Forsberg et al. (1999).106 Proline 
is often found in turn motifs in proteins and has the ability to interrupt α-helices and β-strands, 
thus replacement of prolines could lead to a conformational and functional change. The P200L 
variant is listed as probable pathogenic in dbSNP; though on a closer look no clinical link to 
pathogenesis exists. Also, Forsberg et al. did not link the P197L variant to pathogenesis. A strong 
link of this variant with CD is therefore rather unlikely. Another proline change was detected in the 
glucokinase regulatory protein (GCKR, rs1260326) that is located between two motifs which are 
thought to be directly involved in binding of phosphoesters. The SNV is strongly associated with 
lower fasting glucose levels and fasting insulin levels and higher triglyceride levels that reduces 
type II diabetes risk in the French population.97 The protective link of the SNV with diabetes is 
interesting, but it is not likely that the SNV has an opposite effect in CD. SNVs following the 
recessive model represent targets of high interest under the assumption of a strong inherited 
genetic background of the disease. Only one such SNV could be identified in genes associated with 
CD risk loci. However, the SNV identified in SNAPC4 is located in a site of high acceleration, which, 
although the SNV was predicted to be damaging by SIFT (with low confidence), disagrees with an 
important function of the residue. Also, SNAPC4 is located in the same genetic risk region identified 
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by GWAS as CARD15, which is a much stronger candidate for Crohn’s disease. Two small SVs were 
detected in CD risk loci associated genes (TNFSF18, DENND1B), but the variants are shared with the 
mother and father respectively. Summarized, no strong candidate variants were identified in genes 
associated with CD risk loci that are sufficient to explain the disease outbreak in the child. However, 
distinct inheritance of several of these variants could overcome an unknown threshold to develop 
the disease. As shown, the sSV in TNFSF18 and the MST1 missense SNV were (likely) inherited by the 
mother, while the FUT2 nonsense variant and DENND1B variants are shared between the father and 
child. 
 
5.5. Regions of homozygosity in relation to known Crohn’s disease risk loci 
Regions (or runs) of homozygosity (ROHs) are long stretches without heterozygosity in the diploid 
state. Multiple studies have identified ROHs associated with other complex traits, such as 
schizophrenia and late onset of Alzheimer’s disease and there is evidence that ROHs can be used to 
uncover hidden recessive variants in complex disease. This has been proven to be particular useful 
in investigating autosomal recessive disorders in populations with a high prevalence of 
consanguinity. Additionally, larger differences in ROHs could be shown between cases and controls 
in various studies.98 Although many ROHs were found to overlap with known CD risk loci, no over-
representation of known CD risk loci in ROHs could be identified in the child’s genome compared 
to healthy individuals. Therefore, it is unlikely that autozygosity in CD risk regions is responsible for 
CD in the presented case. 
 
5.6. Genetic variants associated with other inflammatory diseases 
Many risk genes associated with inflammatory traits are shared between multiple diseases. It is 
likely that some genetic variants in genes involved in other inflammatory diseases could contribute 
to the child’s phenotype. Risk loci and associated genes (based on the GWAS catalog) were 
investigated for the following diseases: ankylosing spondylitis, asthma, celiac disease, 
inflammatory bowel disease (IBD, which is a distinct entry to ulcerative colitis and CD in the GWAS 
catalog), leprosy, multiple sclerosis (MS), psoriasis, rheumatoid arthritis (RA), systemic lupus 
erythematosus (SLE), type 1 diabetes and ulcerative colitis (UC). A larger number of missense SNVs 
in the HLA genes were predicted to be damaging, however the MHC regions are highly 
polymorphic which naturally leads to a large number of SNVs. It is difficult to assess if any of these 
variants have actually damaging effects. Although many SNVs were predicted to be damaging and 
occur at conserved positions, the alternative allele is the most common allele in the central 
European population for the variants in CIITA, ERBB3 and FRMD4B, while the minor allele frequency 
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of the remaining SNVs is not very low (>0.2). The allele frequencies of some SNVs remain unknown 
with only six of them in sites of conservation. Among these are the MST1 and NOD2 SNVs 
(discussed above) and two SNVs identified in genes of regions associated with celiac disease 
(KIAA1109, FRMD4B). Information of the gene function for both genes is very limited, thus it remains 
unknown what (if any) role they could have in inflammatory diseases. The remaining two SNVs with 
unknown allele frequencies were identified in the gene for interferon regulatory factor 5 (IRF5) and a 
phenol sulfotransferase gene (SULT1A2). The IRF5 SNV is not included in dbSNP130, is located in a 
site of conservation and was predicted to be damaging by both applied prediction tools. IRF5 has 
been associated with UC, RA and SLE and especially the association to UC makes this an interesting 
candidate gene for CD. However, this variant is not unique to the child and thus other factors are 
likely more important. The remaining SNV (SULT1A2) is located in a region associated with early 
onset of IBD, however other genes such as IL27 and EIF3C are also located in this region and no 
direct link between SULT1A2 and IBD has been made so far. Three short SVs were identified in 
exons or splice-junctions of DENN1B, TNFSF18 (both discussed above) and CSMD1. CSMD1 (cub and 
sushi multiple domains 1) is associated with MS and the 1-basepair deletion was predicted to cause 
nonsense mediated decay. CSMD1 has been reported to inhibit classical complement pathway 
activation and might thus play a role in inflammation.107 Only one large SV was identified to affect 
the coding region of a gene associated with the investigated inflammatory diseases. The affected 
gene is coding for the growth hormone receptor (GHR) that has been identified in a region 
associated with SLE. However, no direct link between the gene and the disease has been made yet 
and the deletion of exon 3 has been previously detected and described to increase the 
responsiveness to growth hormone. 
This analysis revealed additional variants that could be involved in CD pathogenesis that are yet 
not clearly linked to CD etiopathogenesis. However, a more profound analysis of the variants (i.e. 
genetically modified cell and mouse models) or the verification of the variants in a larger case 
cohort are required. It is important to emphasize that all of the above variants are not unique to the 
child or follow the recessive model of inheritance, and therefore fail to explain a Mendelian cause 
of the child’s disease. 
 
5.7. Everything else - the remaining genetic variability 
Genetic regions with a higher density of variations in the family trio (or just the child), compared to 
putative healthy individuals could hint towards potential risk factors. However, in a heatplot no 
substantial differences could be observed in the SNV density across the whole genome, except for 
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regions close to the centromers and some repeat regions, which is probably a result of 
mismapping. 
Neither known CD risk variants nor other variants associated with inflammation suffice to explain 
the child’s phenotype. Therefore, the analysis was extended to all genes that carry potential 
damaging genetic variants that 1) contribute to compound heterozygosity, 2) follow the recessive 
model of inheritance and/or 3) are located in sites of high conservation. Among the SNVs following 
the recessive model, only 15 were identified in sites of conservation. Ten of them show minor allele 
frequencies >0.2 (BRWD1, C2orf73, GBE1, GOLGA4, LOXL4, NOM1, OBSL1, both SNVs in PCDHA1 and 
PSDM9). The remaining five were detected in PCDHB7, MPHOSPH8, KRT76, KCNJ12 and BEST2. 
Besides MPHOSPH8 and BEST2 all SNVs are included in dbSNP130. The SNV in KRT76 was not further 
investigated as in a newer build of dbSNP (134) the minor allele frequency is reported to be >0.2. 
KCNJ12 belongs to the potassium channel, inwardly rectifying subfamily J. The gene’s function 
remains in great parts unknown. PCDHB7 is encoding for proto-cadherin-Beta 7 that might be 
involved in cell-cell adhesion, and thus could influence the structural integrity of the epithelial. The 
SNV in MPHOSPH8 (M-phase phosphoprotein 8) has been included in the newer dbSNP build 134 
(rs75390100) with a minor allele frequency of T=0.042 (CEU). Expression of MPHOSPH8 was similar 
in the blood samples of all three individuals with the child being lowest. Both applied SNV 
prediction tools designated this SNV as damaging. Data about MPHOSPH8 is scarce, but it has been 
described to target the E-cadherin promoter and to recognize methyl-H3K9 marks, thus directing 
DNA methylation to repress tumor suppressor gene expression and, in turn, has an important 
function in epithelial-to-mesenchymal transition and metastasis.108 
The SNV in BEST2 has been included in the dbSNP build 134 (rs79300835) and shows a minor allele 
frequency of 0.042. The SNV was verified using Sanger sequencing and the occurrence in the 1000 
Genomes data set (1092 samples, Oct. 2011 release) was investigated. Screening of the 1000 
Genome project’s individuals revealed only 84 heterozygous and four homozygous individuals for 
the variant, suggesting a very low allele frequency across investigated human ethnicities. PolyPhen 
predicted this SNV to be possibly damaging, which is in agreement with the low prevalence of 
homozygous individuals. The SNV is located in the first RFP (arg-phe-pro)-transmembrane domain 
(Pfam, PF01062.15) and the first 13 amino acids are highly conserved including the arginine at 
position 8 down to the teleost fishes. The SNV changes the arginine to a glutamine (R8Q). Arginine 
contains a positively charged side chain, while glutamine is uncharged, which could alter the 
properties or stability of the first transmembrane domain. Bestrophin-2 is localized at the 
basolateral membrane of mucin-secreting colonic goblet cells and described to mediate 
bicarbonate transport in the mouse colon.109 Indeed considerable BEST2 transcript levels could only 
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be detected in the RNAseq data of the colon-biopsy of the child, but not in any of the blood 
samples. Interestingly, Yu et al. could demonstrate that Best2–/– mice developed spontaneous 
intestinal inflammation and were highly sensitive to DSS-induced epithelial lesions and colitis 
when comparing them to wild-type mice. However, genotyping the SNV in large cohorts of Crohn’s 
disease and ulcerative colitis patients did not confirm the potential association of this SNV with 
disease risk. Although a higher abundance of the SNV could not be demonstrated in our disease 
cohort compared to the controls, it is possible that larger studies or studies with a different ethnic 
background might find an association, but a high impact of BEST2 in CD is rather unlikely. 
Several genes show SNVs that possibly contribute to compound heterozygosity, whereas only few 
of these SNVs include at least one SNV that was predicted to be damaging or were not predicted at 
all. The HLA-A gene and three mucin genes (MUC2, MUC4 and MUC16) carry at least one SNV 
predicted to be damaging from either mother or father and additional SNVs from the other parent. 
The possible involvement of these genes, influencing the mucus layer and antigen presentation, 
has been discussed in the introduction. For the remaining genes with compound heterozygosity 
only few have known functions. For example, decreased expression levels of NLRP1 (NLR family, 
pyrin domain-containing 7) have been associated with Crohn’s disease.110 Faustin et al. suggested 
that NLRP1 is a direct sensor of bacterial components in host defense against pathogens. Muramyl-
dipeptide (MDP) leads to a 2-step oligomerization of NLRP1 involving ribonucleotide triphosphates, 
which then activates CASP1.111 Another variant was detected in CCHCR1 (coiled-coil alpha-helical rod 
protein 1), that has been associated with abnormal keratinocyte proliferation, which is a key feature 
of psoriatic epidermis.112 SLC19A1 presents another gene with compound heterozygous SNVs. 
Chapkin et al. showed that mice compound heterozygous for the folate transporter SLC19A1/RFC1 
and folate-binding protein FOLR1/FBP (FBP(+/-) RFC1(+/-) mice) showed a higher number of 
aberrant crypt foci per centimeter colon compared to FBP(+/-) mice and controls.113 However, the 
results concerning compound heterozygous variants have to be regarded with care as usually only 
one of the SNVs contributing to compound heterozygosity was predicted to be damaging. The 
remaining SNV(s) might not add any additional effect. 
Three large deletions were identified that probably follow the recessive model of inheritance, 
which affect the exons of SPINK5L2/SPINK14 (Kazal type serine protease inhibitor 5-like 2), GUCY2GP 
and CCDC135. Variants in the SPINK5L2 related gene SPINK5 (LEKTI) have been associated with 
Netherton syndrome, asthma and atopic dermatitis, thus representing an interesting target for CD 
pathogenesis. The identified deletion in SPINK5L2 leads to the loss of exon three in the child’s 
genome, while the parents both still have the respective region, at least in a hemizygous state. The 
data is supported by all sequenced libraries, which is a strong proof for the existence of this variant. 
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However, no expression of SPINK5L2 was detected in the blood samples and colon biopsy of the 
child. It remains unclear how (or if) this variant is involved in CD pathogenesis. The remaining 
recessive deletion affects GUCY2GP that is likely a pseudogene and thus of little interest. 
Both models, the recessive and compound heterozygous inheritance, do not yield sufficient 
evidence to explain the presented CD case. Therefore, additional variants were screened in exonic 
sites of conservation, as these locations likely have functional (or regulatory) consequences. 
Multiple genes were identified that are likely involved in immune system processes. Among the 
most interesting SNVs is one in FURIN, a gene that is involved in the function of regulatory T-cells. 
The SNV is not included in dbSNP and was predicted to be damaging by both prediction tools. 
FURIN deficient regulatory T-cells have been shown to be less protective in a transfer colitis 
model.114 FURIN has also been shown to cleave pro-TGFB1 to produce biological active TGFB1.115 
Two SNVs have been identified in the toll-like receptor gene TLR10. One of these two SNVs shows a 
low minor allele frequency (0.025) in the central European population. The child was found 
homozygous for this variant and additionally both SNVs were predicted to be damaging by both 
applied prediction tools. Other interesting candidates include variants in NLRP12 (inflammasome), 
IL22RA2 (interleukin-22 receptor, alpha 2) that might be an antagonist of IL-22 in the regulation of 
inflammatory responses,116 SIGLEC1 (sialoadhesin) that is expressed on macrophages and facilitates 
antigen recognition of B-cells117, FREM1/TILRR (FRAS1-related extracellular matrix protein 1), ITGAX 
and ITGA3 (integrins) and MMP9 (matrix-metalloproteinase 9). ITGAX is a leukocyte surface molecule 
and has been associated with systemic lupus erythematosus, whereas ITGA3 has been shown to 
promote MMP9 production in human gastric carcinoma cell lines,118 which in turn has been found 
to be upregulated in IBD and a mediator of tissue damage in colitis.119 TILRR is a product of 
alternative splicing of the FREM1 mRNA and is a co-receptor of IL-1RI. TILRR might regulate Toll-like 
receptor/interleukin 1 receptor signal transduction.120 
All of the above mentioned variants could play a role in CD pathogenesis, but they cannot explain 
a strict Mendelian cause of the disease, as they are shared with the parents. Still, it might be worth 
pursuing these variants in cell/mouse models and diseased patients. As no evidence for a 
Mendelian disease-like genotype could be identified, it is likely that a large number of variants with 
smaller effects are responsible for CD in the presented case. A functional protein network based on 
all missense SNVs filtered by the gene ontology term “immune system process” was generated 
with STRING. While many genes remained without connection, several clusters could be identified  
including: antigen recognition and processing (HLA genes, MHC class I and II), proteasome function 
(PSMB9), innate immune responses to virus infections (2-prime,5-prime oligoadenylate synthetases 
(OAS) genes), DNA repair (XRCC5, MSH3, MSH6, MLH1, EXO1), chemokines (CCL22, CCL23, CX3CR1, 
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CX3CL1), complement system (C5AR1, C5, C7, C8A; CFI, CFHR1, CFH; CR1, CR2), NADPH oxidase 
complex (CYBA, NCF1, NCF2) and pattern recognition and signaling associated pathways (NOD2, 
TLR3, NLRX1, IL1RL1, TNFRSF11A, TNFRSF13B, IRAK1, IRAK2, IRAK3, IKBKAP, CHUK). Only few clusters 
include genes with putative recessive SNVs (HLA-DPB1 (potential damaging SNV), HLA-C, HDAC5, 
TLR6, TLR10, TNFRSF1B, POLL (potential damaging SNV), CYBA (potential damaging SNV) and NLRX1. 
The number of non-recessive SNVs predicted to be damaging is much higher and these SNVs affect 
all above mentioned clusters, except PSMB9 and the OAS genes. These findings highlight the 
complexity of the genetic findings. While any of these variants could contribute to CD 
pathogenesis, it is impossible to identify the true-positive associations in this study with very 
limited number of individuals (N=3) without further functional studies and/or studies using larger 
cohorts. 
 
5.8. Differential expression and genetic variants in differentially expressed genes 
The transcriptomes of all three family members were investigated to identify differentially 
expressed genes. Expression levels were determined with the widely used Cufflinks software89 that 
are reported as fragments per kilobase of exon model per million mapped fragments (FPKM). 75 
genes were identified as 5-fold upregulated and 12 genes as 5-fold downregulated in the child 
compared to its parents. Among these are many genes involved in inflammation, i.e. several genes 
are associated with immune cell function and development (CD177, C19orf59, ARG1, CST7, 
TNFSF13B, IL4), and with pattern recognition and associated downstream signaling (CLEC4D, 
HMGB2, TLR5, NLRC4, IRAK3, CR1). Several of the identified genes have been shown to be 
differentially expressed in CD patients. Increased levels of S100A12 (S100 calcium binding protein 
A12) in serum were found in patients with IBD compared to patients with irritable bowel syndrome 
(IBS) and can be used to discriminate both groups.121 S100A12 is a ligand of the multi-ligand 
binding receptor for advanced glycation end products (RAGE) that has been associated with a larger 
number of inflammatory and autoimmune diseases, including type 1 diabetes and rheumatoid 
arthritis. Binding of S100A12 to RAGE has been shown to trigger cellular activation, with generation 
of key proinflammatory mediators.122 Interestingly, Hoffman et al. also reported that blockade of 
S100A12/RAGE interaction i.e. by administration of soluble RAGE (sRAGE), that functions as a decoy 
molecule for the ligands efficiently, prevents inflammation in an IL-10 null mice colitis model. 
Additionally, the expression levels of S100A8 and S100A9 are increased in the child compared to the 
parents. Both molecules are ligands of RAGE that have been reported to induce pro-inflammatory 
responses associated with an increased vascular permeability due to a loss of endothelial cell–cell 
contacts and cell junction proteins.123 Higher concentrations of MMP9 (matrix-metalloproteinase 9) 
have been reported to be significantly increased in the sputum of CD patients compared to 
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controls,124 which is in agreement with high MMP9 expression levels detected in the child. Arijs et 
al. tried to identify genes corresponding to a response to Infliximab (IFX) in CD patients. They 
identified 697 significant probe sets between Crohn’s disease colitis responders and non-
responders. The top five genes were TNFAIP6, S100A8, IL11, G0S2 and S100A9 that were sufficient to 
completely separate both groups.125 Expression levels of all five genes were higher in non-
responders than in responders. Three of these genes, TNFAIP6, S100A8 and S100A9 were found 
upregulated in the child, compared to its parents. The child was, among other things, treated with 
IFX and repeat colonoscopy after treatment still showed active disease after maximum therapy. 
Whether the higher expression of TNFAIP6, S100A8 and S100A9 in the child indeed counteracted 
IFX response remains speculative, but poses an interesting finding. Another interesting result is the 
higher expression of TLR5 in the child, as a nonsense mutation in the TLR5 receptor, that most likely 
recognizes bacterial flagellin126, has been reported to protect persons of Jewish ethnicity against 
CD.127 If a loss of TLR5 protects against CD, an increased expression of TLR5 might have opposite 
effects. Several of the higher expressed genes are involved in pathogen recognition and clearance. 
One example is the above mentioned TLR5, but also CR1 (complement factor 1), HMGB2 (high 
mobility group box 2), IRAK3 (interleukin receptor-associated kinase 3) BGR/CLEC7A/DECTIN1 (C-type 
lectin domain family 7, member A) and PGLYRP1 (peptidogylcan recognition protein 1). CR1 is present 
on red blood cells and binds to circulating complement-opsonized particles that are then 
transferred to macrophages in the liver and spleen for clearance.128 CLEC7A was identified as a 
surface receptor of beta-glycans on macrophages, and thus functions as a pattern recognition 
receptor for funghi and some bacteria.129 Lack of HMBGs has been reported to reduce activation of 
TLR3, -7 and -9, thus an increased level of HMGB2 might lead to an increased TLR response. IRAK3 is 
upregulated in a cytokine dependent manner upon LPS exposure.130 Upregulation of this gene 
raises further evidence for the high activity of the antimicrobial sensing pathways and downstream 
cascades in the child. 
The genes detected to be differentially expressed in the child were screened for genetic variants 
that are predicted to be damaging. Five genes were identified, namely CR1, VNN1, IL4R, EMR1 and 
MMP9 that carry such variants. However, as these SNVs are not unique to the child it is unlikely that 
they are responsible for the expression changes. Also, non-exonic SNVs are likely more important 
as they could affect regulatory elements. It is however difficult to assess the effect of noncoding 
SNVs on the expression level, as this would require cloning or genetically modification of cell 
and/or animals for each variant. The coding SNVs are still noteworthy, as an increased level of 
potentially malfunctioning proteins might exhibit unexpected consequences in pathogenesis. 
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5.9. Strand specific transcriptome analysis 
Extending the work on the transcriptome analysis in the family example, expression of closely 
occurring sense/antisense (S/AS) transcript pairs was investigated in the transcriptomes derived 
from lymphoblastoid (LBL) cell lines of putative healthy individuals (five individuals of the 1000 
Genome project),99 three classical Hodgkin lymphoma (cHL) cell lines (kindly provided by Ohle 
Ammerpohl and Reinert Siebert)100 and transcriptomes of murine small intestine and colon which 
were generated in duplicates101. As no tool was publically available to assess S/AS transcription on 
the genome-wide level using next generation sequencing technologies I developed Janus to fill 
this gap. Janus was applied to the transcriptomes mentioned above for detection of S/AS pairs in 
general and identification of differentially expressed S/AS pairs. Data for five LBL cell lines was 
generated using two different technologies (SOLiD whole transcriptome analysis kit (WTAK)101 and 
Illumina GA IIx (kindly provided by Ralf Sudbrak and Hans Lehrach).102 Prior identification of S/AS 
pairs, the performance of both technologies was compared which revealed a higher background 
noise in the Illumina data. This noise manifests as expression in ‘exonic’ regions on the strand 
opposite to the template strand (the “antisense” strand). An example is given in Figure 25A, where 
the expression of FLNA (second strand) generates an echo on the opposite (first) strand in the 
Illumina data. The exon-intron structure is preserved on the first strand, which is highly unlikely, 
given conserved splice-site associated motifs. The SOLiD data on the contrary shows almost no 
expression on the first strand. Thus the noise level was investigated in all exonic regions by 
calculating the mean and standard deviation of the noise across exons (Figure 25B and C). The 
results support the hypothesis that the Illumina library is less efficient in preserving the strand as is 
the SOLiD data. This gives a good explanation for the high antisense tag density in exonic regions 
observed by He et al. who used the Illumina GA, which could not be confirmed by Klevebring et al., 
who used the SOLiD system.78,79 It can thus be assumed that some of the differences between the 
two studies result from the obvious technical bias (background noise) of the two sequencing 
protocols. This underlines the importance to assess the ‘noise’ level, i.e. the error rate of the library 
preparation, before identifying antisense events. It should be added, that preliminary results using 
a novel protocol for strand specific Illumina libraries (ScriptSeq™ mRNA-Seq Library Preparation Kit) 
suggest that it is possible to generate Illumina libraries with a noise level comparable to the SOLiD 
data (data not shown). Previous publications mention a high abundance of antisense tags in both 
the promoter and terminator regions of genes.78,103,104 Therefore, the occurrence of antisense 
transcription in promoter and terminator regions, here defined as 1 kb before and after the 
transcript start and end site, was investigated. Using cutoff criteria of a minimum length of 150 bp 
and a mean coverage per base of five for the antisense transcripts, identified antisense expression 
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in 740 promoter and 980 terminator regions in the cHL (hg18 mapped data, 32.110 annotated 
transcripts) and 2100 promoter and 2400 terminator regions in the LBL data set (hg19 mapped 
data, 66.065 annotated transcripts) (Table 10). Interestingly, when considering antisense events 
with low coverage in the promoter and terminator regions, the amount of antisense tags in 
promoter regions is higher than in terminator regions, while this shifts towards more antisense 
tags in terminator regions when considering only higher covered antisense events. This could be 
caused by a higher mismapping in promoter regions, maybe due to conserved motifs of 
transcription factor binding sites and TATA-like sequences, which generates a higher noise level. 
Another explanation is that there is more low level antisense transcription occurring in promoter 
regions and stronger antisense transcription in terminator regions. Also, it is possible that S/AS 
pairs in head-to-head conformation show lower expression than S/AS pairs in tail-to-tail 
conformation. 
Among the huge amount of detected S/AS pairs, multiple pairs could be detected which show 
mutually exclusive expression of one transcript in some samples, and mutually exclusive 
expression of the other transcript in others. Examples with high confidence for this type of S/AS 
pair could be identified in all three data sets. This demonstrates that differential S/AS expression 
does not only occur between different tissues, but also between individuals. 
Besides differentially expressed S/AS pairs I screened for S/AS pairs which show similar expression 
for both transcripts but differ in expression per sample. It could be argued this is caused by 
different library performance (i.e. this region was just unlucky in some samples) or a coverage bias 
might persist despite normalizing for the total coverage per sample. However, as shown in the 
example for the LBL data set (Figure 28), GLB1 shows a similar expression rate in all samples while 
TRIM71 and the unknown antisense event show a positively correlated expression, which differs 
between samples. It is unlikely that the observed co-expression is due to coverage effects. 
Katayama et al. suggested that long noncoding RNAs might be involved in S/AS pairs, reasoned by 
a higher number of S/AS pairs detected by random primed cap analysis gene expression (CAGE) 
compared to oligo-dT primed CAGE.103 It could be speculated, that the identified AS event 
upstream of TRIM71 might present such a noncoding RNA, as no exon-intron structure is visible. 
Interestingly, in the same paper Katayama et al. reported a frequent concordant regulation of S/AS 
pairs. Another study by Watanabe et al. raises further evidence of a high occurrence of positively 
correlated S/AS pairs.131 The reason for this remains unclear, but it could be due to the fact, that 
transcription of one strand makes the other strand more accessible as well and palindromic 
sequences in regulatory regions, such as promoter regions might be used by both strands. In this 
case the observed transcript could be nonsense transcription, which ends by the first possible 
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encountered transcription end signal. This might explain why antisense transcripts in promoter 
regions are often described as short and long noncoding RNAs. However, it is not unlikely that 
these antisense transcripts have some function, as they do not occur in all promoter or terminator 
regions of every expressed gene. Multiple studies showed that noncoding RNAs might alter the 
chromatin conformation or lead to a local change of methylation if they are located within 
promoter regions.132–134 The occurrence of co-expressed S/AS pairs was also shown for the cHL data 
set and in the different murine tissues. 
Using the data available to us, no link between sense and antisense transcription and methylation 
of CpG islands could be made, except weakly for one case, which might be coincidental 
(Supplementary figure 9, Supplementary table 43). It is possible that the limited number of CpG 
islands interrogated by the chip (27k) prevented identification of CpG methylation conditional 
antisense expression. A larger data set or data based on histone modification might lead to new 
results, as a link to histone methylation has been shown before, i.e. in the case of the p21 antisense 
transcript. 77 
By investigating known SNV positions (generated by the 1000 Genomes Consortium),99 some SNVs 
were identified in the LBL data set that show signs of strand specific allelic imbalance. While this is 
a very interesting finding, it remains unknown if this poses a mechanism to avoid potential 
inhibitory effects on transcription occurring on both strands simultaneously. Janus also identifies 
S/AS specific allelic imbalance for positions that are not known to be SNV positions. Yet, most of 
these positions can be traced back to regions that are difficult to map to (i.e. HLA), repeat regions, 
pseudogenes and genes with multiple copies, thus these results have to be considered with care. 
Janus proved to be very efficient in the identification of regions transcribed in antisense to other 
transcribed regions. Taken together, detection of differentially expressed and co-expressed S/AS 
pairs proved to be difficult but manageable. 
 
5.10. Conclusions 
A large number of genetic variants have been identified in genes of the child that may potentially 
influence immune responses. However, no single variant could be identified that argues for a 
Mendelian cause of the child’s phenotype. Additionally, examination of several monogenic 
diseases with a CD-like phenotype did not result in probably disease associated genetic variants 
and no de novo variants were identified in coding regions of the child. However, it cannot be ruled 
out that some variants were not detected by the SNV calling algorithms. Screening for genetic 
variants that have been previously associated to CD (GWAS studies) showed that many of these 
variants are present in the child. Yet, it could be shown that the family trio does not carry more of 
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these risk loci than other putative healthy individuals and that the child did not receive an unusual 
high inherited burden of CD risk loci than would be expected by random and independent 
inheritance of each locus. Further, no overrepresentation of CD risk loci in regions of homozygosity 
could be shown compared to putative healthy individuals. Therefore, the known CD risk loci were 
excluded as causative on their own, as more genetic variants must be involved. Investigation of 
genes involved in other inflammatory diseases revealed additional putative damaging genetic 
variants in potential CD relevant genes. However, no single variant could be identified that is likely 
causative for the phenotype. Investigated of all recessive, compound heterozygous and SNVs in 
phylogenetic conserved locations identified one recessive SNV in BEST2 that was confirmed by 
Sanger sequencing. Although this SNV is associated with bicarbonate transport by goblet cells and 
thus represents a very interesting candidate for CD, no higher prevalence of the variant could be 
detected in CD or UC patients (N=1066) compared to controls (N=1468). Despite this, the variant is 
rare and only few homozygous individuals (N=10) were identified. Therefore this variant might 
underlie a higher selection pressure, suggesting an important impact on gene function. Although 
the variant alone is unlikely to cause a CD phenotype itself, it might add to a predisposition 
towards CD. 
Investigation of large deletions did not yield a reliable recessive variant that effects exons and 
might be associated to CD. It must be kept in mind, that not all genetic variants might have been 
detected in all three individuals or that the zygosity of the variants was not assigned correctly. 
Assuming a no major causative variant was missed, the results indicate that the child’s phenotype 
is, despite a strong genetic bias, probably not caused by a single genetic variant, but by a 
combination of several. It is enticing to speculate the variants in FUT2 and MST1 (and probably 
some more) that are shared with either parent might contribute to the pathogenesis by synergistic 
effects in the child that overcome an unknown threshold necessary to develop a pathogenic 
phenotype. With the current state of knowledge of CD pathogenesis, general gene function and 
available sequencing technologies it was not possible to explain the child’s phenotype by a single 
causative variant. Despite this, this thesis provides a blue-print for the identification of potential 
rare risk variants in an otherwise overwhelming amount of genetic variants in a case of complex 
disease. Indeed, the applied approach was successful in the identification of a missense variant in 
the BEST2 gene that was as a very good candidate for a Mendelian disease gene that upon 
validation proved to be rare, but also comparably common in the normal population. 
Also in the context of next generation sequencing, in this thesis I developed Janus as a tool to 
investigate the nature of antisense transcription on the genome-wide level. As shown, the tool is 
very efficient in the identification of sense/antisense transcript pairs, is capable to detect S/AS pairs 
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that show mutually exclusive expression of one transcript in some samples and expression of the 
other in others, as well as S/AS pairs that are positively correlated. This tool might prove useful for 
the understanding S/AS expression in connection with disease phenotypes. 
 
5.11. Perspective 
Identification of causative variants in complex diseases proved to be very complicated. A lack of 
functional information of many genes, the inaccessibility of some genetic regions by NGS and 
basically no prediction tools for non-coding variants limit the use of whole-genome sequencing in 
complex diseases. Future improvements of the sequencing technology (i.e. by higher read lengths) 
and genetic variant calling algorithms will overcome some of these problems, as they will allow the 
detection of variants in regions that are yet difficult to assess (i.e. the highly polymorphic genes of 
the MHC region). As the costs for genome sequencing with a decent coverage steadily drops, it 
becomes more feasible to sequence bigger families or ethnic groups that makes identification of 
common causative variants easier, which could also pinpoint to reoccurring non-coding variants in 
disease cohorts. Very soon the first studies will be published that are performing a GWAS-like 
analysis on exome data. This approach has a much better resolution than GWAS studies and will 
lead to the discovery of new disease genes. However, this is still not perfect, as exome sequencing 
will miss genetic variants in regulatory genetic elements and cannot assess epigenetic 
modifications. Once the costs for sequencing dropped enough, whole-genomes and epigenomes 
will take over and overcome these issues. The identification of genome-wide disease associated 
genetic variants at single nucleotide resolution will drastically increase our knowledge of the 
genetic basis of many diseases and might result in new therapeutic targets. 
6. Summary (English) 
In this study, the genome and transcriptome of a family trio with a severe case of CD with very early 
onset was analyzed by whole-genome and transcriptome sequencing. The family history and the 
early onset (1.5 years), suggest a very strong genetic background of the disease. Genes involved in 
monogenic diseases presenting with a CD-like phenotype were investigated and excluded as no 
genetic variants linked to disease could be identified. Further, investigation of potential de novo 
single nucleotide variants (SNVs) did not result in any verified coding SNV. The occurrence of 
known CD-risk associated variants was investigated, but no higher occurrence of CD-risk associated 
was detected in the family trio compared to putative healthy individuals. Also, the child does not 
carry more of the known CD-risk loci than the parents. Several genetic variants were identified in 
the genes associated to CD risk loci (i.e. a nonsense SNV in FUT2 and a missense SNV in MST1), 
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which proved to be shared with either mother or father. No sufficient evidence was detected that 
known CD risk variants and risk genes can explain the child’s phenotype. Multiple genes involved 
in other inflammatory diseases were found to carry genetic variants, but none of them are likely to 
explain the CD phenotype in a Mendelian model. Therefore all genes were screened for variants 
that follow the recessive model of inheritance, are compound heterozygous or located in 
phylogenetically conserved locations. By this approach a recessive variant was detected in BEST2, a 
gene associated with bicarbonate transport by goblet cells in the mouse model, which proved to 
be rare, especially in the homozygous state, but not more uncommon than in healthy controls. In 
agreement with its suggested function, BEST2 expression was not detectable in the transcriptomes 
derived from blood, but only in the transcriptome from a colon biopsy of the child. Additionally, a 
large deletion following the recessive model was detected, that affects exon three of SPINK5L2. 
However, no expression of SPINK5L2 was observed in any of the transcriptomes. Although no single 
variant was identified that is likely causative for the child’s phenotype, this thesis presents a blue-
print for the identification of potentially disease associated genetic variants in a very limited 
number of genomes. 
As the second main result of the thesis a tool, Janus, was developed that is capable of identifying 
transcriptional active regions (TARs) in antisense to other TARs. To the best of my knowledge, no 
tool to investigate sense and antisense expression on the genome-wide level using next 
generation sequencing data existed prior to this work. Janus shows that antisense transcription is a 
very common phenomenon and that, with Janus, sense/antisense pairs with differential expression 
affecting only one or both strands equally can be identified. Janus might be a useful tool to identify 
differences in antisense expression in case-control studies. 
 
7. Summary (German) 
Während dieser Arbeit wurde das gesamte Genom und Transkriptom einer Familie (gesunde Eltern, 
erkranktes Kind) sequenziert, in der ein schwerer Fall mit frühem Ausbruch (1,5 Jahre) von Morbus 
Crohn (Crohn’s disease, CD) auftritt. Der familiäre Hintergrund und der frühe Ausbruch suggerieren 
einen starken genetischen Hintergrund der Erkrankung. In dieser Arbeit habe ich die Gene 
monogentischer Erkrankungen mit CD-ähnlichen Phänotypen untersucht, jedoch konnten keine 
krankheitsassozierten genetische Varianten in den assoziierten Genen identifiziert werden, so dass 
diese Erkrankungen ausgeschlossen wurden. Potentielle de novo Einzel-Nukleotid-Varianten (single 
nucleotide variants, SNVs) die in kodierenden Bereichen liegen wurden identifiziert, konnten aber in 
einem nachfolgendem Schritt nicht verifiziert werden, so dass diese ebenfalls als Ursache 
auszuschließen sind. Auch eine Analyse der bekannten CD-assoziierten genetischen Varianten 
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zeigte keine Anreicherung dieser Varianten in den Genomen des Trios im Vergleich zu anderen 
putativ gesunden Individuen. Zudem habe ich gezeigt, dass das Kind, basierend auf den 
bekannten CD-Risiko loci, im Vergleich zu den Eltern kein höheres CD-Risiko trägt. Einige neue 
genetische Varianten konnten in Genen nachgewiesen werden, die aufgrund einer oder mehreren 
anderen gentischen Varianten mit CD assoziiert sind. Zu diesen Varianten zählt eine Stop-Mutation 
in FUT2, sowie eine Variante in MST1, die zu einem Aminosäureaustausch führt. Beide Varianten 
wurden nicht exklusiv im Kind gefunden, sondern werden jeweils mit einem Elternteil geteilt. Es 
gibt keinen Hinweis darauf, dass die detektierten, bekannten CD-Risikovarianten ausreichend sind 
um den Phänotypen des Kindes zu erklären. Eine Analyse der Gene anderer entzündlicher 
Erkrankungen erbrachte ebenfalls keine Variante, die in einem Mendelschen Modell zu einem CD-
Phänotyp führen könnte. Daher wurde die Analyse auf alle genetischen Varianten erweitert, die 
dem rezessiven Vererbungsmodell folgen oder zusammengesetzt heterozygot sind, sowie 
Varianten in phylogenetisch konservierten Regionen. Mit diesem Ansatz konnte eine rezessive 
Variante in BEST2 identifiziert werden, einem Gen dessen Produkt mit dem Transport von 
Bikarbonat durch Becher-Zellen assoziiert ist. Diese Variante tritt selten, bzw. homozygot sehr 
selten auf, konnte aber im Vergleich mit gesunden Kontrollen nicht häufiger in Patienten mit 
entzündlichen Darmerkrankungen nachgewiesen werden. Anhand der analysierten Transkriptome 
konnte gezeigt werden, dass BEST2 zwar in der Kolonbiopsie des Kindes exprimiert wird, allerdings 
nicht in den drei Transkriptomen aus Blut. Außerdem konnte eine große, rezessive Deletion in 
SPINK5L2 nachgewiesen werden, die ein ganzes Exon des Gens betrifft. Allerdings konnte keinerlei 
Expression des Gens in einem der Transkriptome festgestellt werden. Obwohl der Phänotyp des 
Kindes an keiner einzelnen genetischen Variante festgemacht werden kann, wird mit dieser Arbeit 
ein methodisches Vorgehen gezeigt, wie potentielle krankheitsassoziierte genetische Varianten in 
einer sehr begrenzten Anzahl von Genomen gefunden werden können. 
Ein weiterer Teil meiner Arbeit war die Entwicklung eines Programms, Janus, dass der 
Identifizierung von transkriptionell aktiven Regionen (TARs) in antisense Richtung zu anderen TARs 
dient. Nach bestem Wissen ist dies das erste Programm um genomweit sense und antisense 
Expression mit Hilfe der Next-Generation-Sequencing-Technologie zu erfassen. Es wurde gezeigt, 
dass antisense Transkription sehr häufig auftritt, und dass Janus sense/antisense-Paare identifizieren 
kann, die eine differentielle Expression eines oder beider DNA-Stränge zeigen. Janus hat das 
Potential zu interessanten Entdeckungen bezüglich der Veränderung von antisense Transkription 
in Krankheitsstudien beizutragen. 
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Supplementary table 1 Crohn’s disease risk variants with known odds ratios described in the GWAS catalog. 
Genes are ordered by highest odds ratio and genes mapping directly to SNV positions are bold. For multiple entries of the same 
SNV, the most complete or most recent entry was chosen. Lower and upper limits of the 95% confidence interval are shown in 
brackets. GWAS catalog data was accessed 05/01/2012.  NR = not reported. The odds ratio is a measure of the probability of 
an event to occur in two situations. An odds ratio of 1 means both events are equally likely, while a higher OR means the event 
is more likely in group 1 (here in CD patients). 
# gene(s) variant OR reference 
1 NOD2 rs2066847-C 3.99 [NR] 45 
 NOD2, CYLD, SNX20, NKD1 rs2076756-G 1.66 [1.48-1.88] 50 
 NOD2 rs17221417-G 1.29 [1.13-1.46] 135 
2 IL23R rs11209026-G 2.66 [2.36-3.00] 12 
 IL23R rs11465804-? 1.89 [1.47-2.44] 57 
 IL23R rs11805303-T 1.39 [1.22-1.58] 136 
3 MUC19, LRRK2 rs11564258-A 1.74 [1.55-1.95] 12 
 LRRK2, MUC19 rs11175593-T 1.54 [NR] 45 
4 IRGM rs1000113-T 1.54 [1.31-1.82] 136 
 IRGM rs13361189-? 1.38 [1.15-1.66] 137 
 IRGM rs7714584-G 1.37 [1.28-1.47] 12 
 IRGM rs11747270-G 1.33 [NR] 45 
5 SLCO6A1 rs7705924-G 1.48 [1.17-1.87] 50 
6 IL12B rs10045431-? 1.45 [1.27-1.64] 57 
7 HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A rs9258260-T 1.45 [1.21-1.68] 50 
8 PSMB10 rs11574514-A 1.44 [1.35-1.52] 50 
9 PTGER4 rs1992660-? 1.42 [1.24-1.67] 138 
 PTGER4 rs9292777-T 1.37 [1.28-1.48] 50 
 PTGER4 rs11742570-C 1.33 [1.27-1.39] 12 
 PTGER4 rs4613763-C 1.32 [NR] 45 
10 CCR6,FGFR10P,RNASE2 rs2301436-? 1.37 [1.22-1.53] 57 
11 IBD5 rs2188962-? 1.36 [1.21-1.52] 57 
12 PTPN2 rs2542151-G 1.35 [NR] 45 
13 ATG16L1 rs3792109-A 1.34 [1.29-1.40] 12 
 ATG16L1, SAG, DGKD, INPP5D, USP40 rs2241880-G 1.32 [1.24-1.41] 50 
 ATG16L1 rs3828309-G 1.25 [NR] 45 
 ATG16L1 rs10210302-T 1.19 [1.01-1.41] 136 
14 NKX2-3, SLC25A28, GOT1, ENTPD7, CNNM1, COX15, CUTC rs11190141-C 1.34 [1.25-1.43] 50 
 NKX2-3 rs4409764-T 1.22 [1.17-1.27] 12 
 NKX2-3 rs11190140-T 1.20 [NR] 45 
 NKX2-3 rs10883365-G 1.20 [1.03-1.39] 136 
15 PTPN22 rs2476601-G 1.31 [NR] 45 
16 NELL1 rs1793004-? 1.30 [1.12-1.52] 138 
17 TCERG1L rs10734105-G 1.27 [1.10-1.43] 50 
18 ZNF365 rs10995271-C 1.25 [NR] 45 
 ZNF365 rs10761659-G 1.23 [1.18-1.29] 12 
 ZNF365, ERG2, ADO rs7076156-G 1.19 [1.10-1.30] 50 
19 SLC22A4, SLC22A5, IRF1, IL3 rs12521868-T 1.23 [1.18-1.28] 12 
 IL3, ACSL6, P4HA2, PDLIM4, SLC22A4 rs3091338-T 1.23 [1.08-1.42] 50 
20 MAP3K7IP1 rs2413583-C 1.23 [1.17-1.29] 12 
21 GALC, GPR65 rs8005161-T 1.23 [1.16-1.31] 12 
22 C10orf67 rs1398024-A 1.23 [1.04-1.45] 139 
23 TNFSF15 rs4263839-G 1.22 [NR] 45 
 TNFSF15, TNFSF8 rs3810936-C 1.21 [1.15-1.27] 12 
24 MST1, GPX1, BSN rs3197999-A 1.22 [1.16-1.27] 12 
 BSN, MST1 rs9858542-A 1.09 [0.96-1.24] 136 
25 CDKAL1 rs6908425-C 1.21 [NR] 45 
26 CCL2,CCL7 rs3091315-A 1.20 [1.14-1.26] 12 
 CCL7, CCL2, CCL11, CCL8,CCL13, CCL1 rs3091316-G 1.14 [1.03-1.27] 50 
27 ZMIZ1 rs1250550-G 1.19 [1.15-1.23] 12 
28 IL18RAP,IL12RL2,IL18R1,IL1RL1 rs2058660-G 1.19 [1.14-1.26] 12 
29 UBE2D1 rs1819658-C 1.19 [1.13-1.25] 12 
30 STAT3 rs744166-A 1.18 [NR] 45 
31 CARD9, SNAPC4 rs4077515-T 1.18 [1.13-1.22] 12 
32 C11orf30 rs7927894-T 1.16 [NR] 45 
33 TMEM17, EHBP1, CPAMD8, AK3 rs6545946-C 1.16 [1.06-1.27] 50 
34 SLC43A3, PRG2, PRG3 rs11229030-C 1.15 [1.10-1.39] 50 
35 GCKR rs780093-T 1.15 [1.10-1.21] 12 
36 C8orf84, TERF1, RPL7, RDH10, KCNB2 rs12677663-T 1.15 [1.04-1.28] 50 
37 ITLN1 rs2274910-C 1.14 [NR] 45 
38 THADA rs10495903-T 1.14 [1.09-1.20] 12 
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39 C2orf74,REL rs10181042-T 1.14 [1.09-1.19] 12 
40 ICOSLG rs762421-G 1.13 [NR] 45 
41 SCAMP3, MUC1 rs3180018-A* 1.13 [1.06-1.19] 12 
42 JAK2 rs10758669-C 1.12 [NR] 45 
43 ORMDL3 rs2872507-A 1.12 [NR] 45 
44 SP140 rs7423615-T 1.12 [1.07-1.18] 12 
45 IL10, IL19 rs3024505-T 1.12 [1.07-1.17] 12 
46 SMAD3 rs17293632-T 1.12 [1.07-1.16] 12 
47 TYK2, ICAM1, ICAM3 rs12720356-G 1.12 [1.06-1.19] 12 
48 RTEL1, TNFRS-F6B, SLC2A4RG rs4809330-G 1.12 [1.06-1.18] 12 
49 IL2RA rs12722489-C 1.11 [1.05-1.16] 12 
50 YDJC rs181359-T 1.10 [1.06-1.15] 12 
51 PRDX5, ESRRA rs694739-A 1.10 [1.05-1.16] 12 
52 TNFSF11 rs2062305-G 1.10 [1.05-1.15] 12 
53 TAGAP rs212388-G 1.10 [1.05-1.14] 12 
54 MTMR3 rs713875-C 1.08 [1.04-1.13] 12 
55 CPEB4 rs359457-T 1.08 [1.04-1.12] 12 
 CPEB4 rs359457-T 1.08 [1.04-1.12] 12 
56 FADS1 rs102275-C 1.08 [1.04-1.12] 12 
57 ZFP36L1 rs4902642-G 1.07 [1.11-1.04] 12 
58 FUT2, RASIP1 rs281379-A 1.07 [1.04-1.11] 12 
59 IL27, SH2B1, EIF3C, LAT, CD19 rs151181-G 1.07 [1.03-1.12] 12 
60 BACH2 rs1847472-G 1.07 [1.03-1.11] 12 
61 DNMT3A rs13428812-G 1.06 [1.03-1.10] 12 
62 NDFIP1 rs11167764-C 1.06 [1.02-1.11] 12 
63 PLCL1 rs6738825-A 1.06 [1.02-1.11] 12 
64 ERAP2, LRAP rs2549794-C 1.05 [1.02-1.09] 12 
65 VAMP3 rs2797685-A 1.05 [1.01-1.10] 12 
66 PUS10, PEX13, REL, KIAA1841, C2orf74, PAPOLG, USP34 rs13003464-G 1.05 [1.00-1.40] 50 
67 DENND1B rs1998598-G 1.04 [1.00-1.09] 12 
 
Supplementary table 2 Potential immune functions of genes associated with CD risk. 
The functional description is mainly from OMIM and RefSeq. 
gene(s) function 
NOD2 
- intracellular receptor for bacterial products 
- leads to NF-kB activation 
- induces autophagy in dendritic cells 
- interacts with MHC II antigen presentation machinery 
IL23R 
- associated with JAK2 and STAT3 
- IL-12 stimulation induces production of IL-17 and IFNG by lymphoid cells expressing Thy1, 
stem cell antigen-1, retinoic acid-related orphan receptor (Ror)-gamma-t; (RORC), and IL23R 
MUC19, LRRK2 
MUC19 
- gel-forming mucin 
LRRK2 
- might be involved in the endosomal-autophagic pathway 
IRGM 
- gamma-interferon (IFNG)-induced GTP-binding proteins 
- control of intracellular pathogens 
- plays a role in autophagy 
SLCO6A1 NA 
IL12B 
- produced by macrophages, induced by bacterial lipoproteins via TLRs 
- part of IL12B/p19 complex (=IL23), high expression of IL23 in dendritic cells 
- IL23 enhances IFNG secretion by memory T-cells in IL-2 dependent manner 
- induces production of IL22 in T-cells 
HLA-F, MOG, HLA-G, GABBR1, HLA-H, UBD, HLA-A HLAs = human leukocyte antigen, involved in MHC presentation of antigens 
PSMB10 - part of the immunoproteasome - processing of MHC class I peptides  
PTGER4 - Involved in migration of Langerhans’ cells to lymph nodes 
CCR6 
- CC chemokine receptor 
- might interact with beta-defensins and promote adaptive immune responses by 
recruiting dendritic and T cells to the site of microbial invasion 
IBD5 NA 
PTPN2 
- potential tumor suppressor gene 
- expression might modify beta-cell responses to dsRNA 
- might counter dsRNA induced apoptosis 
ATG16L1 
- component of the autophagy complex 
- required for autophagy in dendritic cells 
- ATG16L1 deficient macrophages produce high amounts of IL-1β and IL-18 
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gene(s) function 
NKX2-3 
- induces expression of MADCAM1, which is probably involved in homing of lymphocytes 
and macrophages 
- homozygous KO mice lack MADCAM1 expression 
PTPN22 - might impair antigen dependent response of B- and T-cell receptors  
NELL1 NA 
TCERG1L NA 
ZNF365 NA 
SLC22A4/SLC22A5 NA 
MAP3K7IP1 - may interact in the signaling between TFGBR and TAK1 
 GPR65 - might be involved in elimination of  auto reactive immature thymocytes 
C10orf67 NA 
TNFSF15 
- might induce apoptosis of endothelial cells by activation of JNK, p38 MAPK and caspases 
- inducible by IL-1 and TNF 
- induces NFkB expression in death receptor 3 expressing cells 
- enhances IL2RA and IL2RB expression of T-cells, and thus IL-2 dependent proliferation and 
secretion of IFNG and GMCSF. 
MST1 - delayed macrophage activation in KO mice 
CDKAL1 NA 
CCL7, CCL2 
CCL7 
- promotes inflammatory cellular response via induction of TGFB1 
- cleaved CCL7 acts as chemokine antagonist and dampens inflammation 
CCL2 
- regulated by NFkB 
- attracts leukocytes to sites of inflammation 
ZMIZ1 NA 
IL18RAP - co-expression with IL18R1 required for IL-18 dependent activation of NFkB and JNK 
UBE2D1 - might induce ubiquitination of p53 by E6AP 
STAT3 - acute phase response gene - activates gp130, which is required for IL-6 dependent T-cell recruitment 
CARD9 
- interacts with CARD domain of BCL10 and leads to NFkB activation 
- key transducer of dectin-1 (PRR of myeloid phagocytes) signaling 
- synergistic effect with NOD2 
C11orf30 NA 
TMEM17, EHBP1, CPAMD8, AK3 
TMEM17, EHBP1, AK3 
- NA 
CPAMD8 
- member of complement component 3 family, involved in innate immunity and damage 
control 
SLC43A3, PRG2, PRG3 
SLC43A3 
- NA 
PRG2, PRG3 
- cytotoxic polypeptide 
- microbicidal activity against gram-negative and gram-positive bacteria and fungi 
GCKR facilitates both canonical and noncanonical Wnt signaling in B lymphocytes140 
C8orf84 NA 
ITLN1 NA 
THADA NA 
C2orf74,REL NA 
ICOSLG 
- enhances T-cell proliferation and production of IL-2 dependent cytokines 
- increased expression on B-cells and monocytes  and decreased expression in dendritic 
cells upon TNF-α stimulation 
- increased surface expression on dendritic cells stimulated by GMCSF  
SCAMP3, MUC1 
SCAMP3 
-NA 
MUC1 
- transmembrane mucin 
- physical barrier with antibacterial and anti-adhesive properties 
JAK2 - involved in cytokine receptor signaling - phosphorylates STAT1-5 
ORMDL3 - alters endoplasmic reticulum (ER)-mediated calcium homeostasis and facilitates the unfolded-protein response 
SP140 - induced by IFNG 
IL10, IL19 
IL10 
- secreted in large amounts by regulatory T-cells (Tr1) after stimulation with CD3 and CD46 
antibodies in presents of IL-2 or anti-CD28 
- has anti-inflammatory properties 
- suppresses proliferation of bystander T helper cells 
IL19 
- Member of IL10 family of cytokines 
SMAD3 - involved in response to TGFBR stimulation 
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gene(s) function 
TYK2, ICAM1, ICAM3 
TYK2 
- involved in STAT1-3 and STAT5 phosphorylation and IL-23 dependent STAT4 
phosphorylation 
- might be crucial for IL-12 dependent differentiation of Th1 cells and repression of Th2 
cells 
ICAM1, ICAM3 
- ligand for lymphocyte function-associated antigens 
- provides adhesion signals in immune reactions 
- arrests leukocytes to blood vessels at sites of inflammation 
RTEL1, TNFRS-F6B, SLC2A4RG 
RTEL1, SLC2A4RG 
-NA 
TNFRS-F6B 
- binds to FASL and prevents apoptosis 
IL2RA 
- co-expressed with  CD4 on some T regulatory cells 
- IL2RA (CD25)/CD4 positive T regulatory cells prevent autoimmunity 
- microbial activation of TLR4 mediates maturation of dendritic cells, which overcomes the 
suppressive effects of IL2RA(CD25)/CD4 positive T regulatory cells 
YDJC NA 
PRDX5, ESRRA 
PRDX5 
protective role against oxidative stress 
ESRRA 
- NA 
TNFSF11 - regulator of dendritic cell function - activates anti-apoptotic serine/threonine kinase PKB 
TAGAP - coregulated with IL-2 
MTMR3 NA 
CPEB4 NA 
FADS1 NA 
ZFP36L1 target of IL4 signaling for B-cell survival 
FUT2 - involved in antigen (Lewis antigens) expression in digestive organs 
IL27, SH2B1, EIF3C, LAT, CD19 
IL27 
- expressed by antigen presenting cells 
- triggers expansion of antigen-specific naive CD4-positive T cells and promotes 
polarization towards a Th1 phenotype with expression of gamma-interferon 
- synergistic effect with IL-12 
SH2B1, EIF3C 
- NA 
LAT 
- may play an important role as a molecule downstream of PTKs, which are activated 
earliest upon T-cell stimulation 
CD19 
- reduces threshold for B-cell antigen receptor activation 
BACH2 - expressed in B-cells - regulator of expression 
DNMT3A NA 
NDFIP1 NA 
PLCL1 NA 
ERAP2/LRAP Component of MHC class I antigen presenting pathway 
VAMP3 - involved in phagocytosis 
PUS10 - transduces apoptotic signal downstream of BID to mitochondria 
DENND1B - high expression in dendritic and natural killer cells 
 
 
Digital only table: 
Supplementary table 3 Expression values by RNA-Seq. 
 
Supplementary table 4 Primer sequences used for Sanger sequencing of SNVs. 
primer name primer sequence target gene 
mbBEST2fw GCAACTCAGGCAAGGGTCAG  BEST2 
mbBEST2rev CTCTCGCCACAGGAGTTTGT  BEST2 
mbDN1fw AGCATGACACATGTTGTGTGA  FAM190A (intron) 
mbDN1rev TGGATGAATCTCCTGGGCT  FAM190A (intron) 
mbDN2fw GACTGAAGTGGCTGCTTCTGC  SYT4-SETBP1 (intergenic) 
mbDN2rev CAAGCCCCAAACATCCTGAGG  SYT4-SETBP1 (intergenic) 
mbDN3fw ACGGGTTTACCAAGGGTGTAG  NF1 (exonic, UTR) 
mbDN3rev GATGGGAGTACTGGCATAACAGG  NF1 (exonic, UTR) 
mbDN4fw GAGATGGACAGGTGCTCTTTG  MUC2 
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mbDN4rev AGGTCGGCTTCTGCTGCT  MUC2 
mbDN5fw CGAAGGTCTCTAAGCAGGCG  MST1 
mbDN5rev GAAAGGCGGGTTTGGTCC  MST1 
mbDN6fw CTTGGAAGACCCTGAAGCTG  PLVAP (intron) 
mbDN6rev CAGGCTGGTCTCAAACTCC  PLVAP (intron) 
mbCD19fw CATGCCCACACCTCTCTCC CD19 
mbCD19rev ATAGAGACAAAGACCCGCAGAG CD19 
mbCD19_2fw ACAGAGGGAGATAACGCTGTG CD19 
mbCD19_2rev AATGCAGAGACACCCAGGA CD19 
mbIKZF1fw GCATCCCAGCAGAGAAGCA IKZF1 
mbIKZF1rev TCCCACACACCAGAGGAC IKZF1 
mb_KCNA4fw GGTCAGAGCAATGAGGGAAG KCNA4 
mb_KCNA4rev GAGAGGCTTGCTCACTCCAG KCNA4 
mb_ITGAVfw TTCTCTCGGGACTCCTGCTA ITGAV 
mb_ITGAVrev CTCGGAAATCAATCCCAATG ITGAV 
mb_AURKAIP1fw GTATCCAGTCTGGGCAGGAA AURKAIP1 
mb_AURKAIP1rev GGCCCCTTTACAGCACATC AURKAIP1 
mb_FUT4fw GTCCTACGGAGAGGCTCAGG FUT4 
mb_FUT4rev GCGACTCGAAGTTCATCCA FUT4 
mb_PNKPfw GGTCCGTAACCTGGGTCAG PNKP 
mb_PNKPrev AGCAGTTAATGGTGGGGAAA PNKP 
mb_MMP9fw GGGAAGATGCTGCTGTTCA MMP9 
mb_MMP9rev CCTCACCTCGGTACTGGAAG MMP9 
mb_HCN4fw CTAGATGACGGGGATCTGGA HCN4 
mb_HCN4rev ACACCATCAGCTGGCGTAG HCN4 
mb_TTLL10fw GGATTGTCCAGGGTATTGGA TTLL10 
mb_TTLL10rev GTGTGGCAGAGGCTCTTTCT TTLL10 
mb_C19orf6fw GGTCAGCTCTTCCTCCTCCT C19orf6 
mb_C19orf6rev TGTTTGTGCTCTTCGTCCTG C19orf6 
mb_PAK6fw CCCTCTGACCACTTCGGATA PAK6 
mb_PAK6rev CAACACCTGTGTCCTCACCA PAK6 
mb_KIAA1522fw CTCAATCCTCCGACACCATT KIAA1522 
mb_KIAA1522rev AGCTTACGCAGGGACACACT KIAA1522 
mb_HEG1fw CGTGGTACTGTGGTGCAGAC HEG1 
mb_HEG1rev CAACAGCTGTGCTGTGAACC HEG1 
mb_RASA3fw CACCGAACGCCTTTATTGTT RASA3 
mb_RASA3rev GCTGTCCTCGAGTGATCTCC RASA3 
mb_WNT9Bfw GAGGACTCACCCAGCTTCTG WNT9B 
mb_WNT9Brev TAGGCCTAGTGCTTGCAGGT WNT9B 
mb_LDOC1Lfw CTCTCTCGCACAGCCCTATT LDOC1L 
mb_LDOC1Lrev GTGTGGCCTTCCTTGTGTCT LDOC1L 
mb_SPZ1fw CAGGAAGCAGAACACTGGAG SPZ1 
mb_SPZ1rev CATGCTTAGCCGACACTTCA SPZ1 
mb_C2CD4Afw AGCAGAGAGTGGCCAGATGT C2CD4A 
mb_C2CD4Arev GGATGCAGAACTCAGGGATG C2CD4A 
mb_PTRFfw GCCTTCTTGAAGTCGTCCAC PTRF 
mb_PTRFrev CCAAACTGAGCATCAGCAAA PTRF 
mb_SPTBN4fw TGCAGCTGCTCAAGAAACAC SPTBN4 
mb_SPTBN4rev TGGACCATTCCTGTGAACTG SPTBN4 
mb_IRF5fw ACAGTGACCGACCTGGAGAT IRF5 
mb_IRF5rev CTTGTCACTGGGGATGTCCT IRF5 
mb_KLC3fw ATAGTCCCAGGGGCCAGTTA KLC3 
mb_KLC3rev GCGTACTGGATCACGAGGTT KLC3 
mb_OGFOD2fw GTTGGAACCTTGTCGTCTGG OGFOD2 
mb_OGFOD2rev GTAGGCTGCGGGGATTTTAT OGFOD2 
mb_NOS3fw CAGCTCGCCTCTAGCTCCTA NOS3 
mb_NOS3rev ACCTCCCAGTTCTTCACACG NOS3 
mb_NUMBfw ACAGGCTGAGAGGTGAGGAA NUMB 
mb_NUMBrev CGACCGATGGTTAGAAGAGG NUMB 
mb_IL18BPfw CTGCACAGCACCAACTTCTC IL18BP 
mb_IL18BPrev CTACACCTCCTCTGCCCAAG IL18BP 
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Supplementary figure 1 Detection of antisense events. 
1. The wig files for the forward and reverse strand are searched for continuous blocks of coverage (transcriptionally active regions = TARs) 2. Each TAR is assigned a category, depending on its location 
relative to annotated transcripts. 3. Antisense events are classified by the category of the sense and antisense TAR. For a better overview of different S/AS pair classes see Figure X. 4. The antisense to 
sense coverage ratio is calculated and compared to the antisense noise level, which has been calculated before. If the score does not pass the threshold (z-score >= 1.96), the antisense event is 
rejected. 
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Supplementary figure 2 Examples of possible sense/antisense pairs. 
A-C Schematic representation of sense antisense pairs which often show positively correlated expression patterns. A  An short 
antisense transcript is located in the promoter region of the sense transcript. B S/AS pair in head-to-head conformation. C S/AS 
pair in tail-to-tail conformation. D S/AS pair showing mutually exclusive expression of one transcript. 
 
 
Supplementary figure 3 Assessment of chromosome and allele specific expression. 
At positions in which the chromosomes inherited by the mother and father differ (A) it is possible to determine which 
chromosome shows transcriptional activity. At these positions it is possible, that there is equal expression on either or both 
chromosomes, which results in equal amounts of reads for both alleles on both strands (B), or it could be possible, that the 
sense and antisense events are transcribed mutually exclusive from either chromosome, in which case all forward and reverse 
reads would show only one allele respectively (C). 
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Supplementary table 5 Summary of mapping statistics and raw data output for son. 
 
  
MP genome PE1 genome PE2 genome  PE3 genome PE exome PE trans PE trans biopsy 
raw data forward tags [N]: 445951311 456920738 453283622 629127605 100324928 74271146 75535115 
> forward tags [Gb]: 22.2976 22.846 22.6642 31.4564 5.0162 3.7136 3.7768 
> reverse tags [N]: 445843429 452042578 448523261 629127605 100324928 52832267 73794354 
> reverse tags [Gb]: 22.2922 11.3011 11.2131 22.0195 3.5114 1.3208 1.8449 
> total tags [N]: 891794740 908963316 901806883 1258255210 200649856 127103413 149329469 
> total tags [Gb]: 44.5897 34.1471 33.8773 53.4758 8.5276 5.0344 5.6216 
> x coverage.: 14.8632 11.3824 11.2924 17.8253 2.8425 1.6781 1.8739 
mapped data mapped forward tags [N]: 350124057 323635646 327569904 489808400 73743689 49667174 39726141 
> mapped forward tags [Gb]: 17.5062 16.1818 16.3785 24.4904 3.6872 2.4834 1.9863 
> % of total fw-tags: 78.51 70.83 72.27 77.86 73.5 66.87 52.59 
> uniquely mapped forward tags [N]: 292020440 254222360 258836268 397984051 61847298 39070035 29720947 
> uniquely mapped forward tags [Gb]: 14.601 12.7111 12.9418 19.8992 3.0924 1.9535 1.486 
> % of mapped fw-tags: 83.4 78.55 79.02 81.25 83.87 78.66 74.81 
> number of start points for uniquely fw-mapped tags: 246193228 228435757 238773079 336325047 35972149 8513193 5900407 
> mapped reverse tags [N]: 352567333 176851507 186564467 152977299 35573173 10074259 11723769 
> mapped reverse tags [Gb]: 17.6284 4.4213 4.6641 5.3542 1.2451 0.2519 0.2931 
> % of total rev-tags: 79.08 39.12 41.6 24.32 35.46 19.07 15.89 
> uniquely mapped reverse tags [N]: 296136111 114290096 122811022 118884529 29327592 7108853 7740198 
> uniquely mapped reverse tags [Gb]: 14.8068 2.8573 3.0703 4.1610 1.0265 0.1777 0.1935 
> % of mapped rev-tags: 83.99 64.62 65.83 77.71 82.44 70.56 66.02 
> number of start points for uniquely mapped rev-tags: 254401952 105249172 114749501 106300687 18011844 2529329 2336671 
> total mapped tags [N]: 702691390 500487153 514134371 642785699 109316862 59741433 51449910 
> total mapped tags [Gb]: 35.1346 20.6031 21.0426 29.8446 4.9322 2.7352 2.2794 
> x coverage: 11.7115 6.8677 7.0142 9.9482 1.6441 0.9117 0.7598 
mapped pairs mapped pairs [N]: 403060374 352699284 363680372 499483939 75827547 51609455 43275253 
> mapped pairs [Gb]: 40.306 26.4524 27.276 42.4561 6.4453 3.8707 3.2456 
> x coverage [Gb]: 13.4353 8.8175 9.092 14.152 2.1484 1.2902 1.0819 
> non redundant pairs [N]: 376553573 344691280 357961748 472851886 65767936 51609455 43275253 
> non redundant pairs [Gb]: 37.6554 25.8518 26.8471 40.1924 5.5903 3.8707 3.2456 
> x coverage [Gb]: 12.5518 8.6173 8.949 13.3975 1.8634 1.2902 1.0819 
> % of mapped pairs: 93.42 97.73 98.43 94.67 86.73 100 100 
> unique AAA pairs [N]: 248571059 141781403 147201288 260881994 48378547 9178803 8434136 
> unique AAA pairs [Gb]: 24.8571 10.6336 11.0401 22.175 4.1122 0.6884 0.6326 
> x coverage [Gb]: 8.2857 3.5445 3.68 7.3917 1.3707 0.2295 0.2109 
> % of mapped pairs: 61.67 40.2 40.48 52.23 63.8 17.79 19.49 
> non redundant AAA pairs [N]: 223493788 135855494 143378507 237472494 40363516 9178803 8434136 
> non redundant AAA pairs [Gb]: 22.3494 10.1892 10.7534 20.1852 3.4309 0.6884 0.6326 
> x coverage [Gb]: 7.4498 3.3964 3.5845 6.7284 1.1436 0.2295 0.2109 
> % of mapped pairs: 55.45 38.52 39.42 47.54 53.23 17.79 19.49 
MP = mate-pair, PE = paired-end, exome = agilent sureselect  human all exon v1, trans = transcriptome (WTAK) 
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Supplementary table 6 Summary of mapping statistics and raw data output for mother. 
  MP genome PE1 genome PE2 genome  PE3 genome PE exome PE trans 
raw data forward tags [N]: 458149091 473526191 472770316 523374482 102944572 66924522 
> forward tags [Gb]: 22.9075 23.6763 23.6385 26.1687 5.1472 3.3462 
> reverse tags [N]: 462199362 465875291 457813943 523374482 102944572 64533416 
> reverse tags [Gb]: 23.11 11.6469 11.4453 18.3181 3.6031 1.6133 
> total tags [N]: 920348453 939401482 930584259 1046748964 205889144 131457938 
> total tags [Gb]: 46.0174 35.3232 35.0839 44.4868 8.7503 4.9596 
> x coverage.: 15.3391 11.7744 11.6946 14.8289 2.9168 1.6532 
mapped data mapped forward tags [N]: 363842610 338137021 261876111 393970329 76588175 38924863 
> mapped forward tags [Gb]: 18.1921 16.9069 13.0938 19.6985 3.8294 1.9462 
> % of total fw-tags: 79.42 71.41 55.39 75.28 74.4 58.16 
> uniquely mapped forward tags [N]: 305403784 264501880 202670080 307624797 64306683 29854242 
> uniquely mapped forward tags [Gb]: 15.2702 13.2251 10.1335 15.3812 3.2153 1.4927 
> % of mapped fw-tags: 83.94 78.22 77.39 78.08 83.96 76.7 
> number of start points for uniquely fw-mapped tags: 259492160 240830477 185246492 264184978 38222279 4386661 
> mapped reverse tags [N]: 363384570 195026814 187937260 130802678 35213137 10012262 
> mapped reverse tags [Gb]: 18.1692 4.8757 4.6984 4.5781 1.2325 0.2503 
> % of total rev-tags: 78.62 41.86 41.05 24.99 34.21 15.51 
> uniquely mapped reverse tags [N]: 309028158 125945636 119893972 96523820 29038544 6656923 
> uniquely mapped reverse tags [Gb]: 15.4514 3.1486 2.9973 3.3783 1.0163 0.1664 
> % of mapped rev-tags: 85.04 64.58 63.79 73.79 82.47 66.49 
> number of start points for uniquely mapped rev-tags: 266971231 116910476 109576277 86032711 18418018 1910206 
> total mapped tags [N]: 727227180 533163835 449813371 524773007 111801312 48937125 
> total mapped tags [Gb]: 36.3614 21.7825 17.7922 24.2766 5.0619 2.1965 
> x coverage: 12.1205 7.2608 5.9307 8.0922 1.6873 0.7322 
mapped pairs mapped pairs [N]: 416112766 374416125 335080328 406170232 78481279 41203376 
> mapped pairs [Gb]: 41.6113 28.0812 25.131 34.5245 6.6709 3.0903 
> x coverage [Gb]: 13.8704 9.3604 8.377 11.5082 2.2236 1.0301 
> non redundant pairs [N]: 390720370 367976506 327688502 389301693 69938773 41203376 
> non redundant pairs [Gb]: 39.072 27.5982 24.5766 33.0906 5.9448 3.0903 
> x coverage [Gb]: 13.024 9.1994 8.1922 11.0302 1.9816 1.0301 
> % of mapped pairs: 93.9 98.28 97.79 95.85 89.12 100 
> unique AAA pairs [N]: 266799621 150484729 138515823 194874028 48595950 8792113 
> unique AAA pairs [Gb]: 26.68 11.2864 10.3887 16.5643 4.1307 0.6594 
> x coverage [Gb]: 8.8933 3.7621 3.4629 5.5214 1.3769 0.2198 
> % of mapped pairs: 64.12 40.19 41.34 47.98 61.92 21.34 
> non redundant AAA pairs [N]: 242663400 145707963 132432275 179946092 41779409 8792113 
> non redundant AAA pairs [Gb]: 24.2663 10.9281 9.9324 15.2954 3.5512 0.6594 
> x coverage [Gb]: 8.0888 3.6427 3.3108 5.0985 1.1837 0.2198 
> % of mapped pairs: 58.32 38.92 39.52 44.3 53.23 21.34 
MP = mate-pair, PE = paired-end, exome = agilent sureselect  human all exon v1, trans = transcriptome (WTAK) 
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Supplementary table 7 Summary of mapping statistics and raw data output for father. 
  MP genome PE1 genome PE2 genome  PE3 genome PE exome PE trans 
raw data forward tags [N]: 483587949 455297734 545122442 441176353 105096625 77256598 
> forward tags [Gb]: 24.1794 22.7649 27.2561 22.0588 5.2548 3.8628 
> reverse tags [N]: 485942401 444781261 528971159 441244131 105096625 73769852 
> reverse tags [Gb]: 24.2971 11.1195 13.2243 15.4435 3.6784 1.8442 
> total tags [N]: 969530350 900078995 1074093601 882420484 210193250 151026450 
> total tags [Gb]: 48.4765 33.8844 40.4804 37.5024 8.9332 5.7071 
> x coverage.: 16.1588 11.2948 13.4935 12.5008 2.9777 1.9024 
mapped data mapped forward tags [N]: 344949116 337390407 415336167 334887372 79862683 49646837 
> mapped forward tags [Gb]: 17.2475 16.8695 20.7668 16.7444 3.9931 2.4823 
> % of total fw-tags: 71.33 74.1 76.19 75.91 75.99 64.26 
> uniquely mapped forward tags [N]: 287534155 260856808 333044788 267174954 67176631 38274337 
> uniquely mapped forward tags [Gb]: 14.3767 13.0428 16.6522 13.3587 3.3588 1.9137 
> % of mapped fw-tags: 83.36 77.32 80.19 79.78 84.12 77.09 
> number of start points for uniquely fw-mapped tags: 239941712 237512358 295760020 230668244 38049140 5916853 
> mapped reverse tags [N]: 364283204 210616370 253432829 200553150 39443555 15479389 
> mapped reverse tags [Gb]: 18.2142 5.2654 6.3358 7.0194 1.3805 0.387 
> % of total rev-tags: 74.96 47.35 47.91 45.45 37.53 20.98 
> uniquely mapped reverse tags [N]: 309041756 139570603 175273321 161309752 32708879 10878470 
> uniquely mapped reverse tags [Gb]: 15.4521 3.4893 4.3818 5.6458 1.1448 0.272 
> % of mapped rev-tags: 84.84 66.27 69.16 80.43 82.93 70.28 
> number of start points for uniquely mapped rev-tags: 259950464 129140741 159162927 142948390 19672063 2527013 
> total mapped tags [N]: 709232320 548006777 668768996 535440522 119306238 65126226 
> total mapped tags [Gb]: 35.4616 22.1349 27.1026 23.7637 5.3737 2.8693 
> x coverage: 11.8205 7.3783 9.0342 7.9212 1.7912 0.9564 
mapped pairs mapped pairs [N]: 414305583 370564765 446948994 355043327 82765958 53095185 
> mapped pairs [Gb]: 41.4306 27.7924 33.5212 30.1787 7.0351 3.9821 
> x coverage [Gb]: 13.8102 9.2641 11.1737 10.0596 2.345 1.3274 
> non redundant pairs [N]: 385776682 363128624 431857388 334450104 73154660 53095185 
> non redundant pairs [Gb]: 38.5777 27.2346 32.3893 28.4283 6.2181 3.9821 
> x coverage [Gb]: 12.8592 9.0782 10.7964 9.4761 2.0727 1.3274 
> % of mapped pairs: 93.11 97.99 96.62 94.2 88.39 100 
> unique AAA pairs [N]: 249184807 161643340 213783589 211810054 51714029 13031279 
> unique AAA pairs [Gb]: 24.9185 12.1233 16.0338 18.0039 4.3957 0.9773 
> x coverage [Gb]: 8.3062 4.0411 5.3446 6.0013 1.4652 0.3258 
> % of mapped pairs: 60.15 43.62 47.83 59.66 62.48 24.54 
> non redundant AAA pairs [N]: 221949584 156062383 201783825 193539561 44118023 13031279 
> non redundant AAA pairs [Gb]: 22.195 11.7047 15.1338 16.4509 3.75 0.9773 
> x coverage [Gb]: 7.3983 3.9016 5.0446 5.4836 1.25 0.3258 
> % of mapped pairs: 53.57 42.11 45.15 54.51 53.3 24.54 
MP = mate-pair, PE = paired-end, exome = agilent sureselect  human all exon v1, trans = transcriptome (WTAK) 
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Supplementary table 8 Summary of achieved coverage. 
 genomic coverage (excluding Ns) quantiles  
covered 0x 1x 3x 5x 10x 20x 25% 50% 75% average coverage per coverable base 
mother 0.46% 99.54% 98.96% 98.33% 95.85% 83.83% 39x 31x 23x 34.72 
father 0.12% 99.88% 99.55% 99.10% 97.34% 89.58% 43x 35x 27x 40.28 
son 0.13% 99.87% 99.48% 98.92% 96.51% 84.81% 42x 33x 24x 36.57 
 coverage of refSeq annotated transcripts (excluding Ns) quantiles   
covered 0x 1x 3x 5x 10x 20x 25% 50% 75% average coverage per coverable base 
mother 0.98% 99.02% 97.18% 95.80% 92.81% 84.31% 84x 40x 26x 66.23 
father 0.72% 99.28% 97.54% 96.10% 92.78% 83.68% 89x 41x 26x 69.84 
son 0.64% 99.36% 97.88% 96.64% 93.80% 85.83% 88x 43x 28x 68.58 
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Supplementary table 9 SNV calling statistics. 
 MOTHER FATHER SON 
SNP-type/location known novel known novel known novel 
rsID SNVs: 2995470 - 3055342 - 3027916 - 
novel SNVs: - 312818 - 319877 - 315156 
Venter+Watson SNVs: 17 - 20 - 20 - 
Watson SNVs: 1263 - 1377 - 1396 - 
Venter SNVs: 1933 - 1883 - 2071 - 
gene associated SNVs: 1173779 112517 1199115 113088 1194183 112535 
UTR-SNVs (intron): 210478 21000 213777 21553 211519 21064 
UTR-SNVs (exon): 26517 2344 26711 2331 27140 2355 
neighbourhood-SNVs: 62072 6490 63147 6477 62915 6522 
coding SNV: 13804 1367 13853 1403 14093 1452 
intronic SNV: 860908 81316 881627 81324 878516 81142 
homozygous sense: 7396 470 7422 508 7567 498 
heterozygous missense: 2571 736 2583 734 2559 803 
homozygous missense: 3212 80 3221 73 3321 71 
splice-junction (intron): 157 34 155 28 159 41 
splice-junction (exon, heterozygous): 20 2 27 3 19 5 
splice-junction (exon, homozygous): 13 0 16 1 15 1 
read-through (heterozygous): 10 3 7 2 9 4 
read-through (homozygous): 12 0 14 1 17 0 
altered M (heterozygous): 115 28 120 16 112 19 
altered M (homozygous): 161 2 162 1 161 3 
nonsense (heterozygous): 13 19 12 25 23 23 
nonsense (homozygous): 15 4 15 0 10 2 
new M (heterozygous): 144 22 123 37 152 22 
new M (homozygous): 122 1 131 2 128 1 
New M = base changes leading to a new methionine which might represent a new start-site for transcription; Altered M = changing a methionine into another amino acid, which could possibly remove an 
(alternative) start codon. 
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Supplementary table 10 Bioscope SNV correlation with Illumina iScan 1M human Omniquad chip. 
 SNV calls only SNV calls + consensus calls* 
Mother 2x 5x 10x 20x 1x 2x 5x 10x 20x 
concordant 412156 406207 363984 149562 977270 975848 962268 888112 478435 
unconcordant 3164 2394 1100 235 25679 25268 21904 14072 5831 
concordant 99.24% 99.41% 99.70% 99.84% 97.44% 97.48% 97.77% 98.44% 98.80% 
unconcordant 0.76% 0.59% 0.30% 0.16% 2.56% 2.52% 2.23% 1.56% 1.20% 
 
 SNV calls only SNV calls + consensus calls* 
Father 2x 5x 10x 20x 1x 2x 5x 10x 20x 
concordant 418085 413801 385052 205650 984279 982935 971955 917402 587598 
unconcordant 2658 2066 1130 290 20627 20312 17815 12648 6199 
concordant 99.37% 99.50% 99.71% 99.86% 97.95% 97.98% 98.20% 98.64% 98.96% 
unconcordant 0.63% 0.50% 0.29% 0.14% 2.05% 2.02% 1.80% 1.36% 1.04% 
 
 SNV calls only SNV calls + consensus calls* 
Son 2x 5x 10x 20x 1x 2x 5x 10x 20x 
concordant 415218 409789 374426 180245 982764 981547 969291 905022 545816 
unconcordant 2594 1955 1001 236 22243 21939 19336 13276 5895 
concordant 99.38% 99.53% 99.73% 99.87% 97.79% 97.81% 98.04% 98.55% 98.93% 
unconcordant 0.23% 0.47% 0.27% 0.13% 2.21% 2.19% 1.96% 1.45% 1.07% 
*includes consensus calls for all positions present on the Illumina chip where there was no SNV called by bioscope (reference call) 
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Supplementary table 11 small structural variation (sSV) calling statistics. 
 mother father child 
 known novel known novel known novel 
total sSVs detected: 145,477 48,722 170,158 49,395 149,450 43,328 
no gene association: 88,918 31,585 104,652 32,332 91,224 28,300 
5'-neighbourhood: 1,244 361 1,378 352 1,253 296 
3'-neighbourhood: 1,596 464 1,852 392 1,654 375 
5'-UTR (intronic): 6,394 2,017 7,405 2,016 6,527 1,691 
3'-UTR (intronic): 1,252 439 1,456 414 1,236 385 
5'-UTR (exonic): 189 48 203 48 199 46 
3'-UTR (exonic): 1,395 298 1,623 336 1,407 296 
intronic: 44,269 13,417 51,346 13,417 45,708 11,860 
splice-junction (intronic): 13 3 18 6 20 7 
splice-junction (exonic): 11 7 12 1 10 4 
exonic: 196 83 213 81 212 68 
 
Supplementary table 12 large structural variation (lSV) calling statistics. 
 
 mother father child 
B
io
sc
op
e 
total lSVs detected [N] 5099 5059 4693 
heterozygous variants [N] 1827 1593 1062 
homozygous variants [N] 3272 3466 3631 
insertions [N] 1716 1832 814 
deletions [N] 3158 2979 3817 
double* [N] 225 248 62 
large indels >= 3000 bp 1349 1421 1351 
deletions >= 3000 bp 1271 1351 1319 
K
or
be
l total deletions 15892 22763 113104 
deletions >= 3000 bp 3273 3491 6273 
 deletions >= 3000 bp, overlapping ANY Korbel lSV   1185 
* two lSVs at the same location. 
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Digital only tables: 
Supplementary table 13 Manually reviewed lSVs. 
Supplementary table 14 Sanger sequencing of potential de novo SNVs. 
 
A B 
  
Supplementary figure 4 Origin determination by mitochondrial variations based on Röhl et al. 2001. 
Both parents have a „K“ mitotype, significant predominance of Ashkenazi matches, based on a comparison with > 40,000 mt DNA sequences. A father, B mother 
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Supplementary table 15 Overview of noncoding SNVs detected in the child in genes associated with monogenic phenocopies of Crohn disease. 
trait gene symbol 5'-neighbourhood 3'-neighbourhood 5'-UTR (intron) 
5'-UTR 
(exon) 
3'-UTR 
(exon) intron 
Blau syndrome NOD2■ 1 2 0 1 0 24 (3) 
C1 esterase inhibitor deficiency SERPING1 1 1 (1) 0 0 0 6 
CGD NCF2 11 (1) 1 2 0 2 39 (1) 
CGD NCF1 0 0 0 0 0 0 
CGD CYBA 3 5 (1) 0 0 1 8 
CVID ICOS 3 3 0 0 3 24 
CVID CD19■ 3 (2) 2 (1) 0 0 0 2 (2) 
CVID TNFRSF13B 4 11 0 0 3 (2) 51 (2) 
CVID TNFRSF13C 2 (1) 0 0 0 1 0 
Hyper-IgM syndrome CD40LG 0 0 0 0 0 1 (1) 
IPEX FOXP3 0 1 0 0 0 1 
Wiskott-Aldrich syndrome WAS 0 0 0 0 0 2 
X-linked Agammaglobulinemia BTK 0 0 1 0 1 3 
Numbers in brackets represent fraction of novel SNVs. ■ genes also associated with Crohn’s Disease 
 
Supplementary table 16 Nonsynonymous SNVs detected in the child in genes associated with monogenic phenocopies of Crohn’s disease. 
gene symbol rsID chrom position phyloP type zygosity ref allele 
allele 
A 
allele 
B 
reads 
ref 
reads 
alt freqA freqC freqG freqT SIFT 
SIFT 
score 
SIFT 
AA PolyPhen dScore 
NCF2 rs2274064 chr1 181809010 -0.337 missense hom T C C 0 29 - 0.514 - 0.486 tolerated 1.00 K181R benign -0.089 
NCF1 rs62475423 chr7 73831604 -1.034 missense hom G A A 0 3 na na na na tolerated 0.84 G99S benign -0.283 
CD19■ - chr16 28851412 3.013 missense het G T G 2 2 na na na na damaging (low confidence) 0.00 W111C 
probably 
damaging 3.083 
CD19■ rs2904880 chr16 28851897 0.938 missense het C G C 11 12 - 0.347 0.653 - tolerated 0.17 L174V benign -0.054 
NOD2■ rs2066842 chr16 49302125 -1.986 missense het C T C 11 10 - 0.683 - 0.317 tolerated 0.26 P268S benign 0.74 
NOD2■ rs2066845 chr16 49314041 3.304 missense het G G C 25 9 na na na na damaging 0 G908R probably damaging -3.854 
CYBA rs4673 chr16 87240737 1.009 missense hom A G G 0 28 - 0.750 - 0.250 tolerated 0.56 Y72H probably damaging -3.516 
TNFRSF13B rs34562254 chr17 16783716 2.027 missense het G G A 7 6 - 0.903 - 0.097 tolerated 0.52 P251L probably damaging -3.265 
IL10RA rs2229113 chr11 117374880 0.451 missense hom A G G 0 41 0.392 - 0.608 - tolerated 0.31 R351G benign - 
XIAP rs5956583 chrX 122862192 2.373 missense hom A C C 0 39 na na na na tolerated 0.15 Q423P benign -3.788 
■ genes also associated with Crohn’s Disease, conserved region (phyloP >2.0,   follows the recessive model. 1000G CEU frequencies taken from NCBI (these can be +-strand or –strand) 
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Supplementary table 17 Noncoding SNVs detected in the child in conserved regions in genes associated monogenic phenocopies of Crohn disease. 
gene 
symbol rsID chrom position phyloP location zygosity 
ref 
allele 
allele 
A 
allele 
B 
reads 
ref 
reads 
alt 
CD19■ - chr16 28851705 2.352 intron het C G C 12 6 
SERPING1 rs1005510 chr11 57123798 2.347 intron hom C T T 0 26 
NCF2 rs3818364 chr1 181809370 2.191 intron hom G T T 0 13 
Includes only SNVs with phyloP score >= 2.0. ■ genes also associated with Crohn’s Disease 
 
 
Supplementary table 18 small structural variations detected in the child in genes associated with monogenic phenocopies of Crohn disease. 
gene 
symbol rsID chrom start end type reference 
alternative 
allele zygosity location 
NCF2 rs10641967 chr1 181790126 181790126 insertion site - ATG homozygous 3'-neighbourhood 
NCF2 rs67311370 chr1 181806839 181806839 deletion a - hemizygous intronic 
ICOS rs10578138 chr2 204518019 204518020 deletion TG - hemizygous intronic 
ICOS rs56148633 chr2 204523890 204523890 deletion t - hemizygous intronic 
ICOS - chr2 204527663 204527664 deletion AGA C hemizygous intronic 
ICOS rs67643841 chr2 204531749 204531749 insertion site - G hemizygous intronic 
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Supplementary table 19 Nonsynonymous SNVs predicted to be damaging associated with genes in proximity of GWAS Crohn’s disease SNVs. 
Two nonsense SNVs were detected in FUT2 and IKZF1, which are located in conserved region (phyloP 2.791 and 3.308 respectively). The IKZF1 SNV could not be replicated by Sanger and the 
FUT2 SNV was confirmed even though the father is also heterozygous for this variant. SNVs in conserved regions were also detected in CD19, MST1 (both not replicated by Sanger), NOD2 and 
GPX1. One SNV following the recessive model of inheritance was detected in a site of acceleration in SNAPC4 (phyloP -3.617). 
rs
ID
 
ge
ne
 
sy
m
bo
l 
ch
ro
m
 
po
si
tio
n 
ph
yl
oP
 
ty
pe
 
zy
go
si
ty
 
re
f 
al
le
le
 
al
le
le
 
A
 
al
le
le
 
B
 
re
ad
s 
re
f 
re
ad
s 
al
t 
fr
eq
A
 
fr
eq
C
 
fr
eq
G
 
fr
eq
T 
SI
FT
 
SI
FT
 
sc
or
e 
SI
FT
 
A
A
 
Po
ly
Ph
en
 
dS
co
re
 
APOB48R rs40832 chr16 28416217 -1.271 missense hom T C C 0 12 - 1.000 -  not scored NA NA possibly damaging -3.166 
ATG16L1 rs2241880 chr2 233848107 -2.150 missense het A G A 22 20 - 0.528 - 0.472 tolerated 0.51 T204A possibly damaging (uc002vtz.1) -2.456 
BSN rs34762726 chr3 49664214 1.495 missense hom G A A 0 6 0.222 - 0.778 - not scored NA A741T possibly damaging -2.8 
C1orf106 rs296520 chr1 199147601 0.448 missense hom C T T 0 3 na na na na damaging (low confidence) 0.03 R538C benign -1.957 
CD19 - chr16 28851412 3.013 missense het G T G 2 2 na na na na damaging (low confidence) 0 W111C probably damaging -4.544 
FUT2 rs601338 chr19 53898486 2.791 nonsense het G G A 13 18 na na na na - - W154* - - 
GALC rs421262 chr14 87470966 -0.894 missense hom T C C 0 71 - 0.992 - 0.008 tolerated 0.72 T625A possibly damaging -2.972 
GCKR rs1260326 chr2 27584444 0.550 missense hom T C C 0 68 - 0.556 - 0.444 tolerated 0.28 L446P probably damaging -3.325 
GPX1 rs11549656 chr3 49369838 2.870 missense hom G A A 0 12 na na na na not scored NA P200L - - 
GSDMB rs2305479 chr17 35315743 -1.142 missense hom C T T 0 56 0.472 - 0.528 - damaging (low confidence) 0 G291R probably damaging -3.57 
IKZF1 - chr7 50337822 3.308 nonsense het G T G 24 6 na na na na - - E29* - - 
IL27 rs181206 chr16 28420904 1.956 missense het A G A 4 7 - 0.333 - 0.667 tolerated 0.09 L119P possibly damaging -3.708 
LRRK2 - chr12 38915756 1.354 missense het A G A 35 8 na na na na damaging 0.02 K137E benign -2.929 
MST1 rs71324987 chr3 49698754 2.623 missense het A G A 7 3 na na na na damaging 0 C298R probably damaging -3.975 
NOD2 rs2066845 chr16 49314041 3.304 missense het G G C 25 9 na na na na damaging 0 G908R probably damaging -3.854 
RASIP1 rs2287922 chr19 53924038 1.266 missense hom G A A 1 2 0.592 - 0.408 - damaging 0 R601C probably damaging -4.898 
RTEL1 - chr20 61791918 1.072 missense het T T C 15 6 na na na na tolerated 0.15 S726P probably damaging -3.989 
SNAPC4 known to 1000G chr9 138391866 -3.617 missense hom C A A 0 11 na na na na 
damaging 
(low confidence) 0 A1412S benign -2.853 
 follows the recessive model, conserved region (phyloP >2.0).  known CD risk loci.1000G CEU frequencies taken from NCBI (these can be +-strand or –strand). 
 
Supplementary table 20  Exonic and splice-junction small SVs in genes in proximity of GWAS Crohn’s disease SNVs. 
One small deletion was detected in the end of the last exon in TNFSF18, which was not predicted to cause nonsense mediated decay. A 1-basepair insertion was detected very close to a splice-
acceptor in DENND1B (3 bp from exon). 
gene symbol rsID chrom start end type zygosity ref allele alternative allele location 
SIFT 
causes nonsense 
mediated decay? 
TNFSF18 - chr1 171277162 171277163 deletion hemizygous TG - exonic no 
DENND1B rs11411505 chr1 195842930 195842930 insertion site hemizygous - T splice-junction (intronic) - 
Mother homozygous for TNFSF18 deletion, Father also hemizygous for DENND1B. 
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Digital only tables: 
Supplementary table 21 Detected CD associated SNVs (meta-analysis). 
Supplementary table 22 Known Crohn’s Disease associated SNVs detected (GWAS catalog). 
Supplementary table 23 Overview of noncoding SNVs associated with Genes in proximity of GWAS CD SNVs in the child. 
Supplementary table 24 Noncoding SNVs in conserved regions of Crohn’s Disease associated genes. 
Supplementary table 25 Overview of noncoding small structural variations in genes associated with Crohn’s Disease. 
 
Supplementary table 26  Nonsynonymous SNVs in genes involved in other inflammatory diseases, which are predicted to be damaging. 
Nine genes carry variants in conserved regions and five of them were predicted to be damaging by both applied prediction tools (NOD2, MST1 (already excluded by Sanger sequencing), ITGAX, 
IRF5 and ERBB3). Four of the variants pose novel variants, as they are not included in dbSNP130 (FRMD4B, IRF5, KIAA1109 and LRRK2). 
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BMP4 rs17563 chr14 53487272 1.422 missense hom A G G 0 28 - 0.556 - 0.444 tolerated 0.06 V152A probably damaging -2.534 
C1QTNF6 rs229526 chr22 35911368 2.42 missense het G G C 26 26 - 0.778 0.222 - tolerated 0.85 P42R probably damaging -3.786 
CCRL2 rs3204849 chr3 46425074 -2.024 missense het T T A 23 15 0.233 - - 0.767 damaging 0.00 F179Y benign -3.681 
CD6 rs11230562 chr11 60532762 -0.349 new Met het C T C 2 4 - 0.833 - 0.167 tolerated 0.22 T217M probably damaging -4.44 
CD6 rs11230563 chr11 60532785 0.577 missense het C T C 7 4 - 0.722 - 0.278 tolerated 0.10 R225W possibly damaging -2.186 
CIITA rs8046121 chr16 10903434 1.244 missense hom A G G 0 29 0.025 - 0.975 - tolerated 1.00 R174G possibly damaging -3.505 
CIITA rs7197779 chr16 10910428 2.299 missense hom A G G 0 17 - - 1.000 - tolerated 0.64 Q900R probably damaging -3.397 
ERBB3 rs773123 chr12 54781265 2.845 missense het A T A 20 22 0.117 - - 0.883 damaging (low confidence) 0.01 S1119C probably damaging -4.703 
FRMD4B rs9831516 chr3 69312751 3.208 missense hom G A A 0 25 1.000 - - - - - - probably damaging -3.175 
FRMD4B - chr3 69313097 3.258 missense het G G C 12 12 na na na na - - - possibly damaging -2.837 
GSDMB rs2305479 chr17 35315743 -1.142 missense hom C T T 0 56 0.472 - 0.528 - damaging (low confidence) 0.00 G291R probably damaging -3.57 
HLA-B rs41541519 chr6 31432043 -0.688 missense het T T A 3 2 0.967 - - 0.033 damaging (low confidence) 0.02 T167S benign -1.86 
HLA-B rs1131215 chr6 31432495 -1.819 missense hom C A A 0 2 - - 0.592 0.408 tolerated 1.00 D98Y probably damaging -3.522 
HLA-B rs1050529 chr6 31432594 0.357 missense het C T C 2 6 0.258 - 0.742 - damaging (low confidence) 0.05 A65T possibly damaging -2.878 
HLA-B rs1050518 chr6 31432620 1.647 missense het T T A 15 7 na na na na damaging (low confidence) 0.04 Q56L possibly damaging -3.04 
HLA-C rs1050328 chr6 31346134 0.364 missense hom G A A 0 8 na na na na tolerated 0.07 R243W probably damaging -4.926 
HLA-C rs1050357 chr6 31346859 1.672 missense het C T C 13 3 na na na na damaging (low confidence) 0.03 E197K possibly damaging -2.689 
HLA-C rs2308574 chr6 31347039 0.654 missense het A G A 5 2 na na na na tolerated 0.06 Y137H probably damaging -3.462 
HLA-C rs1050409 chr6 31347480 1.9 missense het G T G 3 5 na na na na damaging (low confidence) 0.02 A73E probably damaging -3.122 
HLA-DQB1 rs35418872 chr6 32737883 -0.916 missense hom T A A 0 3 na na na na - - D167V possibly damaging -3.685 
HLA-DRB1 rs17879995 chr6 32660050 1.572 missense het T T G 2 10 0.900 0.100 - - - - N62H probably damaging -3.687 
HLA-DRB5 known to 1000G chr6 32597800 -0.595 missense het C T C 12 4 na na na na 
damaging 
(low confidence) 0.03 R77Q possibly damaging -2.43 
IL17REL rs5771069 chr22 48777607 -1.432 missense hom A G G 0 12 0.392 - 0.608 - damaging (low confidence) 0.00 L333P benign -1.458 
IL1RL2 rs2302612 chr2 102218140 0.347 missense hom T C C 0 20 0.792 - 0.208 - damaging (low confidence) 0.00 L550P benign -2.407 
IL27 rs181206 chr16 28420904 1.956 missense het A G A 4 7 - 0.333 - 0.667 tolerated 0.09 L119P possibly damaging -3.708 
121 
 
IRF5 - chr7 128375070 2.132 missense het T T C 6 2 na na na na damaging 0.03 L264P probably damaging -3.969 
ITGAX rs2230429 chr16 31282036 2.052 missense het C G C 13 7 - 0.708 0.292 - damaging 0.01 P517R possibly damaging -2.743 
KIAA1109 - chr4 123445422 2.748 missense het C T C 33 10 na na na na - - - probably damaging -3.242 
LCE3D rs61745411 chr1 150818909 0.446 missense het C A C 13 22 na na na na - - G43V unknown ? 
LRRK2 - chr12 38915756 1.354 missense het A G A 35 8 na na na na damaging 0.02 K137E benign -2.929 
MST1 rs71324987 chr3 49698754 2.623 missense het A G A 7 3 na na na na damaging 0.00 C298R probably damaging -3.975 
NOD2 rs2066845 chr16 49314041 3.304 missense het G G C 25 9 na na na na damaging 0.00 G908R probably damaging -3.854 
RNF186 rs1541185 chr1 20014115 -1.503 missense het C T C 6 5 - 0.764 - 0.236 tolerated 0.12 A23T possibly damaging -2.878 
SLC9A4 rs1014286 chr2 102515532 -1.259 missense hom G A A 0 46 - 0.319 - 0.681 damaging (low confidence) 0.00 G784S benign -1.781 
SULT1A1 rs9282861 chr16 28525015 1.603 missense het C T C 35 26 na na na na damaging 0.01 R213H benign -2.531 
SULT1A2 rs10797300 chr16 28514697 2.545 missense het G G A 8 9 na na na na tolerated 0.39 P19L probably damaging -3.36 
TLR8 rs3764880 chrX 12834747 -1.233 altered Met hom A G G 0 13 na na na na damaging (low confidence) 0.00 M1V benign -2.941 
TNFRSF14 rs4870 chr1 2486265 -0.599 missense het T T C 6 8 na na na na tolerated 0.17 K17R probably damaging -2.768 
WDFY4 rs7072606 chr10 49603980 0.392 missense het T T C 13 7 - 0.075 - 0.925 damaging 0.05 S214P possibly damaging -3.6 
WDFY4 rs2170132 chr10 49683408 0.407 missense het T T C 20 13 - 0.333 - 0.667 damaging 0.02 S239P benign -1.961 
WDFY4 rs7097397 chr10 49695402 1.07 missense hom G A A 0 6 0.375 - 0.625 - tolerated 0.44 R527Q possibly damaging -3.605 
WDFY4 rs2292584 chr10 49856421 -0.452 missense het C T C 12 5 0.417 - 0.583 - damaging (low confidence) 0.01 P256L benign -2.24 
■ genes also associated with Crohn’s Disease,  follows the recessive model, conserved region (phyloP >2.0) 
 
 
 
Supplementary table 27  Exonic and splice-junction sSVs in genes associated with other inflammatory diseases. 
The variants in DENN1DB and TNFSF18 have been discussed above, as these genes are also possibly associated with CD. The remaining variant is a deletion in CSMD1 (cub and sushi multiple 
domains 1) which was predicted to cause nonsense mediated decay and found to follow the recessive model of inheritance. 
trait rsID chrom start end type reference allele 
alternative 
allele zygosity 
associated 
gene location 
SIFT 
causes 
nonsense 
mediated 
decay? 
Asthma rs11411505 chr1 195842930 195842930 Insertion site2 - T hemizygous DENND1B■ splice-junction (intronic) - 
Celiac disease - chr1 171277162 171277163 deletion1 TG - hemizygous TNFSF18■ exonic no 
Multiple sclerosis rs34128718 chr8 3254412 3254412 deletion1,2,3 C - homozygous CSMD1 exonic yes 
1shared with mother; 2shared with father; 3 following recessive model; ■ genes also associated with Crohn’s Disease 
 
 
Supplementary table 28 Large structural variations in proximity of genes involved in other inflammatory disease. 
Six large deletions were detected in proximity of genes associated with inflammatory diseases. One of the deletions includes the third exon of the growth hormone receptor (GHR), which has been 
associated to an increased responsiveness to growth hormone. GHR has also been mentioned in the context with systemic lupus erythematosus. One deletion following the recessive model of 
inheritance was identified in CSMD1, a multiple sclerosis associated gene. 
like DG Var [id] gene_symb chrom loose start loose end length teresa val dot score trait 
122 
 
 (20kb range) 
- CRB1 chr1 195534187 195537759 3745 hemi - hemi (+) Asthma (GWAS catalog gene) 
59103 SCHIP1 chr3 160738319 160741679 3538 - hemi hemi + Celiac disease (GWAS catalog gene) 
39518 CSMD1 chr8 4108127 4114595 6592 hemi hemi hom +++ Multiple sclerosis (GWAS catalog gene) 
62242 BANK1 chr4 103005737 103008451 3031 hemi hom hemi + Systemic lupus erythematosus (GWAS catalog gene) 
99119 GHR* (exons, 65 bp) chr5 42662319 42668587 6471 hemi hemi hemi + 
.0031 INCREASED RESPONSIVENESS TO GROWTH HORMONE [GHR, EX3DEL] (OMIM) 
 
Systemic lupus erythematosus 
(GWAS catalog gene) 
102022 MEG3, RTL1 chr14 100404330 100409664 5392 hemi hemi hemi (+) Type 1 diabetes (GWAS catalog gene) 
*causes nonsense mediated decay (SIFT), follows recessive model. Fraction of deleted exons in [bp] given in brackets. 
 
Digital only tables: 
Supplementary table 29 Overview of noncoding SNVs in genes involved in other inflammatory diseases. 
Supplementary table 30 Noncoding SNVs in genes associated with inflammatory diseases following the recessive model (also including one non-inflammatory disease: Parkinson). 
Supplementary table 31 Overview of noncoding SNVs in genes associated with other inflammatory diseases in the child in locations of high conservation. 
 
Supplementary table 32 Small structural variations in genes associated with inflammatory diseases in the GWAS catalog. 
trait 3'-neighbourhood 
5'-
neighbourhood 
5'-UTR 
(intronic) 
5'-UTR 
(exonic) 
3'-UTR 
(exonic) intronic 
splice-
junction 
(intronic) 
exonic 
Ankylosing spondylitis 3 (1) 0 9 (4) 0 1 30 (4) 0 0 
Asthma 2 0 7 (2) 0 2 114 (18) 1 0 
Celiac disease 14 (2) 10 57 (12) 4 7 (3) 325 (73) 0 1 (1) 
Crohn's disease 4 (1) 3 (1) 22 (1) 0 3 221 (32) 0 0 
Crohn's disease and 
sarcoidosis (combined) 1 (1) 0 0 0 1 (1) 1 0 0 
Inflammatory bowel disease 0 2 1 0 0 9 (1) 0 0 
Inflammatory bowel disease 
(early onset) 3 0 16 (5) 0 0 20 (6) 0 0 
Leprosy 0 0 0 0 1 (1) 1 0 0 
Multiple sclerosis 8 (2) 7 11 (1) 0 4 (2) 465 (77) 0 1 
Psoriasis 1 2 6 0 2 39 (3) 0 0 
Rheumatoid arthritis 0 4 17 (1) 0 1 73 (10) 0 0 
Systemic lupus erythematosus 5 4 27 (7) 0 6 (2) 188 (31) 0 0 
Type 1 diabetes 4 (1) 4 29 (2) 0 4 160 (30) 0 0 
Ulcerative colitis 2 10 (1) 9 (1) 1 0 120 (20) 0 0 
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Supplementary table 33  Nonsynonymous SNVs detected in the child following the recessive model of inheritance which are predicted to be damaging. 
Among the genes with SNVs following the recessive model of inheritance are 15 located in conserved regions. Two of these are not included in dbSNP130 (BEST2 and MPHOSPH8), though the 
BEST2 can also be found in the 1000 Genome data set. 
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ANKRD35 rs6670984 chr1 144272951 -0.572 missense C T 0 49 - 0.625 - 0.375 damaging  (low confidence) 0.00 P428S benign 0.379 
ANO7 rs7590653 chr2 241812032 -0.33 missense G A 0 10 0.278 - 0.722 - damaging  (low confidence) 0.00 E912K benign -0.122 
BEST2 known to 1000G chr19 12724429 2.236 missense G A 0 22 na na na na tolerated 0.30 R8Q possibly damaging 0.576 
BRWD1 rs2183573 chr21 39496175 2.39 missense A G 0 29 0.403 - 0.597 - tolerated 0.10 S1511P probably damaging 2.08 
C12orf71 rs61741737 chr12 27126181 1.729 missense G A 0 21 0.125 - 0.875 - - - - possibly damaging 1.728 
C14orf37 rs2273442 chr14 57633447 0.996 missense G C 0 34 - 0.528 0.472 - damaging  (low confidence) 0.00 Q613E benign -1.705 
C17orf74 rs72842820 chr17 7269858 -0.909 new Met G A 0 25 0.139 - 0.861 - damaging (low confidence) 0.00 V43M probably damaging 2.461 
C17orf90 rs61742303 chr17 77245179 0.533 missense A T 0 46 0.819 - - 0.181 tolerated 0.10 K50N probably damaging 1.918 
C2orf73 rs55714450 chr2 54415516 2.365 missense C A 0 17 0.375 0.625 - - damaging  (low confidence) 0.00 H30N benign 0.068 
CCDC137 rs11150805 chr17 77249210 1.095 missense C T 0 27 - 0.847 - 0.153 damaging  (low confidence) 0.01 R177W probably damaging 3.235 
CCDC60 rs1064319 chr12 118350916 0.497 missense A G 0 31 0.625 - 0.375 - tolerated 0.27 I46V probably damaging 0.703 
CDC20B rs444527 chr5 54445856 1.299 missense G A 0 23 - 0.806 - 0.194 damaging  (low confidence) 0.03 R499W probably damaging 3.039 
COL4A3 rs28381984 chr2 227843875 1.477 missense C T 0 50 - 0.5 - 0.5 - - - probably damaging 1.751 
EPHA8 rs606002 chr1 22788340 -2.083 missense T C 0 19 0.658 - 0.342 - damaging  (low confidence) 0.00 S457P - - 
FAM75D1 - chr9 83797224 0.337 new Met T G 1 11 na na na na tolerated 0.10 I673M possibly damaging 1.785 
FCRLB rs34868416 chr1 159963943 0.844 missense G A 0 12 0.117 - 0.883 - tolerated 0.13 G383D possibly damaging 1.88 
FRG2B known to 1000G chr10 135288967 -1.606 missense G A 0 15 na na na na - - - possibly damaging 2.882 
GBE1 rs2229519 chr3 81780820 2.468 missense T C 0 21 0.681 - 0.319 - damaging 0.04 R190G benign 0.91 
GOLGA4 rs11718848 chr3 37341463 2.503 missense C A 0 25 0.389 0.611 - - tolerated 0.06 Q1028K possibly damaging 1.253 
H1FNT rs1471997 chr12 47009862 0.307 missense G A 0 6 - 0.819 - 0.181 damaging  (low confidence) 0.00 R174Q benign 0.192 
HAP1 rs4796693 chr17 37138109 0.478 splice-junction G A 0 15 0.792 - 0.208 - tolerated 0.33 S357L probably damaging 1.521 
HAP1 rs4796603 chr17 37144241 1.512 missense A T 0 9 0.125 - - 0.875 tolerated 0.26 S58T possibly damaging 1.134 
HLA-DPB1 rs1042131 chr6 33156580 1.949 missense C A 0 20 na na na na damaging (low confidence) 0.05 A85E benign 0.645 
KATNAL2 rs3744863 chr18 42814298 -0.378 missense C T 0 19 na na na na tolerated 0.31 A446T probably damaging 1.757 
KCNJ12 rs73979896 chr17 21259801 2.462 missense C T 1 4 na na na na damaging 0.01 A185V benign 0.899 
KRT76 rs11170271 chr12 51453662 2.408 missense C T 0 24 - 0.861 - 0.139 damaging 0.01 A283T possibly damaging 1.31 
LLGL2 rs1671036 chr17 71063780 1.362 missense G A 0 38 - 0.458 - 0.542 damaging 0.04 R45H benign 0.573 
LOC100131320 rs4662674 chr2 130454633 -0.549 missense G A 0 22 na na na na - - A159T benign 0.083 
LOXL4 rs1983864 chr10 100007443 2.355 missense T G 0 34 0.708 0.292 - - damaging 0.00 D405A probably damaging 2.431 
MCPH1 rs2083914 chr8 6289562 -0.460 missense G T 0 25 - - 0.847 0.153 damaging (low confidence) 0.02 R304I probably damaging 2.11 
MCPH1 rs12674488 chr8 6325714 -0.544 missense C A 0 47 0.153 0.847 - - tolerated 0.17 T682N probably damaging 1.739 
MPHOSPH8 known to 1000G chr13 19122202 3.165 missense G T 0 21 na na na na 
damaging 
(low confidence) 0.00 D460Y probably damaging 2.655 
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MUC20 rs2688542 chr3 196938622 0.752 missense G C 0 15 na na na na - - - probably damaging 2.683 
NOM1 rs2302443 chr7 156454985 3.014 missense G C 0 34 - 0.444 0.556 - damaging (low confidence) 0.05 V804L benign 0.217 
OBSL1 rs1983210 chr2 220129661 2.503 missense C G 0 9 - 0.292 0.708 - tolerated 0.29 E264D possibly damaging 0.194 
OR10A6 rs7933807 chr11 7906367 0.708 missense A C 0 43 0.5 0.5 - - damaging 0.00 V140G probably damaging 1.918 
OR10G4 rs4936880 chr11 123392194 1.943 missense A G 0 18 0.592 - 0.408 - damaging 0.00 R235G probably damaging 1.674 
OR10G4 rs4936881 chr11 123392374 1.961 missense A C 0 42 na na na na damaging 0.01 K295Q benign 1.155 
OTOL1 rs3921595 chr3 162704399 0.668 missense A C 0 14 0.5 0.5 - - damaging (low confidence) 0.03 E470A possibly damaging 1.313 
OVCH2 rs7927138 chr11 7684462 0.640 missense C T 0 22 - 0.556 - 0.444 damaging (low confidence) 0.00 R19Q benign -1.448 
PCDHA1 rs2240695 chr5 140148335 2.532 missense G T 0 13 0.569 0.431 - - damaging 0.00 C759F - - 
PCDHA1 rs7701755 chr5 140162285 1.470 missense G T 0 37 - - 0.4 0.6 damaging 0.02 S440I - - 
PCDHA1 rs4141841 chr5 140183616 2.044 missense C T 0 8 0.592 - 0.408 - damaging 0.04 A691V - - 
PCDHB16 rs61742755 chr5 140544447 0.342 missense C T 3 38 na na na na damaging 0.01 A710V benign 0.812 
PCDHB7 rs62378900 chr5 140534665 2.089 missense G T 0 6 na na na na damaging 0.01 V689L probably damaging 1.387 
PKD1L2 rs7191351 chr16 79807455 0.523 missense T A 0 16 0.617 - - 0.383 damaging  (low confidence) 0.00 Q120L probably damaging 1.719 
POLL rs3730477 chr10 103330046 0.400 missense G A 1 22 - 0.806 - 0.194 tolerated 0.06 R438W probably damaging 3.207 
PON1 rs854560 chr7 94784020 -0.305 new Met A T 0 43 0.569 - - 0.431 damaging 0.04 L55M benign 1.047 
PRPH2 rs390659 chr6 42774142 1.302 missense G C 0 24 - - 0.183 0.817 tolerated 1.00 Q304E probably damaging 2.079 
PSMD9 rs14259 chr12 120838179 2.408 missense A G 0 25 0.431 - 0.569 - damaging 0.05 E197G benign 1.372 
PTPRN2 rs1130496 chr7 157652656 1.335 missense C T 0 28 0.825 - 0.175 - tolerated 0.11 R213H possibly damaging 2.14 
RALGAPA1 rs2274068 chr14 35222928 -0.374 missense T C 0 35 0.444 0.556 - - damaging (low confidence) 0.00 T980A benign 0.081 
RGL3 rs167479 chr19 11387765 1.341 missense G T 0 4 na na na na damaging 0.00 P162H probably damaging 1.684 
RGPD3 rs72627454 chr2 106439933 1.283 missense C T 0 61 - 0.583 0.417 - tolerated 0.46 D111N - - 
RIBC2 rs1022478 chr22 44200620 -2.443 missense C G 0 10 0.875 - 0.125 - damaging 0.04 F195L benign 0.23 
SEC16B rs7522194 chr1 176172092 0.861 missense C A 0 34 0.167 0.833 - - tolerated 0.34 Q560H possibly damaging 2.451 
SEL1L2 rs41275404 chr20 13860309 0.936 missense G A 0 27 0.167 - 0.833 - damaging  (low confidence) 0.00 R75C possibly damaging 2.855 
SEMA3F rs1046956 chr3 50197930 -0.574 new Met T A 0 11 0.667 - - 0.333 tolerated 0.23 L503M benign 0.232 
SERPINA3 rs4934 chr14 94150556 0.343 missense G A 0 26 0.514 - 0.486 - damaging  (low confidence) 0.01 A9T possibly damaging 1.571 
TBC1D1 rs6811863 chr4 37638581 -1.976 missense G C 0 40 - 0.542 0.458 - - - - possibly damaging 2.164 
VWF rs1800378 chr12 6042463 0.413 missense T C 0 23 0.389 - 0.611 - tolerated 1.00 H484R possibly damaging 0.173 
ZNF142 rs3770213 chr2 219216616 -0.646 missense A T 0 41 0.7 - - 0.3 damaging (low confidence) 0.00 L956H possibly damaging 2.595 
ZNF79 rs13292096 chr9 129231007 0.486 missense C T 0 45 - 0.458 - 0.542 tolerated 0.13 T31I possibly damaging 1.851 
conserved region (phyloP >2.0) 
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Supplementary table 34 Expression values calculated with Cufflinks (FPKM) for MPHOSPH8 and BEST2 in the transcriptomes from blood and colon biopsy (only for the child). 
Expression of the highest expressed isoform of MPHOSPH8 is very similar in all three individuals, though slightly higher in the mother (4.08) compared to the father and child (2.48, 2.74). The gene 
is also expressed in the tissue of the colon biopsy on a similar level. BEST2 is not expressed in the blood samples, but the colon biopsy shows expression. 
trans_id gene_symbol FPKM_mother FPKM_father FPKM_child FPKM_child_biopsy 
uc001umf.1 MPHOSPH8 0.38 0.25 0.43 0.06 
uc001umg.2 MPHOSPH8 0.27 0.17 0.21 0.16 
uc001umh.1 MPHOSPH8 4.08 2.48 2.74 3.11 
uc001umi.2 MPHOSPH8 0.01 0.01 0.01 0.09 
uc002mux.1 BEST2 0.00 0.00 0.00 1.16 
 
Supplementary table 35  Exonic SNVs in other genes contributing to compound heterozygosity with at least one SNV predicted to be damaging. 
Among multiple genes with SNVs contributing to compound heterozygosity, only nine genes carry at least two SNVs which are distinctly inherited and predicted to be damaging (FBXW10, FLG, HLA-
A, KCNJ12, MUC2, PNMT, SYNE2, TEKT4, TTLL12). 
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C6orf15 rs1265054 chr6 31187622 -0.396 heterozygous missense 0.458 - 0.542 - T C 26 8 T C 16 5 - SNP tolerated 1 K165E benign -0.672 
C6orf15 rs2233976 chr6 31187973 0.485 heterozygous missense 0.083 - 0.917 - T C 22 19 T C 13 14 SNP - not scored N/A 0 probably damaging 2.541 
CCHCR1 rs130072 chr6 31220463 2.235 heterozygous missense na na na na T C 23 15 T C 14 11 SNP - not scored N/A 0 probably damaging 1.945 
CCHCR1 rs130067 chr6 31226490 -0.61 heterozygous missense na na na na T G 28 18 T G 21 22 - SNP tolerated 0.35 E275D benign 0.147 
CCHCR1 rs11540822 chr6 31226877 1.915 heterozygous missense na na na na T A 14 13 T A 8 6 SNP - not scored N/A 0 probably damaging 2.709 
CCHCR1 rs3130453 chr6 31232828 0.936 heterozygous nonsense na na na na T C 22 23 T C 26 17 SNP - - - - - - 
DNAH8 rs1738254 chr6 38855748 0.5 heterozygous missense - 0.933 - 0.067 G A 17 8 G A 11 14 SNP - tolerated 0.53 G473R benign -0.062 
DNAH8 rs1678674 chr6 38867357 1.814 heterozygous missense 0.05 - 0.95 - G A 18 20 G A 20 20 SNP - damaging 0.04 A727T benign 1.317 
DNAH8 rs874808 chr6 38881271 1.448 heterozygous missense - 0.583 - 0.417 G A 35 16 G A 39 16 - SNP tolerated 1 G807E benign -0.713 
DSPP ? chr4 88755386 -0.387 heterozygous missense na na na na G A 3 3 G A 9 4 SNP - tolerated 0.21 G850S unknown ? 
DSPP ? chr4 88756292 1.559 heterozygous missense na na na na G A 2 4 G A 2 2 - SNP not scored N/A NA possibly damaging 0.614 
FBXW10 rs62073746 chr17 18588350 0.463 heterozygous missense na na na na T A 36 15 T A 20 14 SNP - 
damaging 
(low confidence) 0 I23N possibly damaging 1.98 
FBXW10 ? chr17 18612686 0.607 heterozygous missense na na na na T C 9 3 T C 7 6 - SNP not scored N/A 0 probably damaging 3.586 
FLG ? chr1 150543068 1.231 heterozygous missense na na na na A C 26 6 A C 20 23 SNP - 
damaging 
(low confidence) 0 S1046A probably damaging 0.905 
FLG rs11582087 chr1 150545480 0.546 heterozygous missense na na na na T G 17 11 T G 26 11 - SNP 
damaging 
(low confidence) 0.01 S181R probably damaging 1.871 
FRG2B ? chr10 135289084 -1.759 heterozygous missense na na na na T C 9 2 T C 12 3 SNP - not scored N/A 0 benign -1.372 
FRG2B ? chr10 135290193 0.485 heterozygous missense na na na na T A 41 8 T A 34 13 - SNP not scored N/A 0 benign 1.834 
FRG2B rs9630045 chr10 135290216 0.514 heterozygous missense na na na na G C 27 10 G C 32 8 SNP - not scored N/A 0 probably damaging 1.183 
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FSIP2 ? chr2 186363112 3.23 heterozygous missense na na na na G C 18 9 G C 19 6 - SNP not scored N/A NA possibly damaging 2.612 
FSIP2 rs16827154 chr2 186379025 -0.704 heterozygous missense 0.5 - - 0.5 T A 31 16 T A 16 14 SNP - - - - benign 1.17 
FSIP2 rs17826534 chr2 186379602 0.789 heterozygous missense 0.508 - 0.492 - G A 23 27 G A 16 24 SNP - - - - benign 1.146 
HLA-A rs707910 chr6 30018642 1.065 heterozygous missense na na na na G A 8 8 G A 5 2 - SNP 
damaging 
(low confidence) 0.03 R68K benign 0.313 
HLA-A rs1059526 chr6 30019197 0.999 heterozygous missense na na na na G A 3 5 G A 5 3 SNP - 
damaging 
(low confidence) 0.03 A173T benign 0.577 
HLA-A rs1137631 chr6 30021016 -0.573 heterozygous new Met 0.142 - 0.858 - G A 25 10 G A 18 4 SNP - 
damaging 
(low confidence) 0.04 V364M benign 0.931 
IGSF3 rs41301291 chr1 116928940 0.773 heterozygous new Met - 0.983 - 0.017 T C 21 24 T C 22 17 SNP - not scored N/A 0 probably damaging 2.116 
IGSF3 ? chr1 116948152 2.299 heterozygous missense na na na na T C 15 7 T C 5 9 - SNP tolerated 0.3 E434G benign 1.454 
KCNJ12 rs8076599 chr17 21259545 -1.181 heterozygous missense na na na na G A 29 13 G A 22 20 SNP - not scored N/A 0 benign -0.432 
KCNJ12 ? chr17 21259662 2.841 heterozygous missense na na na na G A 24 7 G A 26 6 - SNP damaging 0 E139K probably damaging 1.91 
KCNJ12 ? chr17 21259680 2.841 heterozygous missense na na na na G A 27 7 G A 25 6 SNP - damaging 0 G145S probably damaging 2.295 
KCNJ12 rs1714864 chr17 21259714 2.462 heterozygous missense na na na na T C 34 18 T C 34 11 SNP - not scored N/A 0 probably damaging 2.579 
KCNJ12 rs72846667 chr17 21259878 2.462 heterozygous missense na na na na T C 39 9 T C 39 7 - SNP not scored N/A 0 possibly damaging 1.284 
KRT27 rs981684 chr17 36189338 1.951 heterozygous missense 0.433 - 0.567 - G A 27 11 G A 25 13 SNP - not scored N/A 0 benign -1.392 
KRT27 rs17558532 chr17 36189402 2.749 heterozygous missense - 0.833 - 0.167 T C 6 12 T C 8 10 - SNP not scored N/A 0 possibly damaging 0.862 
KRT27 rs17558560 chr17 36190185 0.82 heterozygous missense - 0.525 - 0.475 T C 24 13 T C 15 14 SNP - not scored N/A 0 benign 1.306 
L1TD1 ? chr1 62445477 -1.585 heterozygous missense na na na na G A 5 11 G A 22 7 - SNP not scored N/A 0 benign -0.244 
L1TD1 rs2457828 chr1 62445875 0.819 heterozygous missense - - 0.133 0.867 A C 5 4 A C 6 5 SNP - 
damaging 
(low confidence) 0 K329N benign 1.421 
LRRC37A3 rs17857225 chr17 60322621 -6.264 heterozygous missense na na na na T G 2 2 T G 3 2 SNP - not scored N/A 0 benign 0.01 
LRRC37A3 rs62071406 chr17 60322733 -1.046 heterozygous missense na na na na T A 21 9 T A 4 8 - SNP not scored N/A 0 possibly damaging 1.28 
MUC16 rs61742668 chr19 8854018 -0.67 heterozygous missense na na na na G A 9 11 G A 22 13 SNP - 
damaging 
(low confidence) 0 P731L probably damaging 1.728 
MUC16 rs61732552 chr19 8929374 -1.299 heterozygous missense 0.975 - 0.025 - G A 17 12 G A 23 11 - SNP not scored N/A 0 benign 0.653 
MUC16 ? chr19 8932562 -1.312 heterozygous missense na na na na T C 13 12 T C 15 17 - SNP not scored N/A 0 benign 1.242 
MUC16 ? chr19 8936370 -0.855 heterozygous missense na na na na T C 20 20 T C 23 17 - SNP not scored N/A T4024A benign 0.494 
MUC16 ? chr19 8950974 -0.965 heterozygous missense na na na na T C 9 11 T C 15 8 SNP - not scored N/A 0 benign 0.647 
MUC2 rs2856111 chr11 1065747 1.688 heterozygous missense - 0.092 - 0.908 T C 6 3 T C 3 2 - SNP damaging 0.03 L58P probably damaging 2.309 
MUC2 rs41411848 chr11 1071074 1.657 heterozygous missense - 0.183 - 0.817 T C 7 6 T C 6 4 - SNP tolerated 0.33 V457A benign 0.555 
MUC2 rs57737240 chr11 1071757 -0.521 heterozygous missense - 0.175 0.825 - G C 4 5 G C 5 6 - SNP tolerated 0.5 S562T benign 0.327 
MUC2 ? chr11 1082760 -3.036 heterozygous missense na na na na A C 11 3 A C 9 6 - SNP not scored N/A NA benign 0.225 
MUC2 rs56219745 chr11 1082872 -0.413 heterozygous missense na na na na G C 18 11 G C 16 14 - SNP not scored N/A 0 benign 1.397 
MUC2 rs11245947 chr11 1083057 -1.01 heterozygous missense na na na na G A 12 6 G A 16 5 SNP - not scored N/A 0 possibly damaging 1.245 
MUC4 rs62284986 chr3 196959830 1.596 heterozygous missense 0.25 - 0.75 - G A 26 16 G A 18 9 SNP - tolerated 0.1 A2102V probably damaging 1.656 
MUC4 rs2550240 chr3 196981550 1.781 heterozygous missense - 0.45 0.55 - G C 22 13 G C 17 9 - SNP tolerated 0.16 N1228K benign 0.548 
MYOM1 rs2230165 chr18 3178873 0.368 heterozygous new Met - 0.85 - 0.15 G A 12 6 G A 6 5 - SNP 
damaging 
(low confidence) 0.04 T215M possibly damaging 2.631 
MYOM1 rs1791085 chr18 3205158 1.884 heterozygous missense - 0.1 0.9 - G C 9 3 G C 9 5 SNP - not scored N/A 0 benign -1.381 
NBPF10 ? chr1 144009678 -0.727 heterozygous missense na na na na G A 40 10 G A 22 4 SNP - 
damaging 
(low confidence) 0.04 E209K - - 
NBPF10 ? chr1 144038905 -1.544 heterozygous missense na na na na G A 14 5 G A 6 6 SNP - not scored N/A 0 - - 
NBPF10 ? chr1 144072072 -0.941 heterozygous missense na na na na G A 7 3 G A 12 9 - SNP not scored N/A V628I - - 
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NEB ? chr2 152114413 3.45 heterozygous missense na na na na G A 18 13 G A 9 13 - SNP damaging 0 R4977C probably damaging 2.714 
NEB rs6713162 chr2 152204772 1.779 heterozygous missense 0.825 - 0.175 - G A 18 8 G A 20 18 SNP - not scored N/A 0 benign -0.855 
NLRP1 rs11651270 chr17 5365801 0.646 heterozygous altered Met - 0.483 - 0.517 T C 11 3 T C 9 5 - SNP tolerated 1 M1188V benign -2.797 
NLRP1 ? chr17 5374527 -0.518 heterozygous missense na na na na T C 33 17 T C 18 20 SNP - 
damaging 
(low confidence) 0.01 Q1177R benign 0.487 
NLRP1 ? chr17 5403637 0.322 heterozygous missense na na na na G C 32 13 G C 44 8 SNP - not scored N/A 0 benign 0.585 
PIK3C2G rs11044004 chr12 18326719 1.66 heterozygous missense - 0.583 - 0.417 T C 17 11 T C 12 5 SNP - not scored N/A 0 benign 0.56 
PIK3C2G rs7133666 chr12 18335076 2.501 heterozygous missense 0.075 0.925 - - A C 15 13 A C 18 12 - SNP not scored N/A 0 possibly damaging 1.875 
PLA2G4F ? chr15 40226736 0.85 heterozygous missense na na na na T C 34 19 T C 33 14 SNP - not scored N/A 0 possibly damaging 1.815 
PLA2G4F rs73403546 chr15 40230115 -0.783 heterozygous missense - 0.067 0.933 - G C 6 4 G C 6 3 - SNP tolerated 1 L248V benign 0.103 
PLB1 rs6753929 chr2 28615485 3.131 heterozygous missense - 0.225 0.775 - G C 26 14 G C 15 18 - SNP damaging 0 V212L probably damaging 1.503 
PLB1 rs11681826 chr2 28667537 -0.548 heterozygous altered Met 0.758 - 0.242 - G A 13 10 G A 8 10 SNP - not scored N/A 0 benign -0.891 
PNMT rs72554035 chr17 35079524 1.075 heterozygous missense na na na na T C 20 15 T C 17 16 SNP - not scored N/A 0 probably damaging 3.736 
PNMT ? chr17 35079776 -0.642 heterozygous missense na na na na T C 11 4 T C 4 6 - SNP not scored N/A 0 probably damaging 3.355 
PRIM2 rs6913546 chr6 57354843 0.384 heterozygous missense na na na na G A 36 21 G A 27 18 SNP - not scored N/A 0 benign -0.304 
PRIM2 rs9476080 chr6 57506116 1.942 heterozygous missense na na na na G A 27 9 G A 25 9 - SNP not scored N/A 0 probably damaging 3.192 
SLC19A1 ? chr21 45776396 2.486 heterozygous missense na na na na G A 14 5 G A 11 3 SNP - not scored N/A 0 probably damaging 1.617 
SLC19A1 rs1051266 chr21 45782222 0.909 heterozygous missense 0.433 - 0.567 - T C 8 4 T C 5 3 - SNP tolerated 0.35 H27R benign -1.909 
SYNE2 rs9944035 chr14 63517529 2.357 heterozygous missense - 0.042 - 0.958 T C 19 23 T C 6 14 SNP - damaging 0.01 I574T probably damaging 1.913 
SYNE2 rs12881815 chr14 63674348 1.947 heterozygous missense 0.058 - 0.942 - G A 21 9 G A 25 11 - SNP tolerated 0.06 E1298K possibly damaging 0.767 
SYNM rs3743242 chr15 97487151 0.357 heterozygous missense 0.917 - - 0.083 T A 25 13 T A 20 19 SNP - not scored N/A 0 probably damaging 3.682 
SYNM rs3743244 chr15 97487788 -2.088 heterozygous missense 0 0.867 - 0.133 T C 12 17 T C 21 14 - SNP not scored N/A 0 benign -0.283 
SYNM rs5030699 chr15 97489318 1.289 heterozygous missense 0.075 - 0.925 - T C 2 5 T C 4 4 - SNP not scored N/A 0 benign 1.563 
SYNM rs7167599 chr15 97490122 0.325 heterozygous missense - 0.133 0.867 - G C 27 10 G C 9 10 - SNP tolerated 1 G1344A benign 0.881 
TEKT4 rs11164112 chr2 94901349 -0.486 heterozygous missense 0.775 - 0.225 - G A 8 2 G A 5 2 SNP - not scored N/A 0 benign -0.594 
TEKT4 ? chr2 94904333 0.441 heterozygous missense na na na na T C 6 2 T C 2 5 - SNP not scored N/A 0 probably damaging 1.506 
TEKT4 ? chr2 94904378 1.401 heterozygous missense na na na na G C 8 3 G C 9 4 SNP - not scored N/A 0 possibly damaging 0.888 
TPCN2 rs72928978 chr11 68587940 2.498 heterozygous missense 0.142 - 0.858 - G A 5 5 G A 2 4 SNP - tolerated 0.06 V219I probably damaging 1.05 
TPCN2 rs3750965 chr11 68596736 0.689 heterozygous missense 0.717 - 0.283 - G A 18 9 G A 11 7 - SNP not scored N/A 0 benign 0.56 
TTLL12 rs11704935 chr22 41902298 1.288 heterozygous new Met - 0.942 0 0.058 T C 13 9 T C 9 5 - SNP not scored N/A 0 possibly damaging 2.097 
TTLL12 rs138951 chr22 41909027 -0.61 heterozygous missense 0.208 - 0.792 - G A 24 11 G A 16 9 SNP - 
damaging 
(low confidence) 0.02 R84W possibly damaging 2.842 
TXNRD2 rs5992495 chr22 18262984 -0.695 heterozygous missense - - 0.2 0.8 T G 8 3 T G 7 7 - SNP tolerated 0.65 S299R benign -0.908 
TXNRD2 rs5748469 chr22 18287099 2.528 heterozygous missense 0.325 0.675 - - A C 6 5 A C 7 4 SNP - not scored N/A 0 probably damaging 1.774 
ZAN ? chr7 100187883 -1.252 heterozygous missense na na na na T C 8 2 T C 11 4 - SNP not scored N/A 0 benign 0.013 
ZAN ? chr7 100188297 -0.353 heterozygous missense na na na na T C 18 6 T C 23 7 SNP - tolerated 0.32 L878P benign 0.173 
ZAN rs314298 chr7 100209050 -0.475 heterozygous missense 0.633 - 0.367 - T C 4 3 T C 5 3 SNP - not scored N/A 0 benign 0.806 
ZAN rs314300 chr7 100212023 2.573 heterozygous missense - 0.542 - 0.458 G A 14 12 G A 17 14 SNP - not scored N/A 0 probably damaging 1.836 
ZAN ? chr7 100226564 1.283 heterozygous missense na na na na A C 12 6 A C 11 10 SNP - not scored N/A 0 possibly damaging 1.582 
ZNF518A rs41291604 chr10 97909001 1.431 heterozygous altered Met 0.925 - 0.075 - G A 12 14 G A 11 11 SNP - not scored N/A 0 benign 0.57 
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ZNF518A rs3814226 chr10 97910052 3.455 heterozygous missense na na na na G A 9 11 G A 10 11 - SNP 
damaging 
(low confidence) 0 R1328Q probably damaging 2.108 
ZNF717 rs63417460 chr3 75868726 0.663 heterozygous missense na na na na G A 39 7 G A 34 7 - SNP - - - benign 0.37 
ZNF717 rs3009024 chr3 75869071 1.56 heterozygous missense na na na na T C 23 24 T C 39 13 - SNP - - - benign 0.753 
ZNF717 ? chr3 75869075 -0.825 heterozygous missense na na na na G C 25 20 G C 20 26 SNP - - - - benign 0.373 
ZNF717 ? chr3 75869431 -1.356 heterozygous altered Met na na na na G A 27 24 G A 16 8 - SNP - - - benign 0.165 
ZNF717 rs3009020 chr3 75869443 -2.345 heterozygous missense na na na na T C 34 20 T C 15 22 - SNP - - - benign 0.361 
ZNF717 ? chr3 75869449 -1.613 heterozygous missense na na na na T C 22 31 T C 27 16 - SNP - - - benign -0.448 
ZNF717 ? chr3 75870713 -2.49 heterozygous missense na na na na T C 28 18 T C 32 22 - SNP - - - benign 0.283 
ZNF717 ? chr3 75870820 -0.994 heterozygous missense na na na na A C 42 9 A C 41 9 SNP - - - - possibly damaging 1.307 
ZNF717 ? chr3 75870842 -0.529 heterozygous missense na na na na T G 21 13 T G 19 13 - SNP - - - benign -0.992 
ZNF717 ? chr3 75873510 1.181 heterozygous missense na na na na G A 40 17 G A 36 8 - SNP not scored N/A NA benign 0.883 
 
Supplementary table 36  Functional associations of genes listed in Supplementary table 35. 
The list of genes containing compound heterozygous SNVs contains several genes associated with CD relevant immune functions (mucin genes MUC2, MUC4, MUC16; inflammasome NLRP1) and 
related diseases (colitis-associated colon cancer: SLC19A1; psoriasis: CCHCR1). 
gene function / association (as hyperlinks) 
C6orf15 na 
CCHCR1 the aberrant function of CCHCR1 may lead to abnormal keratinocyte proliferation which is a key feature of psoriatic epidermis.112 
DNAH8 na 
DSPP expressed by the ectomesenchymal derived odontoblast cells (OMIM) 
FBXW10 protein-ubuquitin ligase  (OMIM) 
FLG facilitates epidermal differentiation and maintains barrier function (OMIM) 
FRG2B na 
FSIP2 na 
HLA-A class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. 
IGSF3 na 
KCNJ12 potassium channel (OMIM) 
KRT27 na 
L1TD1 na 
LRRC37A3 na 
MUC16 Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.141 
MUC2 The MUC2 is a major carrier of the sialyl-Tn antigen in all IM cases and in most gastric carcinoma cases.142 
MUC4 Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease.143 
MYOM1 na 
NBPF10 na 
NEB involved in skeletal muscle morphology (OMIM) 
NLRP1 significant KPNA1-, NLRP1- and NLRP3-gene expression phenotypes associated with human genotypes of Crohn's disease, Huntington's disease and rheumatoid arthritis110 
PIK3C2G regulates diverse cellular responses, such as cell proliferation, oncogenic transformation, cell migration, intracellular protein trafficking, and cell survival (OMIM) 
PLA2G4F na 
PLB1 expressed in the entire human epidermis with an accumulation in the dermoepidermis junction (OMIM) 
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PNMT phenylethanolamine N-methyltransferase (OMIM) 
PRIM2 primase *warning* pseudogenes probably present (OMIM) 
SLC19A1 Use of a novel genetic mouse model to investigate the role of folate in colitis-associated colon cancer.113 
SPTBN5 linking membrane proteins, membrane lipids, and cytosolic factors with the major cytoskeletal filament systems of the cell (OMIM) 
SYNE2 na 
SYNM na 
TEKT4 na 
TPCN2 putative cation-selective ion channel (OMIM) 
TTLL12 na 
TXNRD2 thioredoxin reductase that could directly reduce proteins such as insulin 
ZAN species-specific binding of sperm to eggs (OMIM) 
ZNF518A na 
ZNF717 na 
 
Supplementary table 37  Excerpt of potential damaging exonic SNVs in conserved regions of other functional interesting genes in the child. 
This list exhibits a very short list of possibly damaging missense SNVs which were selected by gene function. A complete list can be found in Supplementary table 38 (only digital available). Among 
the genes in this list are IL22RA2, TLR10, SIGLEC1, ECD, MMP9, ITGA3 and XRCC6 which have a very low minor allele frequency (IL22RA 0.017; TLR10 0.028; SIGLEC1 0.083, ECD 0.069) or 
are not included in dbSNP130 (MMP9, ITGA3, XRCC6). 
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XRCC6 - 2.599 chr22 40362166 heterozygous missense na na na na A W 4 2 damaging 0.00 K100I possibly damaging 2.706 
UNC5C rs2289043 2.711 chr4 96325345 homozygous altered Met - 0.597 - 0.403 A G 0 116 damaging 0.03 M721T benign 0.975 
LIMS1 - 2.196 chr2 108642546 heterozygous missense na na na na T W 18 6 damaging 0.01 F17Y probably damaging 2.024 
ITGAX rs2230429 2.052 chr16 31282036 heterozygous missense - 0.708 0.292 - C S 13 7 damaging 0.01 P517R possibly damaging 1.241 
ILF3 - 2.746 chr19 10653866 heterozygous missense na na na na A R 10 3 damaging (low confidence) 0.00 K460E probably damaging 1.724 
IL22RA2 rs28385692 2.490 chr6 137524533 heterozygous missense - 0.017 - 0.983 A R 25 20 damaging (low confidence) 0.03 L16P benign 0.642 
CD5 rs2229177 2.317 chr11 60649811 heterozygous missense - 0.403 - 0.597 C Y 23 23 damaging (low confidence) 0.00 A471V probably damaging 1.985 
BEST2 known to 1000G 2.236 chr19 12724429 homozygous missense na na na na G A 0 22 tolerated 0.30 R8Q possibly damaging 0.576 
ANP32A - 2.024 chr15 66900116 heterozygous missense na na na na T K 13 4 damaging 0.00 E8A possibly damaging 0.69 
BIRC7 - 2.637 chr20 61338227 heterozygous missense na na na na G R 13 4 damaging 0.00 G112S possibly damaging 1.114 
DOCK5 rs61732769 2.622 chr8 25230527 heterozygous new Met na na na na C Y 13 18 damaging 0.01 T469M probably damaging 1.452 
ECD rs2271904 2.399 chr10 74564381 heterozygous missense - 0.069 - 0.931 T Y 32 19 damaging 0.00 D634G possibly damaging 0.92 
ECD - 2.307 chr10 74566661 heterozygous missense na na na na T K 17 17 damaging 0.03 D504A probably damaging 2.234 
FURIN - 2.262 chr15 89220552 heterozygous missense na na na na C Y 9 2 damaging 0.01 R81C probably damaging 2.927 
LRMP rs1908946 3.220 chr12 25134382 homozygous missense - 0.542 0.458 - G C 0 47 tolerated 0.09 C253S probably damaging 1.586 
MAP3K1 rs702689 3.272 chr5 56213200 homozygous missense 0.681 - 0.319 - G A 0 89 - - - probably damaging 1.641 
MMP9 - 2.604 chr20 44076428 heterozygous missense na na na na A M 3 2 tolerated 0.11 K638T probably damaging 1.892 
NLRP12 rs34436714 2.275 chr19 59019125 heterozygous missense 0.236 0.764 - - C M 32 20 tolerated 0.17 G39V probably damaging 1.99 
SIGLEC1 rs34924243 2.633 chr20 3630126 heterozygous missense 0.083 - 0.917 - C Y 23 14 damaging (low confidence) 0.00 R464H probably damaging 2.568 
TLR10 rs11466653 2.376 chr4 38452630 homozygous altered Met - 0.028 - 0.972 A G 0 70 damaging 0.00 M326T possibly damaging 1.258 
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TLR10 rs11096957 2.095 chr4 38452886 homozygous missense 0.653 0.347 - - T G 0 61 damaging (low confidence) 0.00 N241H probably damaging 2.641 
HGF - 3.285 chr7 81230076 heterozygous missense na na na na G R 24 27 tolerated 0.15 A46V probably damaging 1.608 
IGSF3 rs61786577 3.238 chr1 116948027 heterozygous missense na na na na G R 28 19 tolerated 0.06 R476C probably damaging 2.888 
IGSF3 rs61786651 2.450 chr1 116957982 heterozygous missense na na na na C Y 43 11 damaging 0.02 D254N probably damaging 2.055 
FREM1 rs7023244 3.278 chr9 14809370 heterozygous missense - - 0.819 0.181 G K 21 15 - - - possibly damaging 2.491 
HBXIP - 3.196 chr1 110751878 heterozygous missense na na na na G R 25 10 damaging (low confidence) 0.00 P45L - - 
NUAK1 rs3741883 3.086 chr12 104985068 heterozygous missense - 0.139 0.861 - G S 18 18 tolerated 0.15 P543R possibly damaging 1.833 
ITGA3 rs61730081 3.064 chr17 45506848 heterozygous new Met na na na na G R 22 11 tolerated 0.06 V474M probably damaging 2.243 
 follows the recessive model,  verified by Sanger 
 
Digital only table: 
Supplementary table 38 Genetic variants in conserved coding regions of genes. 
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Supplementary table 39  Functional associations of genes listed in Supplementary table 37. 
Functional descriptions are mainly from OMIM. Several SNVs were identified in genes involved in apoptosis (UNC5C, LIMS1, ANP32A, BIRC7, DOCK5, MAP3K1, HGF, HBXIP, NUAK1), T-cell 
development and function (ITGAX, CD5, FURIN, LRMP, IGSF3), pattern recognition (TLR10) and inflammatory signaling (ILF3, IL22RA2, TILRR). 
 
  
gene symbol function / OMIM (as hyperlinks) 
XRCC6 High levels of autoantibodies to p70 and p80 have been found in some patients with systemic lupus erythematosus.[provided by RefSeq 2008]. 
UNC5C Thiebault et al. (2003) hypothesized that the UNC5 netrin-1 receptors may also be dependence receptors that induce apoptosis when unbound to their ligand.144  
LIMS1 Fukuda et al. (2003) concluded that PINCH1 is an obligate partner of ILK and both are indispensable for proper control of cell shape change, motility, and survival.145  
ITGAX Leukocyte surface antigen p150,95, plays a part in leukocyte adhesion [OMIM] 
ILF3 In nonstimulated cells, NF90 was mostly nuclear, but T-cell activation resulted in its accumulation in the cytoplasm. The authors concluded that nuclear export of NF90 is required for IL2 mRNA stabilization.146  
IL22RA2 Xu et al. (2001) concluded that IL22RA2 may be important as an IL22 antagonist in the regulation of inflammatory responses.116  
CD5 human T-cell surface glycoprotein [OMIM] 
BEST2 Best2–/– mice exhibited enhanced inflammation, slow recovery from DSS-induced colitis, and altered mucin biogenesis raise the possibility that Best2 may play a role in inflammatory bowel diseases.109  
ANP32A Jiang et al. (2003) identified a pathway that regulates mitochondria-initiated caspase activity. In this pathway, PHAP protein promoted caspase-9 activation after apoptosome formation.147 
BIRC7 expression of BIRC7 blocked apoptosis induced by engagement of FAS, tumor necrosis factor receptor-1 (TNFR1), death receptor-4 (DR4), and DR5), as well as apoptosis induced by chemotherapeutic agents, with a potency comparable to that observed with BIRC2 and BIRC4.148 
DOCK5 Failure of DOCK5 signaling, together with p53 and TNFRSF10A/D-related cell cycle and death pathways, may play a critical role in abrogating apoptosis.149  
ECD Novel regulator of p53 stability and function. May also be a transcriptional activator required for the expression of glycolytic genes (GeneCards, UniProtKB/Swiss-Prot). 
FURIN Furin-deficient regulatory T cells were less protective in a T-cell transfer colitis model and failed to induce FOXP3 in normal T cells.114  
LRMP is expressed in a developmentally regulated manner in lymphoid cell lines and tissues150 
MAP3K1 full-length mouse Mekk1 generates antiapoptotic signals, while a 91-kD C-terminal Mekk1 fragment induces apoptosis.151 
MMP9 Two known gelatinases, MMP-2 and MMP-9, are upregulated during IBD. Epithelial-derived MMP-9 is an important mediator of tissue injury in colitis, whereas MMP-2 protects against tissue damage and maintains gut barrier function119 
NLRP12 NALPs are implicated in the activation of proinflammatory caspases (e.g., CASP1) via their involvement in multiprotein complexes called inflammasomes (Tschopp et al., 2003) [OMIM] 
SIGLEC1 Serum IgM, but not IgG, titers were significantly decreased in Sn-deficient mice. Oetke et al. (2006) suggested that SN has a role in regulating cells of the immune system rather than influencing steady-state hematopoiesis.152  
TJP2 Tight junction proteins 
TLR10 TLR10 belongs to the Toll-like receptor (TLR) family of proteins homologous to the Drosophila Toll protein, which regulates hematopoiesis and innate immune responses to microbial pathogens in the adult fly. [OMIM] 
HGF Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation153 
IGSF3 The Ig-like domains are of the V type, and a search of the sequence databases revealed that the IGSF3 protein is 32% identical to human V7, a leukocyte surface protein.154 
FREM1/TILRR Data suggest that TILRR is an IL-1RI co-receptor, which associates with the signaling receptor complex to enhance recruitment of MyD88 and control Ras-dependent amplification of NF-kappaB and inflammatory responses120 
HBXIP suppressor of var1, 3-like 1 protein interacts with HBXIP, previously identified as a cofactor of survivin in suppression of apoptosis155 
NUAK1/ARK5 ARK5 suppresses the apoptosis induced by nutrient starvation and death receptors via inhibition of caspase 8 activation.156  
ITGA3 The results suggest that the production of MMP-9 by MKN1 cells was potentiated by the alpha3beta1 integrin-laminin-5 interaction, which facilitated their invasion via degradation of the matrix.118 
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Supplementary table 40  sSVs in coding regions of other genes following the recessive model. 
Only a small number of sSVs was detected in exonic regions. Among these are small insertions in ZNF717, REC8 and TCEAL6 and small deletions in MRPL18 and KRTAP19-6. 
        child mother father  
  
rsID chr start end length type ref allele 
allele 
A 
zyg. 
score 
cov. 
cutoff 
zyg. 
score 
cov. 
cutoff 
zyg. 
score 
cov. 
cutoff transcript id 
transcript 
symbol type 
SIFT 
causes 
nonsense 
mediated 
decay 
- chr3 75869245 75869245 2 insertion site - TG 0.0828 0.9394 0.9637 2.8387 0.9682 1.6818 NM_001128223 ZNF717 exonic na 
rs66936880 chr6 160131636 160131638 3 deletion GTT - 0.3176 1.1111 0.9721 2.1429 1.000 6.5000 NM_014161 MRPL18 exonic yes 
rs10690822 chr14 23716246 23716246 3 insertion site - GAA 0.4256 1.1538 0.9510 1.5833 0.9818 1.9615 NM_005132 REC8 exonic yes 
rs72241443 chr21 30835853 30835853 1 deletion G - 0.0039 0.0000 0.9842 3.4000 1.000 4.0800 NM_181612 KRTAP19-6 exonic na 
- chrX 101282436 101282436 1 insertion site - G 0.0277 0.8182 0.9075 1.4138 0.5407 1.2000 NM_001006938 TCEAL6 exonic na 
zyg. score = experimental zygosity score; cov. cutoff = ratio of clipped normal coverage / number of non redundant reads 
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Supplementary table 41  Summary of genes 5-fold up- or downregulated in the child compared to parents. 
All data derived from blood samples. Most of the genes upregulated in the child can be traced back to inflammatory functions, also some have known associations with IBD (S100A12, MMP9, VNN1, 
TLR5, SLC2A3, MAPK3, MAPK14, TNFAIP6, VNN1), which is also true for the downregulated genes (i.e. A2M, TBET, PTGDR, FGFBP2). Several of the differential expressed genes are associated 
with development and function of immune cells (CD177, C19orf59, ARG1, CST7, TNFSF13B, IL4) and antigen recognition and related downstream cascades (CLEC4D, HMGB2, TLR5, NLRC4, 
IRAK3, CR1). 
  mother father son function (hyperlinks to references, mainly from OMIM) 
gene up/down FPKM 
x-fold of 
mother 
FPKM 
x-fold of 
father 
FPKM 
Possible immune-system relevant function / link to IBD 
CD177  2.149 1.531 118.097 54.97 77.14 
Proteinase 3 (PR3) is a major autoantigen in anti-neutrophil cytoplasmic antibodies (ANCA)-associated systemic vasculitis (AASV), 
and the proportion of neutrophils expressing PR3 on their membrane (mPR3+) is increased in AASV. PR3 gene transcription is 
dependent upon CD177 expression.157 
ARG1  1.005 1.532 34.678 34.51 22.63 Arginase 1 (ARG1) inhibits T-cell proliferation by degrading extracellular arginine, which results in decreased responsiveness of T cells to CD3/TCR stimulation. In humans, ARG1 is stored in inactive form within granules of polymorphonuclear neutrophils158 
S100A12  45.242 62.289 1326.530 29.32 21.30 Increased levels of circulating S100A12 are found in IBD, compared to IBS. When used to distinguish IBD from IBS adult patients, serum S100A12 levels exhibit moderate performance121 
C19orf59  5.922 7.935 167.412 28.27 21.10 RT-PCR analysis showed that this gene is differentially expressed in mast cells159 
PLSCR1  1.326 3.353 39.614 29.88 11.81 
Herein, we provide evidence that PR3 was externalized during apoptosis and was associated with human phospholipid scramblase-
1 (hPLSCR1), a protein that has been implicated in the bidirectional movement of plasma-membrane phospholipids in response to 
high cytosolic calcium levels, injury, or apoptotic insult160 
SERPINB1  5.061 8.584 124.694 24.64 14.53 One function of SERPINB1 may be to protect neutrophils from elastase and other serine proteases that are highly expressed in these cells161 
IL4R  1.897 9.295 59.097 31.16 6.36 
It had previously been demonstrated that gain-of-function polymorphisms in the interleukin-4 gene are associated with increased 
output of interleukin-4, which in turn is associated with asthma, skin-test positivity, and higher total concentrations of serum IgE 
(OMIM)162 
S100A8  462.212 1070.270 11856.900 25.65 11.08 
S100A8 and S100A9 induce a specific inflammatory pattern in endothelial cells which is characterised by the induction of a 
prothrombotic and pro-inflammatory response and an increased vascular permeability due to a loss of endothelial cell–cell 
contacts123 
MMP9  1.757 1.499 28.963 16.48 19.32 MMP-9 concentrations, but not those of TIMP-1, were significantly greater in the sputum supernatant in SA and CRD patients compared to controls124 
GYG1  4.179 3.685 68.402 16.37 18.56 glycogen storage disease163 
VNN1  3.639 2.881 52.793 14.51 18.32 Vanin-1 is expressed by enterocytes, and its absence limits intestinal epithelial cell production of proinflammatory signals
164 
Vnn1 -/- mice better controlled inflammatory reaction and intestinal injury165 
ANXA3  7.262 5.668 104.147 14.34 18.38 Over-expression studies suggested AnxA3 might be involved in death promotion during lactacystin-mediated neuronal death, since caspase-3 activation was significantly stronger upon neuronal AnxA3 over-expression166 
TNFSF13B  1.736 5.359 40.461 23.30 7.55 This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. [provided by RefSeq, Mar 2011] 
NLRC4  1.217 1.343 16.923 13.90 12.60 Activation of caspase-1 through an NLRC4 dependent pathway is closely associated with the subsequent death of the cell. 
167 
may be an intracellular receptor for lipopolysaccharide and/or other bacterial products168 
CLEC4D  3.123 8.749 56.205 18.00 6.42 Functions as an endocytic receptor. May be involved in antigen uptake at the site of infection, either for  clearance of the antigen, or for processing and further presentation to T cells169 
SLC37A3  2.496 1.008 16.504 6.61 16.38 transmembrane sugar transporter 
C5orf32  5.016 4.170 50.551 10.08 12.12  PROK2  2.690 3.963 33.797 12.56 8.53 KALLMANN SYNDROME 4 
C14orf94  2.363 1.206 16.733 7.08 13.88 Like other augmin subunits, fluorescence-tagged HAUS4 localized to the metaphase spindle and accumulated at centrosomes during interphase. 
DJ442471  8.187 2.750 42.219 5.16 15.35  ALPL  3.954 3.819 37.475 9.48 9.81 deficiency leads to Hypophosphatasia 
METTL9  6.184 6.892 59.821 9.67 8.68  CST7  17.574 18.113 162.629 9.25 8.98 Cystatin F is a recently discovered type II cystatin expressed almost exclusively in immune cells170 
CIR  1.064 1.114 9.510 8.94 8.54  
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  mother father son function (hyperlinks to references, mainly from OMIM) 
gene up/down FPKM 
x-fold of 
mother 
FPKM 
x-fold of 
father 
FPKM 
Possible immune-system relevant function / link to IBD 
S100A9  659.149 1021.900 6943.040 10.53 6.79 
S100A8 and S100A9 induce a specific inflammatory pattern in endothelial cells which is characterised by the induction of a 
prothrombotic and pro-inflammatory response and an increased vascular permeability due to a loss of endothelial cell–cell 
contacts123 
HK3  6.622 9.209 65.327 9.87 7.09  ACSL1  26.070 30.005 231.732 8.89 7.72  
BCL2A1/BFL1  6.979 13.828 76.683 10.99 5.55 D'Sa-Eipper et al. (1996) showed that the BFL1 protein suppresses apoptosis induced by the p53 tumor suppressor protein in a manner similar to other BCL2 family members.171 
ITGAM  4.384 2.692 27.381 6.25 10.17 Nath et al. (2008) identified and replicated an association between the ITGAM gene (120980) on chromosome 16p11.2 and risk of SLE in 3,818 individuals of European descent.172 
MAPK14/p38  4.591 7.930 47.577 10.36 6.00 p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease173 
CD36  2.087 1.914 16.197 7.76 8.46 It is the fourth major glycoprotein of the platelet surface and serves as a receptor for thrombospondin (188060) in platelets and various cell lines. [OMIM] 
RGS19  2.347 4.179 24.084 10.26 5.76  LEPROT  1.817 2.626 17.067 9.39 6.50  
PGLYRP1  6.969 3.626 37.276 5.35 10.28 They concluded that PGRPs are innate immunity proteins that bind the cell wall or outer membrane and exploit the bacterial stress response to kill bacteria.174 
PGD  3.633 2.703 24.119 6.64 8.92  EMR1  1.718 2.252 15.165 8.83 6.73  
HMGB2  3.415 6.009 33.701 9.87 5.61 The lack of HMGBs also resulted in poorer activation of Toll-like receptor-3 (Tlr3), Tlr7, and Tlr9 by their cognate nucleic acids (dsRNA, ssRNA, and hypomethylated DNA, respectively).175 
VCAN  2.916 3.055 22.646 7.77 7.41  UBE2H  1.237 1.411 9.838 7.95 6.97  FBXW7  1.094 1.063 7.894 7.22 7.43  SLC2A3  8.282 7.720 57.301 6.92 7.42 up-regulated in CD including SLC2A3176 
PPP4R2  1.422 2.350 12.647 8.90 5.38  ARNTL  1.518 1.702 11.117 7.32 6.53  
CR1  2.696 2.696 18.215 6.76 6.76 
Microbes as well as immune complexes and other continuously generated inflammatory particles are efficiently removed from the 
human circulation by red blood cells (RBCs) through a process called immune-adherence clearance. During this process, RBCs 
use complement receptor 1 (CR1, CD35) to bind circulating complement-opsonized particles and transfer them to resident 
macrophages in the liver and spleen for removal.128 
YWHAB  3.038 3.583 22.125 7.28 6.18  BC073144  2.180 3.191 16.913 7.76 5.30  H2A/l  1.597 1.512 10.102 6.33 6.68  
TNFAIP6  3.454 2.526 18.519 5.36 7.33 Class prediction analysis of CDc top 20 and top 5 significant genes allowed complete separation between CDc responders and CDc nonresponders. The CDc top 5 genes were TNFAIP6, S100A8, IL11, G0S2, and S100A9125 
CKAP4  4.961 6.191 34.281 6.91 5.54  PYGL  12.157 17.722 89.512 7.36 5.05 GLYCOGEN STORAGE DISEASE VI 
MAPK3  1.051 1.169 6.851 6.52 5.86 Pages et al. (1999) concluded that p44 Mapk apparently has a specific role in thymocyte development.177 
STK4  3.329 3.973 21.952 6.59 5.53 The particular phosphorylation catalyzed by this protein [STK4] has been correlated with apoptosis. [provided by RefSeq, Jul 2008] 
PIK3AP1/BCAP  4.126 4.166 24.274 5.88 5.83 Yamazaki and Kurosaki (2003) found that Bcap -/- mice had altered Nfkb (see 164011) activity with poor expression of Rel (164910) and, to a lesser extent, of RelA (164014), leading to reductions in target gene induction, cell survival, and cell division.178 
IRAK3/IRAKM  6.217 7.353 38.173 6.14 5.19 This contrasts with endotoxin tolerance, in which IRAK-M up-regulation follows proinflammatory cytokine expression caused by LPS exposure130 
CASP3/CPP32  1.397 1.495 7.878 5.64 5.27 Nicholson et al. (1995) developed a potent peptide aldehyde inhibitor and showed that it prevents apoptotic events in vitro, suggesting that apopain/CPP32 is important for the initiation of apoptotic cell death.179 
BGR/DECTIN1  2.050 2.011 10.948 5.34 5.44 Brown and Gordon (2001) identified dectin-1 as a beta-glucan receptor present on macrophages.129 
TLR5  1.451 1.437 7.654 5.27 5.33 indicating that TLR5-stop can protect persons of Jewish ethnicity against CD127 
HBA1  5083.940 220.249 43.593 116.622 5.052  PIGR  11.569 8.004 1.557 7.429 5.140 mediates transcellular transport of polymeric immunoglobulin molecules. [OMIM] 
ISCU  14.357 8.848 1.463 9.812 6.048 Tong and Rouault (2006) concluded that ISCU is involved in a coordinated response to iron deficiency that includes activation of iron uptake, redistribution of intracellular iron, and decreased utilization of iron in Fe-S proteins180 
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  mother father son function (hyperlinks to references, mainly from OMIM) 
gene up/down FPKM 
x-fold of 
mother 
FPKM 
x-fold of 
father 
FPKM 
Possible immune-system relevant function / link to IBD 
SEPT9  15.087 9.597 1.373 10.988 6.990 Septin depletion resulted in chromosome loss from the metaphase plate, lack of chromosome segregation and spindle elongation, and incomplete cytokinesis upon delayed mitotic exit.181 
FIBP  7.755 7.294 1.359 5.706 5.367  BTF3  13.194 14.744 1.014 13.017 14.547 suppresses CED-3-independent apoptosis in c. elegans182 
 
 
Supplementary table 42 Exonic missense SNVs detected in genes differentially expressed in the child compared to the parents. 
Only five differentially expressed genes show potential damaging SNVs (CR1, VCAN, IL4R, EMR1 and MMP9). Only the MMP9 SNV is located in a site of high conservation (phyloP 2.604), but is 
supported only by a very limited number of reads. 
rsID gene symbol chrom position phyloP subtype zygosity ref allele A allele B reads ref reads alt SIFT SIFT score 
SIFT 
AA 
change 
PolyPhen dScore 
rs2274567 CR1 chr1 205820244 0.394 missense hom A G G 0 31 tolerated 0.32 H1663R probably damaging 1.538 
rs309559 VCAN chr5 82869125 0.903 missense het A G A 21 25 damaging (low confidence) 0.00 K1516R benign 0.251 
rs1805011 IL4R chr16 27281373 -0.489 missense het A A C 38 18 tolerated 0.36 E400A possibly damaging 0.764 
rs1805015 IL4R chr16 27281681 1.019 missense het T T C 34 22 tolerated 0.28 S503P possibly damaging 1.839 
rs897738 EMR1 chr19 6852891 1.113 missense hom G A A 0 62 tolerated 0.43 D174N possibly damaging 0.754 
- MMP9 chr20 44076428 2.604 missense het A A C 3 2 tolerated 0.11 K638T probably damaging 1.892 
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Supplementary figure 5 Differentially expressed S/AS pair in cHL cell lines. 
Expression of uc010iqu.1 (CR595965, light blue) is mutually exclusive in L-1236 and KM-H2, while uc003iqi.1 (FSTL5, dark blue) is only expressed in U-HO1. Scale: 0-3 for all tracks. 
  
L-1236 fw 
L-1236 rev 
KM-H2 rev 
KM-H2 fw 
U-HO1 fw 
U-HO1 rev 
CR595965 
FSTL5 
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Supplementary figure 6 Differentially expressed antisense event in Mtus1 in murine tissues. 
B4300010123Rik is expressed in the two small intestine samples (red) but not in colon (blue). Expression of (the long) Mtus1 isoform is lower in the small intestine samples (exons marked by 
arrows). Scale for forward strand: 0-19, scale for reverse strand: 0-82. 
 
 
  
small intestine 1  fw 
colon 1 fw 
small intestine 2  fw 
small intestine 1  
 
small intestine 2 rev 
colon 2 fw 
colon 2 rev 
colon 1 rev 
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Supplementary figure 7 Coexpressed S/AS pair in cHL cell lines. 
A transcript in antisense orientation to uc010siq.1 (light blue) correlates with the expression of the sense transcript (dark blue). Scale 0-5 for all tracks. 
  
L-1236 fw 
L-1236 rev 
KM-H2 rev 
KM-H2 fw 
U-HO1 fw 
U-HO1 rev 
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Supplementary figure 8 Coexpressed S/AS example in Tcf7l1 in murine tissues. 
 A novel transcriptionally active region is visible in both colon samples (blue), which also show expression of Tcf7l1, while neither is expressed in the small intestine samples (red). Scale 0-49 for 
forward and 0-31 for reverse strand. 
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Supplementary figure 9 Differentially expressed antisense event in ZSCAN16 in cHL cell lines. 
ZSCAN16 expression (light blue) was detected in samples L-1236 and U-HO1, but not in KM-H2. Instead KM-H2 shows antisense expression (dark blue) of a small unannotated region. Methylation 
data is available for the two marked positions (last track), where KM-H2 shows a higher degree of methylation than the other two samples (see Supplementary table 43). Scale 0-5 for all tracks. 
 
 
Supplementary table 43 Average beta methylation values for ZSCAN16 (ZNF435) promoter region. 
Methylation was measured in duplicates for L-1236 and KM-H2. The methylation rate in KM-H2 is higher than in the other two samples. KM-H2 is also the only sample that shows expression on 
opposite strand of ZSCAN16, exon 2. 
TargetID SYMBOL CHR MAPINFO L-1236 
AVG_Beta 
KM-H2 
AVG_Beta 
U-HO1 
AVG_Beta 
cg12706983 ZNF435 6 28200218 0,1541 0,5401 0.0433 
cg13665593 ZNF435 6 28200399 0,0680 0,4470 0.0198 
 
L-1236 fw 
L-1236 rev 
KM-H2 rev 
KM-H2 fw 
U-HO1 fw 
U-HO1 rev 
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